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Summary 
Viruses are naturally formed bionanoparticles (BNPs), ranging in size from 22-150 
nm. Remarkably, small viruses are composed of one single protein chain folding into a 
capsid structure with icosahedral symmetry. The icosahedron is built up from 60 
asymmetric units and is the largest closed shell in which every subunit is in an identical 
environment. It is characterized by 2-fold, 3-fold and 5-fold rotational symmetry axes. By 
superposition of different protein oligomerization domains onto the symmetry axes of the 
icosahedron, a nanoparticle with icosahedral symmetry can be designed.  
To test our concept, we have designed a peptide comprising a slightly modified form 
of a pentameric coiled-coil domain of cartilage oligomeric matrix protein (COMP) linked 
to a de novo designed trimeric coiled-coil domain as a single chain. These two different 
oligomeric domains were linked by two glycine residues to provide flexibility between 
them and were fixed in their relative orientation with an intramolecular disulfide bridge. 
Computer modeling predicted that such a design would result in an icosahedral peptide 
based nanoparticle with a diameter of 17 nm. We chemically synthesized the above 
designed peptide and performed refolding studies and biophysical characterization using 
analytical ultra centrifugation (AUC) and electron microscopy (EM), thereby showing the 
formation of icosahedral nanoparticles with a diameter of ~ 17 nm. 
Subsequently, we switched to recombinant expression of the designed peptide. Again, 
we performed refolding studies with the expressed peptide and biophysical 
characterization (AUC and EM), thereby showing the formation of icosahedral 
nanoparticles with a diameter of ~ 17 nm. In addition, we showed that during refolding, 
parameters such as ionic strength, pH of the refolding buffer and presence of glycerol 
influence the formation of icosahedral nanoparticles. Moreover, we observed icosahedral 
nanoparticles in conditions in which the formation of intramolecular disulfide bridges is 
not possible. This showed that even in the absence of intramolecular disulfide bridge the 
helices of the two different oligomeric domains like to be arranged close to each other, as 
this will favor the formation of icosahedral nanoparticles. 
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In parallel, we also modified the designed peptide to include charged residues at the 
interface between the two oligomeric domains. The idea was to fix the relative orientation 
between the two oligomeric domains through ionic interactions. The subsequent 
expression, refolding studies and biophysical characterization showed the formation of 
nanoparticles, but they were lacking icosahedral symmetry. This result showed that the 
design has to be optimized further to obtain icosahedral nanoparticles. 
Moreover, we wanted to study whether in our design principles oligomerization motifs 
other than coiled-coils can be used to form icosahedral nanoparticles. Accordingly, we 
used globular foldon domain as the trimerization domain and the COMP as the 
pentamerization domain. The results showed the formation of nanoparticles, but they 
were lacking icosahedral symmetry. In addition, in the above design we studied the effect 
of linker region by increasing the liker region to four and six residues, but it did not help 
in the formation of icosahedral nanoparticles. However, when the foldon domain 
extended with the trimeric coiled-coil domain as a single trimerization domain and with 
COMP as the penatmerization domain, we observed icosahedral nanoparticles. 
Viruses are known for their induction of strong antibody (B-cell) mediated immune 
response in the host even against the self-antigens. This property is conferred by the 
repetitive arrangement of the antigens on their surface. Peptide based nanoparticles have 
similar properties to viruses, such as self-assembly and most importantly the repetitive 
arrangement of subunits (peptide based nanoparticles are composed of 60 identical 
monomeric chains). Therefore, we wanted to use our system as a ‘repetitive antigen 
display carrier’ in vaccination, as an alternative to viral and viral based platforms such as 
virus like particles (VLPs). To this end, and in order to understand the effect of our 
nanoparticle size on immune response, we built different constructs displaying the pilin 
epitope of Pseudomonas pathogen at their C-terminus. Computer modeling indicated that 
these constructs would form icosahedral nanoparticles of three sizes: small (18 nm), 
medium (23 nm) and large (29 nm). From the refolding studies, we observed mostly 
aggregation and precipitation of the nanoparticles.  
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This effect presumably due to interparticle cross-linking, by the cysteine residues of 
pilin epitope which are present at the periphery of nanoparticles, as we observed 
aggregation of small size icosahedral nanoparticles upon changing from reducing to 
oxidizing condition. Immunization results, because of the aggregation and precipitation 
behavior of nanoparticles, showed poor immune response. However, the immunization 
results showed that our nanoparticles present the attached epitope in their native form, as 
we observed binding against native pilin protein. Moreover, immunization results from 
our laboratory using medium size nanoparticles displaying Salmonella epitope D2 
showed promising results, as we got antibody titer values which were well comparable to 
the values obtained with VLPs. This places our system alongside with VLPs, which are in 
clinical trials as a carrier in vaccination.    
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Nanotechnology 
“The growing field of nanotechnology finds its full expression in the words of that 
abstract of the artist-scientist Leonardo da vinci: ‘Where Nature finishes producing its 
own species, man begins, using natural things and with the help of this nature, to create 
infinity of species.”’ Nobel laureate Jean-Marie Lehn used these words to give an 
outlook on the future and perspectives of supramolecular chemistry [1]. 
The definition of nanotechnology according to National Nanotechnology Initiative 
(NNI) is as follows: research and technology development at the atomic, molecular, or 
macromolecular scale, leading to the controlled creation and use of structures, devices, 
and systems with a length scale of 1-100 nanometers (nm). The advantage of operating 
at the nanoscale realm is that the objects at this scale, take on novel properties and 
functions that differ markedly from those seen in the macro scale. For example, carbon 
nanotubes [2] and gold nanoshells [3], two different types of nanomaterials, have 
physical properties different from carbon or gold on the macro scale. Other examples of 
nanotechnology include dendrimers [4], liposomes [5], and semi-conducting quantum 
dots [6]. 
Ron Hardman [7] nicely describes the impact of nanotechnology with the following 
words “In 1959 Richard Feynman’s seminal talk on nanotechnology, ‘There’s Plenty of 
Room at the Bottom’ [8] presented what was theoretically possible by manipulating 
matter at the atomic and molecular scales. Today, nanotechnology is an applied 
science, a rapidly growing industry generating a diverse array of nanoscale materials 
(e.g., carbon nanotubes, fullerene derivatives and quantum dots). Manipulation of 
materials on a nanometer scale is opening a world of creative possibilities, and the 
benefits afforded by nanoscale technologies are expected to have substantial impacts on 
almost all industries and areas of society (e.g., medicine, plastics, energy, electronics 
and aerospace)”. 
Especially, nanotechnology manifests itself in a wide range of nanoparticles that can 
be useful to biologist as Scott E. McNeil [9] describes the application of 
nanotechnology for the biologist with the following words “nanotechnology manifests 
itself in a wide range of nanoparticles that can be useful to biologist.  
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For example, dendrimers [10, 11] and magnetic nanoparticles [12, 13] are used in 
targeting of cancer cells and in tissue imaging and gold nanoshells [14] in cancer 
therapy and liposomes [15, 16] in gene therapy and drug delivery. Virtually, all of these 
nanoparticles have been designed with chemically modifiable surfaces to attach a 
variety of ligands that can turn these nanoparticles into biosensors, molecular-scale 
fluorescent tags, imaging agents, targeted molecular delivery vehicles, and other useful 
biological tools (Figure 1). An obvious advantage of nanotechnology as it relates to 
biological systems is the ability to control the size of the resulting nanoparticles. 
Nanoparticles are of the same basic size as biological entities (1-100 nm)” (Figure 2). 
  
 
Figure 1. Schematic diagram of multifunctional 
nanoparticle. The nanoparticle’s “corona” (outer surface) 
can be functionalized with hydrophilic polymers, targeting 
molecules, therapeutic molecules, therapeutic drugs, and 
image contrast agents. The interior surface can be solid 
(e.g., quantum dots) or liquid (e.g., liposomes). Reprinted 
from [9], with permission from Society for Leukocyte 
Biology.    
 
 
     
Figure 2. Relative size of nanoparticles compared with familiar items. Reprinted from [9], with 
permission from Society for Leukocyte Biology. 
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As the applications of inorganic, metallic, semiconductor and polymer based 
nanoparticles in biology is increasing, there is also increasing concern about its 
toxicological properties. For example, carbon nanoparticles have been shown to induce 
lipid per-oxidation in the brain cells of fish and pulmonary inflammation in rats [17, 
18]. Therefore, as an alternative people started using peptides and proteins as building 
blocks to build nanoparticles. This opened up a new filed called ‘bionanotechnology’.      
Protein and peptides as building blocks - Bionanotechnology 
Bionanotechnology, a subdivision of nanotechnology focuses on research and 
development of novel nanoscale materials from biological building blocks for medical 
applications such as gene delivery, bio-imaging, drug delivery and vaccine 
development.  
Self-assembly is one of the processes used in nanotechnology to make ensembles of 
nanostructures [19]. Mainly, self-assembly process is exploited in the field of 
bionanotechnology to create novel nanoscale biomaterials. Therefore, in the following 
paragraphs, the self-assembly process is described.  
Self-assembly 
The term “self-assembly” does not have a precise definition, and indeed has often 
been overused. Processes ranging from the non-covalent association of organic 
molecules in solution to the growth of semiconductor quantum dots on solid substrates 
have been called self assembly.  
Whitesides and Grazybowski [19] limit the term “self-assembly” to the following 
definition: “processes that involve pre-existing components which exhibit reversible 
and co-operative assembly of predefined components into an ordered superstructure”. 
In addition, Whitesides and Grazybowski classified the self-assembly process into two 
main kinds: (i) static and; (ii) dynamic self-assembly. Static self-assembly involves 
systems at global or local equilibrium that do not dissipate energy. For example, 
molecular crystals and most of the folded globular proteins are formed by static self-
assembly. In static self-assembly, formation of the ordered structure may require 
energy (for example in the form of stirring), but once it is formed, it is stable.  
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On the other hand, in dynamic self-assembly the formation of structures or patterns 
occurs when the system dissipates energy. Examples are patterns formed during 
reaction and diffusion processes in oscillating chemical reactions.   
 Shuguang Zhang [20] describes the characteristics of self-assembly with the 
following words “Self-assembly is mediated by weak, non-covalent bonds notably 
hydrogen bonds, ionic bonds (electrostatic interactions), hydrophobic interactions, van 
der Waals interactions, and water mediated hydrogen bonds. Although these bonds are 
relatively insignificant in isolation, when combined together as a whole, they govern 
the structural conformation of all biological macromolecules and influence their 
interactions with other molecules. Moreover, it is a powerful approach for fabricating 
novel supramolecular architectures. It is ubiquitous in the natural world. For example, 
lipid molecules form oil drops in water; four hemoglobin polypeptides form a 
functional tetrameric hemoglobin protein; ribosomal proteins and RNA coalesce into 
functional ribosomes”.  
Self-assembled nanoscale bioassemblies derived from nature’s 
design 
Nature has provided us with rich source of self-assembled nanoscale bioassemblies 
such as viruses. By combining molecular biology and recombinant protein expression, 
several self-assembled nanoscale bioassemblies derived from nature’s design have been 
prepared for bionanotechnological applications. It includes:  
- Virus capsid or virus-like particles (VLPs) [21, 22]; 
- Ferritin protein cages [23-25]; 
- Heat shock protein cages [26-28]; 
- Other self-assembled protein cages, such as enzyme complexes [29], chaperones 
[30], and carboxysomes [31].  
 The above mentioned bionanoparticles (BNPs) self-assemble primarily based on 
multiple noncovalent interactions to highly organized nanosystems with a diverse array 
of shapes and sizes (Figure 3).        
 
General Introduction 
 7
Distinctive features of Bionanoparticles: 
Lee and Wang [32] describes the following points which make BNPs more attractive 
when compared to the synthetic nanoparticles. 
• Well organized architectures with a broad selection of sizes in the nanometer 
scale (Figure 3). 
• Monodispersed particles with uniform size and shape. 
• Three dimensional (3D) structures resolved at atomic or near-atomic levels. 
• Economic large scale production in gram or even kilogram quantities. 
• Availability of genomic sequence, through which the composition and surface 
properties can be controlled through recombinant technology. 
• In particular, both genetic and chemical modification techniques can be used to 
model the scaffolds. Thereby, allowing theoretically unlimited alterations of the 
nanomaterials with submolecular precision.   
Bionanoparticles (BNPs) and their characteristic features 
Virus capsid or virus like particles (VLPs) 
Recently, several investigations have recognized virus capsids as versatile building 
blocks that can serve as scaffolds for producing nanomaterials [33-35]. In addition, 
Singh and co-workers [36] describes the usefulness of viral capsids with the following 
words “Viral particles are robust protein cages in the nanometer range exhibiting well-
defined geometry and remarkable uniformity ideal for nanoscale fabrication. The 
atomic structures of many viruses have been resolved allowing researchers to identify 
or modify amino acids in the viral capsid for bioconjugation. With the ease of genetic 
manipulation for producing mutants displaying lysines or cysteines in the accessible 
virus capsid regions, it is feasible to chemically conjugate molecules to those amino 
acids both on the interior and exterior. 
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Figure 3. Structural illustration of protein cages that have been used in bionanotechnology or biomedical applications. Reprinted from [32], with permission from 
Elsevier. 
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Bioconjugation to virus-based nanoparticles has been performed using commercially 
available homo- or hetero-bifunctional linkers using the lysines and/or cysteines of the 
viral capsid [37-40]. Molecules derivatized with NHS-esters can conjugate to the 
lysines, while maleimide-derivatized molecules that are thiol selective can react and 
link with the cysteines”. A schematic representation of commonly used basic 
bioconjugation methods is shown in Figure 4. For example using bioconjugation, 
cowpea mosaic virus (CPMV) has been demonstrated to be a robust platform for 
conjugation with variety of molecules, including fluorescent dyes [41], polyethylene 
glycol (PEG) chains [42], DNA [43], peptides [44], antibodies [35], and 
carbohydrates [45]. 
As virus capsids are relatively rigid, it has also become feasible to display molecules 
in a precise spatial distribution at a nanoscale level. The above point was demonstrated 
using VLPs to display antigens in a repetitive and highly ordered manner for the 
purpose of designing modular system for novel vaccines [46].  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Chemical bioconjugation of viral nanoparticles. Bioconjugation methods for (A) lysines in 
virus capsid reacting with NHS-ester derivatized molecules or (B) thiols of cysteines in virus capsid 
reacting with maleamide-derivatized molecules. Molecule to be conjugated is shown as a filled circle. 
Adapted from reference [36].  
Ferritin protein cages 
Ferritins are a class of iron storage and mineralization proteins found throughout the 
animal, plant and microbial kingdoms.  
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In higher eukaryotes, ferritins are composed of 24 nearly identical subunits and are 
self-assembled into a spherical cage with an octahedral symmetry (4-fold, 3-fold and 2-
fold) [47] (Figure 5). Ferritin has an outer diameter of 12 nm and an inner cavity 
diameter of 8 nm that stores the mineralized iron core [48].  
 
 
 
 
 
 
 
 
 
Figure 5. Human heavy (H) subunit ferritin structure (HuHF). 24 subunits in 432 symmetry viewed 
down the four-fold symmetry axis. Reprinted from [47], with permission from Elsevier. 
 
Ferritin because of its natural mineralization property has been used as a reaction 
vessel for the synthesis of inorganic nanomaterials with controlled dimensions. For 
example, apoferritin (lacking the iron oxide core) has been used in the mineralization of 
metals such as cobalt, nickel and palladium [49-51]. In addition, Kramer and co-
workers showed that the ferritin protein cages can be functionalized through genetic 
engineering to impart specific functionalities for the constrained synthesis of silver 
nanoparticles [23]. 
Other protein cages 
Other protein cages such as heat shock proteins [26-28], enzyme complexes 
(luzamine synthase capsid) [29], chaperones [30], and carboxysomes [31] which are 
similar to virus capsid and ferritin protein cages, have also been used as alternative 
scaffolds. Each individual system is a precisely assembled platform based on symmetry 
based arrangement (octahedral or icosahedral symmetry). Similar to virus like cages, 
these platforms also offer high degree of spatial organization with well characterized 
self- assembly motifs, a major advantage in BNPs for controlling functional group 
density and orientation.  
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Many of these protein cages have been demonstrated with medically relevant 
functionalizations with genetic insertions of heterologous peptides or through 
bioconjugations will be described in the following applications section. 
Biomedical applications of BNPs 
In recent years the polyvalent display nature of BNPs has been exploited to a 
greater degree in biomedical applications such as cell specific drug and gene delivery. 
This is because of the emerging paradigm that the collective binding between multiple 
ligands and receptors often leads to increased affinity, and such multiplex bindings 
elicit fundamentally different biological events when compared with an individual 
ligand binding. For example, Finn and coworkers [45] showed that the polyvalent 
display of carbohydrates (mannose units) on cowpea mosaic virus (CPMV) capsid, 
enhanced their binding affinity for their complementary lectin concanavalin-A (con-A). 
This caused them to exhibit nearly a thousand-fold greater efficiency than monomeric 
mannose units in inhibiting erythrocyte agglutination with concanavalin-A. 
In the following paragraphs, we will see the applications of BNPs in the field of cell 
targeting, drug delivery, bio-imaging and vaccine design. 
Cell targeting 
The principle of targeting specific diseased cell type is to localize the therapeutic 
agent, thereby reducing the potential side effects and increasing the therapeutic 
efficiency.  
The natural affinity of BNPs especially viral capsids to target host cells is exploited 
for cell targeting purposes. For example, polyomavirus VP1 based VLPs naturally 
targets a cell surface glycoprotein with a terminal α 2,3-linked N-acetylneuraminic acid 
[52], and is internalized by the cells via α4β1-integrin receptors [53]. Also, Hepatitis B 
virus large (L)-surface antigen based VLPs naturally targets human hepatocytes and the 
information is specified by the sequence located at the N-terminus of large subunit. 
These VLPs have been demonstrated as safe vehicles for delivery of genes with high ex 
vivo and in vivo transfection efficiencies and high targeting specificity to human 
hepatocyte-derived cells [54, 55]. 
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The natural affinity of viral capsids towards host cells is altered by inserting peptide 
ligands through recombinant cloning technique. Using this technique people have 
produced VLPs with altered affinities. Folk and co-workers [56], genetically inserted 
the urokinase plasminogen activator (uPA) sequences to the VP1 proteins of 
polyomaviruses and showed that the resulting VLPs were directed towards the upA 
receptor expressing cells. In HBV L-surface antigen based VLPs, its native bio-
recognition motif was replaced with epidermal growth factor (EGF) moiety to direct the 
particles to EGF receptor-overexpressing cells [54]. The recombinant cloning in BNPs 
opens vast possibilities of incorporating different cell-specific targeting moieties, but 
the chimeric sequence insertions can vary immensely upon each BNP (location of 
insert) and the composition of peptide insert (number and sequence of amino acids). 
Drug delivery 
The interior hollow cavities of BNPs are exploited to encapsulate small molecules 
for drug delivery by genetic and chemical modifications. Recent studies with polyoma 
VLPs and heat shock protein (Hsp) cages demonstrated the feasibility of packaging 
proteins and chemical compounds within the protein cage.  
  Abbing and co-workers [57] used polyoma VP1 based VLPs to encapsulate 
methotrexate drug (MTX) and green fluorescent protein (GFP). In polyoma virus, VP1 
forms the major capsid protein enclosing the inner coat proteins VP2 and VP3. The 
encapsulation of molecules was achieved by the development of an anchoring 
technique based upon the specific interaction of the inner core protein VP2 with VP1 
pentamers. A stretch of 49 amino acids of VP2 served as an anchor molecule, either 
expressed as a fusion protein with green fluorescent protein (GFP) or covalently linked 
to methotrexate (MTX). The 49 amino acids of VP2 specifically anchored GFP or 
MTX to VP1 pentamers and the further assembly of VP1 pentamers in to capsid 
structure resulted in VP1 VLPs enclosing GFP or MTX. The encapsulated MTX 
retained cytotoxicity in the cells, and destroyed MTX-resistant cells, which suggests 
that the system circumvents the MTX transport. 
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In another study by Douglas and co-workers [27] used small heat shock protein 
(Hsp) cages from Methanococcus jannaschii to encapsulate the anti-tumor drug 
doxorubicin by chemical coupling and showed subsequent release of drug from the 
cage in a pH dependent manner. Hsp assembles into a 24-subunit spherical structure 
with octahedral symmetry, which is 12 nm in diameter and has a porous protein shell 
that allows the free small-molecular exchange between the interior and bulk solution 
[26]. In this study, the Hsp cage was genetically modified to include cysteine residues 
at the interior surface and the (6-maleimidocaprol) hydrazone derivative of doxorubicin 
was linked to the interior surface of this Hsp via coupling of maleimide to cysteine. The 
quantitative analysis by absorbance spectroscopy indicated that 24 doxorubicin 
moieties were encapsulated, and under acidic conditions doxorubicin was selectively 
released through the hydrolysis of hydrazone linkage. This study can be a crucial step 
in future drug delivery designs. 
Bio-imaging 
Based on two main points, BNPs are considered as valuable tools in in vivo or in 
vitro imaging applications. The fist one is the biocompatibility. For example, 
Manchester and co-workers [58] tested the biocompatibility nature of cowpea mosaic 
virus (CPMV) particles by dosing through oral and intravenous route in mice. They 
found out that after several days of dosing, the CPMV particles were detectable in a 
wide variety of tissues including liver, kidney, lung, spleen, and lymph nodes. Thus, 
confirming the biocompatibility nature of CPMV particles.   
The second point is the large surface area presented by the BNPs for coupling 
fluorescent probes. For example, Finn and co-workers showed using cowpea mosaic 
virus (CPMV) particles (made up of 60 subunits) that at least 60 copies of fluorescent 
molecules can be attached to the virus capsid using the highly reactive lysine which is 
present in each subunit [39]. In addition, the rigid and highly ordered surface feature of 
BNPs was exploited to attach imaging agents at designed positions on the surface. This 
resulted in no mobility of attached fluorescent molecules to interact or aggregate with 
each other, which often quenches the fluorescence. Soto and co-workers [59] 
demonstrated that the spatial distribution of carbocyanine dye Cy5 on the virus capsid 
overcomes the problem of fluorescence quenching observed in Cy5 molecules and 
showed increased fluorescence signal. 
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One of the applications of BNPs in bio-imaging is that they are used to sensitively 
image the vasculature during development and disease states such as tumorigenesis and   
atherosclerosis. For example, Manchester and co-workers [60] used fluorescent labeled 
CPMV particles to visualize the vasculature blood flow in living mouse and chick 
embryos to a depth of about 500 µm. In addition, they also showed the intravital 
visualization of human fibrosarcoma-mediated tumor angiogenesis.   
Vaccine development 
Repetitive antigen display concept:  
Repetitive antigen display concept started with the work of Dintzis and co-workers 
[61, 62]. To understand the minimum requirements of antigen for triggering the 
primary B-cell mediated immune response, the group used haptenated polymers as 
antigens and showed that arrays of 20-30 haptens (small organic molecules of defined 
structure), spaced optimally by 5-10 nm, can activate B-cells. Still, these responses 
depend on some T-cell help for activation of B-cells.  
Later, Zinkernagal and co-workers [63] studied the influence of antigen density and 
order on B-cell induction using the antigen glycoprotein of vesicular stomatis virus 
serotype Indiana (VSV-G (IND)). Naturally, VSV-G (IND) exists in a highly repetitive 
form in the envelope of vesicular stomatis virus (VSV-IND) and in a poorly organized 
form on the surface of infected cells. By generating transgenic mice expressing VSV-G 
(IND), the authors showed that the B-cells were unresponsive to the poorly organized 
form of VSV-G (IND) present as self antigen but responded to the same antigen when 
presented in the highly ordered, repetitive manner. Subsequently, Zinkernagal and co-
workers showed that the induction of B-cells is completely independent of the T-cell 
help and concluded that the B-cells respond best against the rigid and highly repetitive 
surface antigens [64].   
Repetitive antigen display was also the key in producing high-titer, high affinity 
monospecific antibodies that were used some time ago to localize the different protein 
subunits within the capsid of bacteriophage T4 [65-67]. Also recently, Aebi and co-
workers [68] used the repetitive antigen display concept to directly visualize the 
dependence of antibody affinity and specificity on antigen presentation. 
  
General Introduction  
 15
Based on the above studies on repetitive antigen display concept, BNPs such as 
virus-like particles (VLPs) and ferritin protein cages are used to present bacterial or 
viral antigens for the production of novel vaccines because of their rigid and repetitive 
surface.  
Virus like particles (VLPs)  
VLPs are a highly effective type of subunit vaccines that mimic the overall structure 
of virus particles without the requirement of containing infectious genetic material [69]. 
VLPs are produced by utilizing the intrinsic property of viral capsid proteins to self-
assemble spontaneously. For example, VLPs of papillomavirus are produced using the 
self-assembly of major capsid protein L1.  
VLPs are considered as strong immunogens because of the following properties: (i) 
they have the authentic conformation of viral capsid proteins seen with inactivated and 
attenuated virus vaccines; and (ii) their ability to induce both B-cell [70] and T-cell 
mediated immune responses in the absence of adjuvants [71, 72]. These properties 
made VLPs as immunogens. For example, the immunization of young healthy woman 
with human papillomavirus (HPV16) VLPs composed of the major structural protein 
L1 induced high titer neutralizing antibodies and protected the patient from HPV 
infection and associated cervical dysplasia [73].   
In addition to vaccine candidates, VLPs are used as ‘repetitive antigen display 
system or carrier’ to present foreign antigens on their surface to create novel vaccine 
candidates [46, 74]. The best studied example is the Hepatitis B-virus core (HBc) 
particles [70, 75-77]. The HBc particles are formed by the self assembly process during 
which the monomers associate to form dimers (stable intermediate form) (Figure 6, A) 
and the dimers further associate to form HBc particles. The assembled particles are 
shown to form two different sized particles of 34 and 30 nm in diameter and correspond 
to a triangulation number T=4 and T=3 packings, containing 120 dimers (240 
monomers) and 90 dimers (180 monomers), respectively. The T=4 capsid structure of 
HBc particle is shown in Figure 6, B. The major immunodominant loop region (ILR) in 
each monomer, which is the preferred region for inserting antigenic sequences, is 
highlighted in Figure 6. The insertion of antigenic sequences is done using chemical 
coupling to the ILR [78] or recombinantly fused to replace the ILR.  
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The examples of HBc particle based novel vaccines include malaria vaccine which 
is in the phase I clinical trial [79, 80] and the universal vaccine for Influenza A virus 
[81, 82].                           
Ferritin protein cage based antigen display system         
Recently, Carter and co-workers showed that ferritin protein cages can be used as an 
alternative ‘repetitive antigen display system’ to HBc particles [83]. They fused the 
HIV-tat peptide to the N-terminus of the monomer and expressed as a fusion protein in 
E.coli. After expression, purification and assembly the resultant chimeric particles are 
shown to elicit a potent antibody mediated immune (humoral) response.      
    
     
     
 
 
 
 
 
 
                                                                                                     
Figure 6. (A) Dimer unit of Hepatitis B-virus core (HBc) particles. Two monomers are depicted in blue 
and red color, respectively. Cys-61, which forms a disulfide bridge between the two monomers, is shown 
in green, and Cys-48, which does not form disulfides, in yellow. The C-terminal regions provide most of 
the interdimer interactions that build the particles. Major immunodominant loop region (ILR) in each 
monomer is highlighted. (B) T=4 HBc particle viewed along the icosahedral three-fold axis. Four 
independent monomers A, B, C and D in the particles are shown in green, yellow, red and blue, 
respectively. In the particle, the immunodominant loop region (ILR) from two monomers is highlighted. 
Reproduced from [77, 84], with permission from Elsevier.      
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De novo designed nanoscale bioassemblies through self-
assembly of peptides and proteins 
Rajagopal and Schneider [85] review the molecular self-assembly using peptide and 
proteins as monomeric building blocks with the following words “As early as 1981, 
Eric Drexler [86] proposed that protein design could be used to fabricate devices 
through a ‘bottom-up’ approach, in which proteins are used as monomeric building 
blocks for the fabrication of higher order structures via self-assembly. Peptides and 
proteins are particularly attractive as building blocks because a great deal is known 
about their folding and stability, and rules governing protein–protein interactions are 
actively being established.  
Based on this knowledge, the field of de novo design emerged and tests our expertise 
in answering the simple question: can one build structural and functional proteins from 
first principles? To date, most de novo design efforts have centered on self-assembled 
proteinaceous structures of finite size. However, the design principles established from 
these endeavors are now being extended to the fabrication of larger nanoscale devices 
and materials. The challenge is twofold: first, to rationally design building blocks 
amenable to self-assembly that form nanostructured materials and, next, to impart 
desired functionality. Functionality can arise from either the extremely small feature 
sizes inherent to the material, such as those needed for photonics applications, or the 
incorporation of specific functional molecules into the self-assembled scaffold. In the 
following section, we will see examples of designed nanoscale bioassemblies through 
self-assembly of peptides and their applications”. 
Peptide nanotubes (cyclic peptide) 
Martin and Kohli [87] review the field of peptide based nanotubes with the 
following words “In 1993, Ghadiri and co-workers described a fascinating class of 
nanotubes that are based on cyclic peptide molecules that consist of an even number of 
alternating D- and L-amino acids. They showed that these molecules self-assemble 
through ‘hydrogen-bonding’ interactions into nanotubes, which in turn self-assemble 
into ordered parallel arrays of nanotubes [88] (Figure 7).  
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The number of amino acid residues in the ring determines the inside diameter of the 
nanotubes obtained; as an example, a 12-aminoacid ring produces nanotubes with an 
inside diameter of 1.3 nm. The chemical functional groups on the outside of the walls 
of these nanotubes can be varied by varying the amino-acid composition of the ring. 
Ghadiri and colleagues have shown a number of biomedical/biotechnological 
applications for these nanotubes. Perhaps the most interesting is as a new class of 
antibiotics against bacterial pathogens. Fernadanez-Lopez et al. [89] showed that cyclic 
peptides comprising six and eight amino acid residues act preferentially on both Gram-
positive and Gram-negative bacteria relative to mammalian cells. These data indicate 
that nanotubes formed from these peptides insert into the cell wall of the bacterium, 
which results in rapid cell death. Ghadiri and colleagues have also shown that these 
nanotubes can function as artificial ion channels in lipid bilayer membranes by self-
assembling across the membrane [90], and ion-transport rates comparable to those of 
naturally occurring ion channels were observed”. 
  
 
 
 
 
 
 
 
 
 
Figure 7. A typical chemical structure of cyclic peptide and schematic representation of the self-
assembly of such peptides into nanotubes and nanotube arrays. Reproduced from [87], with permission 
from Nature publishing Group. 
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Peptide nanofibers (ionic self complementary peptide) 
Zhang and co-workers fabricated nanofibers that are based on linear peptide 
molecules  that consist of an even number of alternating hydrophobic and hydrophilic 
amino acids (natural L-amino acids) [91-93]. They showed that these molecules form 
β-sheet structures in solution with two distinct surfaces-one hydrophilic, the other 
hydrophobic and self-assemble through ‘complementary ionic interactions’ between the 
charged residues to form nanofibers (Figure 8). The nanofibers was shown to form 
interwoven matrices that further form hydrogel with very high water content, >99.5% 
(Figure 8).  
The hydrogel matrix formed by the peptide nanofibers was shown to be a good 
biological material for cell cultures in 3D environment [94]. Thus, providing the first 
de-novo designed scaffolds for three-dimensional cell culture, with potential 
implications for basic studies of cell growth, applied studies in tissue engineering and, 
ultimately, regenerative medicine.   
 
 
Figure 8. The self-assembly process of ionic self-complementary peptide which is <5 nm in size, with 
an alternating polar and nonpolar pattern. The peptides form stable β-strand and β-sheet structures; thus, 
the side chains partition into two sides, one polar and the other nonpolar. They undergo self-assembly to 
form nanofibers with the nonpolar residues inside (green), and + (blue) and – (red) charged residues form 
complementary ionic interactions, like a checkerboard. These nanofibers form interwoven matrices that 
further form a scaffold hydrogel with very high water content, >99.5%. Reproduced from [20], with 
permission from Nature Publishing Group. 
 
For detailed examples of de novo designed nanoscale bioassemblies based on self 
assembly of peptides and proteins, we will refer the readers to the review by Zhang and 
co-workers [20]. 
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Power of symmetry in design of nanoscale bioassemblies 
Yeates and co-workers work 
The use of symmetry as a powerful tool for building large regular objects was 
considered in detail by Yeates and co-workers [95].  Yeates and co-workers described a 
general strategy for designing proteins that self-assemble into large symmetrical 
nanomaterials, including protein cages, filaments, layers and porous materials. In this 
strategy one molecule of protein A, which naturally forms a self-assembling oligomer 
(m), is fused rigidly to one molecule of protein B, which forms another self-assembling 
oligomer (n). The result is a fusion protein, A-B, which self assembles with other 
identical copies of itself into a designed nanohedral particle or material (Figure 9, A). 
What kind of assembly will result depends on the geometric relationship between the 
oligomeric components once they are fused.  
To join the two oligomeric proteins in a relatively rigid fashion, Yates and co-
workers introduced the following method. They first of all choose the oligomeric 
domains whose three-dimensional structures are known and which begin or end in α-
helices. Then the two oligomeric domains were fused by genetically engineering a 
connecting segment that strongly prefers the α-helical conformation. By doing so, they 
ensured that the continuous α-helix extending from one oligomerization domain into 
another provides the rigidity and directionality and also the required geometric 
relationship between the two oligomeric domains (Figure 9, B). They also presented 
‘construction rules’ for creating symmetric nanomaterials from dimeric and trimeric 
oligomerization domains (for details refer to [95]). 
However, Yeates and co-workers design was largely restricted to protein oligomers 
with highly specific geometrical requirements, i.e. one helix of one oligomer has to be 
extended into the other oligomer in a unique angle. Only a few such combinations of 
given protein oligomers are suitable for proper nanoparticle formation using their 
design principles. 
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Figure 9. A general strategy for creating various regular protein assemblies by genetically fusing two 
naturally oligomeric proteins. (A) a dimeric protein (green) is fused to a trimeric protein (red) in an 
arrangement controlled by an α-helical linker (blue). 2 and 3 represent the 2-fold and 3-fold rotation axis. 
Different choices of dimeric and trimeric proteins, combined with varied helical linker lengths, lead to 
different geometries of the symmetry axes (arrows) carried by the component oligomerization domains. 
Depending on the geometry of the symmetry axes, different fusion proteins self-assemble into different 
regular complexes. A tetrahedral shaped protein cage and a two-dimensional hexagonal layer are 
illustrated. (B) A ribbon diagram of a fusion protein showing one method for joining two oligomerization 
domains (red and green) in a relatively rigid fashion. α-helical linker region which extend from one 
oligomeric domain to another is highlighted in blue. (C) A molecular model and experimentally observed 
EM picture of tetrahedral shaped protein cage are shown. Reproduced from [95, 96], with permission from 
Elsevier and Copyright (2001) National Academy of Sciences, U.S.A.                
Our Design  
Virus capsid and capsid like protein cages are finding variety of applications in the 
field of nanomedicine as we have seen before in the introduction. Here, we describe 
that it is possible to imitate virus capsid to design de novo protein or peptide that is able 
to self-assemble into icosahedral (or dodecahedral) shell structures. Our design strategy 
is more novel and flexible when compared to the work of Yeates and co-workers [95].  
C
A 
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Design principle 
 Remarkably, many small viruses are composed of a single polypeptide chain 
assembling into a capsid structure with icosahedral symmetry. A T=1 icosahedron is 
built of 60 identical protein subunits (asymmetric units) and is the largest closed shell 
in which every subunit is in an equivalent environment. It is characterized by 2-fold, 3-
fold and 5-fold rotational symmetry axes (Figure 10, A). By superposition of different 
protein oligomerization domains onto the corresponding symmetry axes of the 
icosahedron and by applying the symmetry elements, a nanoparticle with icosahedral 
symmetry can be designed (Figure 10, B and C).   
Design strategy 
Peter Burkhard [97] describes our design strategy with the following words 
“Monomer of peptidic oligomerization domain D1, which is a synthetic or natural 
peptide having a tendency to form oligomers of m subunits D1, (D1)m, is linked by a 
linker (L) to the monomer of peptidic oligomerization domain D2, which is a another 
synthetic or natural peptide having a tendency to form oligomers of n subunits D2, 
(D2)n. The result is a continuous peptide chain (D1-L-D2). The linker (L) is usually two 
glycine residues (GG) to provide the flexibility between the two domains.  
The continuous peptide chain based on the oligomeric state of D1 and D2, is 
superpositioned onto the corresponding symmetry axes of the icosahedron (Figure 10, 
B). By applying the symmetry elements along the 5-fold, 3-fold and 2-fold rotational 
axes of the icosahedron, the peptide chain (D1-L-D2) self assembles with other 
identical copies of itself into a designed icosahedral shaped nanoparticle (Figure 10, 
C)”.    
Preferred oligomerization domains in our design  
In our designs, we used the well studied protein oligomerization motif ‘α-helical 
coiled-coils’ [98], as the peptidic oligomerization domains (for details on design and 
results refer to chapter 1 of this thesis). Also, by using molecular modeling and 
simulation programs, we designed coiled-coil oligomerization domains in combination 
with other well studied oligomerization domains such as foldon domain of T4 phage 
fibritin protein [99] (for details on design and results refer to chapter 3 of this thesis). 
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Figure 10. Design of peptide based icosahedral nanoparticles. (A) A simple T=1 icosahedron of virus 
capsid with highlighted rotational symmetry elements 5-fold, 3-fold and 2-fold. On the right side, the three 
symmetry axes (5-fold, 3-fold and 2-fold) are drawn by extending from the centre of the icosahedron. (B) 
A pentameric oligomerization domain (green) and trimeric oligomerization domain (blue) joined by a linker 
(turquoise) is superpositioned onto the corresponding symmetry axes of the icosahedron. (C) Applying the 
symmetry elements of the icosahedron to the peptide chain of figure B generates an artificial nanoparticle 
with icosahedral symmetry. The diameter of the designed particle is calculated to be 17 nm.      
  Coiled-coils an introduction:  
The α-helical coiled-coil structural motif mediates subunit oligomerization of a large 
number of proteins [100]. Predictions based on primary sequence analyses suggest that 
roughly 2-3% of all protein residues form coiled-coils [101]. 
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Yu, YB [102] describes the characteristic features of coiled-coils as follows: 
“Coiled-coils consist of two to five amphipathic right-handed α-helices that twist 
around one another to form a left-handed supercoil. Sequences of parallel left-handed 
coiled-coils are characterized by a 7-residue periodicity ("heptad" repeat) and it is 
conventionally denoted as a-b-c-d-e-f-g. Positions a and d are often occupied by 
hydrophobic residues and positions e and g are often occupied by charged residues. 
Such distribution of amino acid residues makes the helices amphipathic with residues a 
and d forming the inter-helical hydrophobic core and the residues at e and g forming 
inter-helical ionic interactions”. For example, the arrangement of residues in parallel 
left-handed dimeric coiled-coil is illustrated by the helical-wheel diagram, as shown in 
Figure 11. 
 
 
 
 
 
 
 
 
 
Figure 11. Helical-wheel diagram of a parallel left-handed dimeric coiled-coil, showing the helical 
cross section. The seven positions in each heptad are labeled a-b-c-d-e-f-g. The core hydrophobic 
interactions and the ionic interactions between the two helices are highlighted. Reproduced from [102], 
with permission from Elsevier.      
 
Stability of coiled-coils is mainly achieved by a distinctive ‘knobs-into-holes’ 
packing of the hydrophobic side chains into a hydrophobic core, which was first 
postulated by Crick [103].  However, sometimes even relatively long polypeptides 
derived from stable coiled-coil domains fail to associate into coiled-coils. In this 
context, it has been shown that distinct coiled-coil ‘trigger sites’ within heptad repeat 
containing amino acid sequences might be necessary to mediate coiled-coil formation 
[104, 105]. 
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As a hallmark, the coiled-coil trigger site of the actin-bundling protein cortexillin I 
contains a distinct inter- and intra-helical salt bridge pattern, which includes charged 
residues even at core positions [106].Other results also suggest that the ionic 
interactions contribute considerably to stability of coiled coils [107-109], thereby 
modulating assembly of coiled coils in a pH-dependent manner [110, 111].  
Why coiled-coils in our design:  
? The symmetry elements of virus capsid (5-fold, 3-fold and 2-fold) can be 
found in coiled-coils as it exists as a dimer, trimer, tetramer and pentamer. 
Some of the best studied examples are the GCN4 leucine zipper [112], 
fibritin [99], tetrabrachion [113] and Cartilage Oligomeric Matrix Protein 
(COMP) [114], representing dimeric, trimeric, tetrameric and penatmeric 
coiled-coils, respectively.  
? Design principles of coiled-coils are well studied and understood [115]. 
? Moreover, based on the work done in our laboratory regarding coiled-coils 
design and analysis. Peter Burkhard summarizes the work done in our lab 
regarding coiled-coils with the following words “in our lab starting from the 
structure determination of the coiled-coil trigger site of cortexillin [106] and 
of intermediate filaments [116], and other coiled-coil proteins [117, 118] 
including the analysis of coiled-coil geometries and interactions [119], we 
have gradually improved our protein de novo design of coiled-coils. Minimal 
protein oligomerization domains based on coiled-coils as building blocks 
have been optimized using a combination of structural biology, biophysics 
and computational approaches [108, 120]. Based on the knowledge obtained 
from these studies we have progressed into the design of peptide 
nanoparticles of smaller in sizes [109]”.      
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Possible applications of our design in the field of nanomedicine 
Peptide based nanoparticles as multifunctional bionanoparticles (BNPs) 
Peter Burkhard describes the promising applications of our peptide based 
nanoparticles as follows: “Peptide nanoparticles can be functionalized in several ways 
(Figure 12):  (1) At either end (N- or C-
terminus) the peptide chain can be extended 
with peptide sequences of a particular 
function like targeting peptides, cell 
penetrating peptides, nuclear localization 
sequences or epitopes from a pathogen. 
Furthermore, specific dyes, chelators (for 
binding of radionuclides), or drugs can 
covalently be attached to the peptide. The 
high density of ligands or dyes will 
significantly increase the avidity for the 
specific receptor or the signal-to-noise ratio in 
imaging applications. (2) The central cavity of 
the nanoparticle with a calculated diameter of 
about 6 nm is ideally suited for the 
encapsulation of quantum dots. For example, 
SeCd nanocrystals can be used as highly efficient fluorescence probes, gold 
nanoparticles as contrasting agents for electron microscopy and iron nanoparticles as 
probes for NMR imaging. (3) The cavity of the pentameric coiled-coil domain allows to 
incorporate small hydrophobic molecules like Vitamin D or Vitamin B12 [121].  
(4) Finally, the trimeric coiled-coil can be modified to allow binding of nucleic acids 
(like the trimeric coiled-coil of the macrophage scavenger receptor) and ultimately a 
gene delivery system can be engineered. By co-assembly of peptide chains with 
different modifications multifunctional nanoparticles can be engineered for a wide 
variety of medical applications”. 
 
Figure 12. Schematic diagram of the 
peptide nanoparticles with possible 
modification sites. The blue and green 
represents the trimeric and pentameric 
coiled-coil domain, respectively. 
Explanations for the specified numbers 
refer to text.    
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In particular, peptide nanoparticles can be used as repetitive antigen display  
platform for synthetic vaccine design. The geometry of the nanoparticles and their 
resemblance to small virus capsids will trigger a strong immune response - a concept 
that is now increasingly exploited for producing novel vaccines that yield high titers of 
specific antibodies [46].  
Our peptide nanoparticles eliminate the need for virus-based designs, and allow for 
high flexibility in vaccine design. Epitopes of any pathogen can readily be engineered 
onto the surface of the nanoparticle, thus allowing for the easy generation of a whole 
variety of different vaccines. Especially, enveloped viruses (e.g. HIV, influenza, Ebola, 
SARS, etc.) represent an ideal target as their surface proteins are characterized by 
trimeric coiled-coil proteins, which are also building blocks of our nanoparticles. 
Therefore, by simply extending the trimeric coiled-coil domain of peptide nanoparticles 
with the virus specific trimeric coiled-coil, an ideal repetitive antigen display system 
against enveloped viruses can be developed.  
In essence the characteristic features of our system can be summarized as follows: 
? Ease of handling in terms of protein expression (E.coli), protein purification 
and storage, hence leading to low production costs (for details on recombinant 
production of peptide nanoparticles refer to chapter 2A of this thesis).   
? Biocompatible and biodegradable, as our system is made up of peptide as the 
building blocks. 
? Our system because of its repetitive nature can be used as a ‘repetitive antigen 
display system’ alternative to virus like particles (VLPs). Specifically, a non-
viral based carrier system (for details on design and results refer to chapter 2B 
of this thesis). 
? As a carrier for presenting epitopes, our system represents an ideal candidate 
for the presentation of trimeric coiled-coil B-cell epitopes, which might 
prove to be an efficient vaccination strategy against enveloped viruses. 
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lquent degradation of the hydrophobic core [7]. Preparation of
such nanocapsules is complex and may be ineffective. Also,
polymeric beads, though mechanically more stable with a
larger loading capacity than liposomes, lack many of the
useful surface properties of a lipid bilayer shell. Furthermore,
they do not biodegrade easily and hence may be toxic.
Here we present the structure-based design of mechani-
cally and chemically stable nanoparticles, using the ability of
peptides and proteins to self-assemble into particles of well-
defined size and shape. Once assembled these peptide nano-
particles can serve as vehicles for drug targeting. Currently
used drug targeting systems include, for example, antibodies
that deliver radioactive isotopes to proliferating blood vessels
[8] and peptides that target tumor blood vessels [9].
Alternatively, peptide nanoparticles can be used as repeti-
tive antigen display systems for the development of vaccines.
During the past decade several immunogenic vaccination
strategies have been identified [10-14]. However, at this point
vaccines for many pathogens worldwide, including malaria
(Plasmodium falciparum) [15],Mycobacterium tuberculosis
[16], group A streptococci [17], hepatitis viruses [11], herpes-
viruses [18], human immunodeficiency virus (HIV) [10,12],
and influenza [19], are still ineffective or simply unavailable.iology, and Medicine 2 (2006) 95–102
Fig 1. Basic concepts of the design. A, Possible regular polyhedra built
from two-, three-, and five-fold symmetry elements. The symmetry
elements are denoted as black symbols. The dodecahedron and the
icosahedron have the same internal symmetry elements and are built from
60 identical 3-dimensional building blocks (asymmetric units). B,
Architecture of the monomeric building block for self-assembly into
regular polyhedra. The building block is composed of an oligomerization
domain 1, a linker domain, and a second oligomerization domain. C, Even
units consisting of trimers and pentamers. The number of monomers
(building blocks) is defined by the least common multiple (LCM) of the
oligomerization states of the two domains 1 and 2 of the building blocks.
Table 1
Possible combinations of oligomerization states
ID Domain
1
Domain
2
Polyhedron type LCM No. of
even units
No of
asymmetric
units
1 5 2 Dodecahedron/
icosahedron
10 6 60
2 5 3 Dodecahedron/
icosahedron
15 4 60
3 4 3 Cube/
octahedron
12 2 24
4 3 4 Cube/
octahedron
12 2 24
5 3 5 Dodecahedron/
icosahedron
15 4 60
6 2 5 Dodecahedron/
icosahedron
10 6 60
7a4 5 4 Irregular 20 1 20
7b* 4 5 Irregular 20 1 20
4 The entries 7a and 7b do not correspond to regular polyhedra but
represent the largest even units that may be formed with oligomerization
states ranging from 2 to 5.
S. Raman et al. / Nanomedicine: Nanotechnology, Biology, and Medicine 2 (2006) 95–10296Because of the broad range of humoral and cellular im-
mune responses they elicit as well as the memory responses
they induce, live attenuated vaccines are still the vaccines of
choice [10-14]. From a practical point of view, however, live
attenuated vaccines raise issues related to manufacturing and
safety that may preclude their widespread use [10-14]. As an
alternative, peptide-based vaccines have been developed and
used for vaccination. However, synthetic peptides alone are
often not immunogenic enough, and a strong immunoadjuvant
is usually included to enhance their immunogenicity. There
remain concerns, however, about toxic adjuvants, which are
critical to the immunogenicity of synthetic peptides [20-22].
Because their architecture is similar to that of virus
capsids, the peptide nanoparticles described here combine
the strong immunogenic effect of live attenuated vaccines
with the purity and high specificity in eliciting immune
responses of peptide-based vaccines, while avoiding both
the safety risks of live attenuated vaccines and the need for
toxic adjuvants of peptide-based vaccines.Methods
Peptide synthesis
The peptide was synthesized by Peptide Specialities
(Heidelberg, Germany). Its purity (N95%) was verified by
high-performance liquid chromatography and mass spectro-
metric analyses.
Refolding of the peptide
The peptide folding procedure was carried out under four
different regimes.
Preparation 1 (oxidizing conditions)
1 mg/mL peptide was dissolved directly in 150 mM
NaCl, 20 mM Tris pH 7.5.
Preparation 2 (reducing conditions)
1 mg/mL peptide was dissolved directly in 150 mM
NaCl, 20 mM Tris pH 7.5, 2 mM dithiothreitol (DTT).
Preparation 3 (denaturation, renaturation under oxidizing
conditions)
0.07 mg/mL peptide was dissolved in 150 mM NaCl,
20 mM Tris pH 7.5, 2 mM DTT, 8 M urea. The solution was
then dialyzed in steps from 150 mM NaCl, 20 mM Tris,
pH 7.5; 8 M urea/4 M urea/2 M urea/no urea. Finally, the
solution was concentrated to 1 mg/mL in 150 mM NaCl,
20 mM Tris pH 7.5.
Preparation 4 (denaturation, renaturation under reducing
conditions)
0.07 mg/mL peptide was dissolved in 150 mM NaCl,
20 mM Tris pH 7.5, 8 M urea, 2 mM DTT. The solution was
then dialyzed in steps from 150 mM NaCl, 20 mM Tris
pH 7.5, 8 M urea and 2 mM DTT/4 M urea and 2 mM DTT/
2 M urea and 2 mM DTT/no urea and 2 mM DTT/no urea
Fig 2. Internal symmetry elements of the dodecahedron. A, A 3D building block composed of domain 1 (blue; coiled coil domain with three-fold symmetry), a
linker segment (cyan), and domain 2 (green; coiled coil domain with five-fold symmetry) is displayed such that the internal symmetry elements of the domains
1 and 2 are superimposed onto the symmetry axes of the polyhedron. The intrahelical disulfide bridge between the helices is displayed in red. B, The complete
coiled coil domains are displayed as cylinders. The additional symmetry objects generated by the three-fold and the five-fold rotational symmetry elements of
the polyhedron are displayed in light colors, whereas the original molecule is displayed in dark colors. The rotational symmetry axes (two-fold, three-fold, and
five-fold) are displayed as red lines in A and B.
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1 mg/mL in 150 mM NaCl, 20 mM Tris pH 7.5.
Analytical ultracentrifugation
Analytical ultracentrifugation (AUC) was carried out on
an Optima XL-A analytical ultracentrifuge (Beckman
Instruments, Palo Alto, CA) equipped with a 12-mm Epon
double-sector cell in an An-60 Ti rotor. Sedimentation
equilibrium runs were performed at 208C at rotor speeds
between 5200 and 15,000 rpm and peptide concentrations of
0.15 to 1.0 mg/mL. Average molecular masses were
evaluated by using a floating baseline computer program
that adjusts the baseline absorbance to obtain the best linear
fit of ln(absorbance) versus the square of the radial distance.
A partial specific volume of 0.73 mL/g was used.
Electron microscopy
Specimens were prepared for electron microscopy (EM)
by negative staining with 2% uranyl acetate and at a peptide
concentration of 0.01 mg/mL. They were analyzed and
photographed on a Zeiss EM910 transmission electron
microscope (Carl Zeiss, Oberkochen, Germany).Results
Design principles
There exist only five regular polyhedra: the tetrahedron,
the cube, the octahedron, the dodecahedron, and the
icosahedron. These polyhedra show different internal
rotational symmetry elements; for example the dodecahe-
dron and the icosahedron have two-fold, three-fold, andfive-fold rotational symmetry axes (Figure 1, A). The cube
and the octahedron are built up from 24 asymmetric units,
whereas the dodecahedron and icosahedron are built up
from 60 asymmetric units, thus generating the largest closed
shell in which every subunit is in an identical environment
[23] (Table 1). These asymmetric units are tri-pyramids, and
each of the pyramid edges corresponds to one of the
rotational symmetry axes; hence the edges of these
asymmetric units represent two-fold, three-fold, four-fold,
or five-fold symmetry axes depending on the type of
polyhedron. If the symmetry axes of peptidic oligomeriza-
tion domains are superpositioned onto the edges of these tri-
pyramids, such 3-dimensional building blocks can be built
up from peptidic oligomerization domains (Figure 2, A and
B). As a consequence, it may be possible to design a peptide
nanoparticle with regular polyhedral symmetry by connect-
ing peptidic oligomerization domains with different oligo-
merization states. Hence, to construct a nanoparticle as a
regular dodecahedron, a continuous peptide chain compris-
ing a trimerization domain, a short linker sequence, and a
pentamerization domain is needed (Figures 1, B and 2, A).
Such a continuous peptide chain will be the basic building
block of the nanoparticle, the content of one asymmetric
unit. A similar approach using dimeric and trimeric proteins
joined in a specific angle by means of a rigid a-helical
linker between the two building blocks has been presented
by Padilla et al. [24].
Protein oligomerization domains are well known; the
most simple and most abundant oligomerization domain is
probably the coiled coil folding motif [25,26]. This
oligomerization motif has been shown to exist as a dimer,
trimer, tetramer, and pentamer. Some of the best-known
Fig 3. Electron micrographs of the peptide nanoparticles. A, The peptide nanoparticles formed under oxidizing conditions (preparation 1). B, The peptide
nanoparticles formed under reducing conditions (preparation 2). C, The peptide nanoparticles formed under oxidizing conditions after denaturation (preparation
3). D, The peptide nanoparticles formed under reducing conditions after denaturation (preparation 4). The pictures were prepared by negative staining with 2%
uranyl acetate; the concentration of the peptide was 0.01 mg/mL. In B the average diameter of the particles is roughly 25 nm. In C and D the average diameter
of the particles is roughly 16 nm.
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tetrabrachion [29], and cartilage oligomerization matrix
protein (COMP) [30], representing dimeric, trimeric, tetra-
meric, and pentameric coiled coils, respectively. Other
simple oligomerization motifs are also known, such as the
trimerization domain (the so-called foldon) of fibritin [28].
If these monomeric building blocks consisting of a
continuous peptide chain composed of two linked oligomer-
ization domains with different oligomerization states assem-
ble, they will first form beven unitsQ (Figure 1, C). The
number of monomers that will assemble into such an even
unit is defined by the least common multiple (LCM) of their
oligomerization states. Hence if the oligomerization domains
of the monomeric building block consist of a trimer and a
pentamer, 15 monomers will form an even unit. The
geometry of these even units, however, may not be regular.
Several of these even units may then further assemble into
larger nanoparticles (cf. Table 1). For example, to form a
dodecahedron four even units composed of 15 monomeric
building blocks each are needed; that is, the nanoparticle
with regular geometry will be composed of 60 monomeric
building blocks (see Figure 4, A). The possible combinations
of oligomerization states of the two domains to form any of
the regular polyhedra are shown in Table 1.Whether the even units will assemble additionally to
form a regular polyhedron depends on (1) the interactions at
the interface between neighboring oligomerization domains
within a nanoparticle, (2) the length of the linker segment,
and (3) the shape of the individual oligomerization domains.
Optimizing the interactions at the interface between
neighboring domains can significantly improve the packing
and stability of the regular polyhedron. Such improvements
can be achieved by optimizing the hydrophobic and the
ionic interactions between the interacting oligomerization
domains or by their chemical cross-linking, for example by
introducing cysteine residues so that a disulfide bridge is
formed between two interacting oligomerization domains
(cf. Figure 2, A). The linker domain should be long enough
to avoid disruption of the protein fold of the oligomerization
domains but short enough to maintain close contact between
the two oligomerization domains.Self-assembly of nanoparticles
According to the principles outlined above [31] we
have rationally designed a peptide nanoparticle com-
posed of a monomeric building block with the following
sequence:
Fig 4. Stereo picture of a computer model of the complete peptide nanoparticle with dodecahedral symmetry. A, The particles are composed from the
pentameric coiled coil domain of COMP (green) and a trimeric de novo designed coiled coil domain (blue). The calculated diameter of this particle is about
16 nm. B, The same nanoparticle as in A but wherein the trimeric coiled coils are further extended by the coiled coil sequence of the HIV surface protein gp41
(red). This portion of the gp41 protein is ideally displayed in many copies on the surface of the nanoparticle to be recognized by an antibody (cyan), thus
eliciting a strong immune response.
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correspond to the slightly modified pentameric coiled coil
domain of COMP [30]. The 26 C-terminal amino acids (blue)
correspond to a de novo-designed minimal trimeric coiled
coil domain according to the principles as outlined by
Burkhard et al. [32-34]. These two oligomerization domains
with different oligomerization states are joined by a linker
segment consisting of two glycine residues (black). Accord-
ing to model building three of the four C-terminal residues of
COMP have been modified to optimize interhelical contacts
between the two oligomerization domains including an intra-
molecular disulfide bridge. The cysteine residues in position
33 and 42 are optimally placed for such an intramolecular
disulfide bridge between the helices. They are at f positions in
the heptad repeats of the respective coiled coils and one turn
away from the respective helix ends (cf. Figure 2, A) and may
form a disulfide bridge without disturbing the coiled coilgeometry of the two oligomerization domains. Finally, the
positively charged N-terminal amino group is replaced by an
acetyl moiety and the negatively chargedC-terminal carboxyl
group is replaced by an amide group to avoid destabilization
of the helices due to their helix-macrodipole [33].
Because of the complexities of folding of a protein
containing intramolecular disulfide bridges, four different
refolding conditions were tested for their assembly into
polyhedral nanoparticles (for details see Methods). In a first
regime (preparation 1) the assembly process of the peptide
at a relatively high concentration was performed under
oxidizing conditions, allowing for disulfide bridge forma-
tion. To test whether the intramolecular disulfide bridge is
needed for proper self-assembly of the peptide into particles
with regular dodecahedral symmetry, the peptide, again at
relatively high concentration, was assembled under reducing
conditions (preparation 2).
able 2
olecular masses of nanoparticles
Concentration
(mg/mL)
MW (kDa) No. of
monomers
No. of
even units
reparation 3 0.15 347 43.9 2.9
0.3 356 45.1 3.0
0.4 461 58.4 3.9
0.6 437 55.3 3.7
0.8 489 61.9 4.1
reparation 4 0.15 633 80.1 5.3
0.25 718 90.9 6.1
0.8 960 121.5 8.1
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molecular disulfide bridge formation and consequently to
aggregation, we tested two other refolding regimes. The
peptide concentration was reduced to minimize intermolec-
ular contacts, and then the peptide was completely denatured
in 8 M urea. Then the refolding process was started by a
stepwise dialysis of the urea under either oxidizing
(preparation 3) or reducing (preparation 4) conditions. In a
final step of preparation 4 the disulfide bridges were allowed
to form by changing to oxidizing conditions.
The assembly behavior of the nanoparticles under these
four regimes was analyzed by AUC to determine the
molecular weight of the aggregates. Furthermore, the
morphology of the aggregates was investigated by EM.
In preparation 1 (1 mg/mL) AUC revealed a mixture of
components with molecular weights ranging from about
380 to 2200 kDa corresponding to aggregates of 48 to
280 monomers. Accordingly, electron micrographs showed
that the peptides do not form spherical nanoparticles but
instead form elongated irregular aggregates (Figure 3, A).
AUC of preparation 2 (1 mg/mL) revealed again a
mixture of components with molecular masses ranging from
about 130 to 330 kDa. This corresponds to nanoparticles
composed of about 16 to 42 monomers. The lowest
molecular mass components roughly correspond to even
units (cf. Figure 1, C), which are composed of 15 peptide
chains. In contrast to preparation 1, under reducing
conditions the peptides do form nanoparticles as shown by
EM (Figure 3, B). The size of these nanoparticles is
variable, however, with diameters ranging from about 15
to 45 nm, but they are not always completely spherical.
The refolding processes starting at lower peptide concen-
trations and complete denaturation of the peptide gave much
more homogeneous results. The measured molecular mass of
the particles from preparation 3 was only slightly concen-
tration dependent (Table 2). At lower final peptide concen-
trations the nanoparticles are composed of three even units,
whereas at higher final peptide concentrations they are
composed of four even units. The latter is in agreement with
nanoparticles with regular dodecahedral symmetry being
composed of four even units or 60 monomeric peptide
chains, respectively (Table 1). As judged by EM the peptide
forms nanoparticles of roughly homogeneous size and
spherical appearance (Figure 3, C). The diameter of these
nanoparticles is about 16 nm, in good agreement with the
value predicted for a modeled regular dodecahedron.
By AUC the measured molecular mass of the particles
from preparation 4 is again concentration dependent
(Table 2). Their sizes range from particles composed of
80 to as many as about 121 peptide chains. Again, the
peptides form nanoparticles of nearly identical size with
mostly spherical appearance (Figure 3, D). The diameter of
the peptide nanoparticles is very similar to that of the
particles from preparation 3. These micrographs were taken
for samples assembled at low peptide concentrations,
conditions under which their molecular mass was shownT
M
P
Pto be close to that of particles with regular dodecahedral
symmetry (Table 2).Discussion
The peptide sequence outlined above was rationally
designed so as to form nanoparticles showing regular
polyhedral symmetry, that is, consisting of 60 monomeric
building blocks (see Figure 4, A). Computer modeling
predicted that such a particle would have a diameter of
about 16 nm and a molecular mass of 473 kDa,
corresponding to a particle composed of 60 monomeric
peptide chains (see Table 2). The appropriate folding
regime was crucial to obtain a homogeneous population
of nanoparticles with regular polyhedral symmetry. This
can be rationalized by the different possibilities of disulfide
formation during the refolding process. In high peptide
concentrations the peptide chains may easily form inter-
molecular disulfide bridges leading to irregular aggregates
(cf. Figure 3, A). Such a behavior was observed in the
refolding procedure of preparation 1: EM revealed elon-
gated aggregates devoid of any regular structure. The
oligomerization properties of the peptide made of two
distinct oligomerization domains joined by a linker
segment, when combined with the formation of intermo-
lecular disulfide bridges between different peptide chains,
leads to a network of peptides, which are cross-linked
either by oligomerization of the coiled coil domains or by
intermolecular disulfide bridges.
Therefore, it is crucial to avoid intermolecular disulfide
bridge formation during refolding. Keeping the system under
reducing conditions in the refolding process (preparation 2)
leads to the formation of spherical nanoparticles. However,
by EM the nanoparticles are not of unique appearance, either
in shape or in size (Figure 3, B). This result is in agreement
with those obtained by AUC, showing that under these
conditions the peptide can form particles of different sizes.
The measured molecular mass represents a distribution of
particles of various sizes. The smaller particles in Figure 3, B
presumably correspond to even units composed of 15
monomers (roughly corresponding to the smallest measured
molecular mass; cf. Table 2), whereas the larger particles are
multiples thereof.When the intramolecular disulfide bridge is
missing, the peptide does form spherical nanoparticles but not
with regular dodecahedral symmetry. This documents the
S. Raman et al. / Nanomedicine: Nanotechnology, Biology, and Medicine 2 (2006) 95–102 101importance of the intramolecular disulfide bridge for proper
formation of nanoparticles with regular symmetry.
The aim was to avoid intermolecular disulfide bridge
formation while allowing for intramolecular disulfide bridge
formation. The coiled coil domains of COMP and of the de
novo-designed trimer are known to form very stable
oligomers [34,35]. During refolding out of 8 M urea these
coiled coil domains will already form in urea concentrations
that are moderately high. Formation of the helices within the
two coiled coil domains will bring the two cysteines of the
same peptide chain into close contact (cf. Figure 2, A).
Furthermore, they will be located close to the center of the
even units and/or the regular dodecahedral particles; hence
they are shielded from the solvent and no longer accessible
for intermolecular contacts. Under oxidizing conditions
(preparation 3) intramolecular disulfide bridge formation
will then immediately and predominantly occur while
avoiding intermolecular cross-linking. However, also under
reducing conditions (preparation 4) the cysteine residues
cannot form intermolecular disulfide bridges and the intra-
molecular disulfide bridge will be formed only when
changing to oxidizing conditions in a final step, that is, when
the cysteine residues are already shielded from the solvent.
The intramolecular disulfide bridge between the two
helices of adjacent oligomers fixes the spatial orientation of
the two helices relative to each other. In agreement with our
design, this disulfide bridge proves to be a prerequisite for
the effective formation of nanoparticles with regular
dodecahedral symmetry.Conclusions
Such nanoparticles with regular polyhedral symmetry
represent an ideal repetitive antigen display system. Surface
proteins of pathogens or fragments of such proteins can
easily be engineered into the peptide sequence of the
nanoparticle. Notably, many surface proteins of pathogens
contain coiled coil sequences. For example, by simply
extending the trimeric coiled coil of the nanoparticle by the
coiled coil sequence of the HIV surface protein gp41, a HIV
vaccine candidates can be designed (Figure 4, B). The
predicted strong immune response against such a vaccine can
be rationalized by the optimal binding geometry of an IgG
molecule to the nanoparticle (cf. Figure 4, B). Whereas in the
past, different kinds of adjuvants were tested to improve the
immunogenicity of an antigen or a specific epitope, such a
repetitive antigen display can strongly augment the immu-
nogenicity of a certain epitope [36], thus avoiding the need
for sometimes highly toxic adjuvants [37]. We have designed
peptide nanoparticles aimed at eliciting a strong immune
response, and our preliminary immunization results confirm
the correctness of this hypothesis.References
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Chapter 2 
 
• Chapter 2 is divided in to Chapter 2A and 2B. Chapter 2A 
deals with “Recombinant production of peptide based 
nanoparticles and their biophysical characterization” 
• Chapter 2B deals with the application part of recombinantly 
produced peptide based nanoparticles as a “Vaccine carrier”. 
• Chapter 2 is written in the following order: first comes the 
‘design principle and results section of chapter 2A and 2B’ 
followed by the ‘Discussion section of chapter 2A and 2B’ and 
finally the ‘Materials and Methods section’ for both the 
chapters.  
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Design principles 
In Chapter 1, we showed that we can prepare nanoparticles by using peptides as 
building blocks. The monomeric chain of the peptide sequence which formed the basic 
building blocks is depicted in Figure 1, A, as synthetic peptide (sp). The purpose 
behind our preparation of peptide based nanoparticles is to use them as carriers in 
vaccination and drug targeting. To prepare the nanoparticles for their application 
studies, the monomeric chains of sp sequence have to be produced in reasonable 
quantities. 
Chemical synthesis of peptide sequence is a costly and troublesome process. 
Therefore, we decided to use the recombinant expression method for the production of 
sp sequence. We choose E.coli as the expression system, because of its ease of 
handling, modular nature, high expression levels and low production costs [1]. In a first 
step towards production, the sp sequence is inserted into the modified prokaryotic 
expression plasmid pPEP-T vector (mpPEP-T), resulting in np1 construct (for details 
regarding mpPEP-T vector refer to Materials & Methods section). In np1 sequence, 
amino acids 23 to 86 correspond to the peptide sequence sp. The extra 22 N-terminal 
amino acids, of vector origin, includes His-tag (brown), residues important for UV-
spectrometer based protein estimation (red), residue for chemical coupling (yellow) and 
thrombin recognition sequence (pink) (for sequence details of np1 construct, refer to 
Figure 1, A). A schematic model of monomeric chain of np1 construct is depicted in 
Figure 1, B. In this model, the intended intramolceular disulfide bridge at the interface 
between the two domains is indicated as a red line.  
In sp sequence, the formation of an intramolecular disulfide bridge between the two 
oligomerization domains is found to be crucial for the formation of nanoparticles with 
regular polyhedral symmetry (refer to Discussion section of Chapter 1). This stresses 
the importance of interactions at the interface between the two domains. We wanted to 
optimize the interactions between the two domains through intramolecular ionic 
interactions. For this reason, the np1 sequence is modified to include charged residues 
at the interface between two domains.  
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Figure 1. A, amino acid sequences of sp, np1 and np2 constructs. In sp, np1 and np2 constructs, the green colored residues represent the pentameric coiled-coil 
domain of COMP and the blue colored residues represent the de novo designed trimeric coiled-coil domain. In sp and np1 constructs, the cysteine residues intended for 
an intramolecular disulfide bridge at the interface between the two domains are highlighted in grey. In np2 construct, the modified residues for intramolecular ionic 
interactions at the interface between two domains are highlighted in grey. In np1 and np2 constructs, the underlined residues represent the 22 N-terminal residues of 
vector origin, which include 6X His-tag (brown), residues important for UV-spectrometer based estimation of protein (red), residue for chemical coupling (yellow) and 
thrombin recognition sequence (pink). The thrombin cleavage site is represented as a vertical line. The a and d positions of the heptad repeats of the pentameric and 
trimeric coiled coil domains are indicated. B, Schematic representation of monomeric chains of np1 and np2 constructs. In the np1 model, the red line depicts the 
intramolecular disulfide bridge; in the np2 model the + and - sign depicts the positive and negatively charged amino acids, respectively. C, Computer generated 
nanoparticle model of np1 and np2 constructs (17 nm in diameter).    
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The modified np1 sequence is called np2 construct (Figure 1, A; the modified 
residues are highlighted in grey). Similar to np1 construct, the first 22 N-terminal 
amino acids of np2 construct are of vector origin (for np2 sequence details refer to 
Figure 1, A). 
In np2 construct, the modification of charged residues was done at b, c, e, f and g 
positions of heptad repeats of the coiled-coil domains of COMP and trimer. Thus not 
affecting the hydrophobic interactions at a and d positions of the heptad repeat, which 
comprise one of the key factors for coiled-coil stability [2, 3]. A schematic model of the 
monomeric chain of np2 construct is depicted in Figure 1, B. In this model, the charged 
residues at the interface between the two domains is indicated as + and -, representing 
the positively and negatively charged amino acids. In Figure 2, computer designed 3D 
model of np2 nanoparticle is depicted, highlighting the charged residues at the interface 
between the pentameric coiled-coil domain of COMP (green helix) and the de novo 
designed trimeric coiled-coil domain (blue helix).  
 
 
 
 
 
 
 
 
 
Figure 2. Computer model of np2 nanoparticle (stereo). The monomeric unit of np2 nanoparticle is 
highlighted with an emphasis on the charged residues at the interface between the pentameric coiled-coil 
domain of COMP (green helix) and the trimeric coiled-coil domain (blue helix). The positively charged 
arginine (R) residues on COMP domain (green helix) and the negatively charged glutamic acid (E) 
residues on trimeric coiled-coil domain (blue helix) is indicated as stick models.        
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Results 
Purification results of np1 and np2 proteins 
The np1 and np2 constructs are expressed and purified along with their N-terminal 
amino acids of vector origin (underlined residues in Figure 1, A). Ni2+-affinity column 
chromatography is used as the method of purification. The purification is carried out 
under denaturing conditions using 8 M urea. (for expression and purification details 
refer to Materials and Methods section). The purification results of np1 and np2 
proteins are summarized in Figure 3. 
np1 protein 
The imidazole eluted fractions of np1 protein is observed to run as a lower and upper 
band which corresponds to a theoretically calculated monomer (10289.7 Daltons) and 
trimer (30869.1 Daltons) (Figure 3, A). Western blot analysis using anti His-tag 
antibody confirmed the presence of monomer and trimer species in the eluted fractions 
of np1 protein (Figure 4). The observed trimeric band in denaturing conditions of SDS-
PAGE suggests about the stability of the trimeric coiled-coil domain. 
np2 protein 
The np2 protein is observed to elute in small amounts during the pH 5.0 elution step 
(lane 4; Figure 3, B). But the majority of the eluted protein is observed in 250 mM 
imidazole elution fractions (lanes 5 to 8; Figure 3, B).  
The eluted fractions are observed to run as a single band which corresponds to a 
theoretically calculated monomer (10372.7 Daltons). However, the observed trimeric 
band in np1 purified samples (Figure 3, A) was absent in np2 purified samples (Figure 
3, B). This suggests about the less stable trimeric coiled-coil domain of np2 protein 
when compared to the trimeric coiled-coil domain of np1 protein.  
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Figure 3. 17% SDS-PAGE of np1 and np2 purified proteins. A, purification results of np1 protein. 1, 2 
and 3 represent 150 mM, 250 mM and 500 mM imidazole elution fractions, respectively. B, purification 
results of np2 protein. FT - Flow through; lane 1 - pH 8.0 wash fraction; lane 2 - pH 6.3 wash fraction; lane 
3 - pH 5.9 elution fraction; lane 4 - pH 5.0 elution fraction; lanes 5 to 8 - 250 mM imidazole elution 
fractions.  In both the gels, M - correspond to molecular weight marker, marked in kilo Daltons (kDa). 
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Figure 4. 15% Tricine SDS-
PAGE and the corresponding 
western blot of np1 elution fractions. 
Lanes 1 and 2 - 250 mM imidazole 
elution fractions of np1 samples. M -
Bio-Rad prestained marker; kDa -
kilo Daltons. 
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Self-assembly properties of np1 protein 
From our design principles, we know that np1 construct is the replica of sp peptide 
except for the first 22 N-terminal amino acids of vector origin (Figure 1, A). In chapter 
1, we showed that the sp peptide formed nanoparticles of regular icosahedral shape 
under two different refolding conditions. The first condition is preparation 3 
refolding, in which the peptide was refolded by step wise dialysis of the urea under 
oxidizing condition. The second condition is preparation 4 refolding, in which the 
peptide was refolded by step wise dialysis of the urea under reducing condition up to 0 
M urea and then to oxidizing condition. These refolding conditions favored the 
formation of intramolecular disulfide bridge in sp peptide, as we showed that in sp 
peptide the formation of intramolecular disulfide bridge is crucial for the formation of 
regular icosahedral shaped nanoparticles. Therefore, for refolding studies of np1 
protein, we decided to refold the protein under preparation 3 and preparation 4 
refolding conditions.  
The np1 protein refolded under the two different refolding conditions was 
characterized by the following techniques: 1. Electron Microscopy (EM) to characterize 
the morphology; 2. Analytical Ultra Centrifugation (AUC) to determine the molecular 
mass; 3. Circular Dichroism (CD) spectroscopy to study the secondary structural 
content and the stability of the nanoparticles.  
Biophysical Characterization 
Electron Microscopy (EM) results 
The preparation 3 refolded protein is observed to form mixed population of 
aggregates of not regular in shape and expected size nanoparticles of ~ 17 nm in 
diameter (Figure 5, A). A single nanoparticle and an irregular aggregate are highlighted 
as inset in Figure 5, A.  
The preparation 4 refolded protein (refolded in 1mM DTT) is observed under two 
different conditions in order to understand the influence of intramolecular disulfide 
bridge on np1 nanoparticle formation. 
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 In the first condition, the sample is observed in the refolding buffer (20 mM Tris pH 
7.5, 150 mM NaCl and 10% glycerol) containing 0 M urea and 1 mM DTT (reducing 
condition; not favoring intramolecular disulfide bridge formation).  
 
 
Figure 5. Electron micrographs of refolded np1 protein under different refolding conditions. A, 
preparation 3 refolded np1 protein (oxidizing condition). Inset: highlighting one single nanoparticle (pink) 
and an irregular aggregate (red) B, preparation 4 refolded np1 protein (reducing condition). Refolded up to 
0 M urea and analyzed in the buffer 20 mM Tris pH 7.5, 150 mM NaCl, 1 mM DTT and 10% glycerol. 
Inset: one single nanoparticle. C, same refolding condition as B, but the protein was dialyzed to remove 
DTT (oxidizing condition). Analyzed in the buffer 20 mM Tris pH 7.5, 150 mM NaCl and 10% glycerol. 
Inset: one single nanoparticle. D, Same condition as C, but the Tris buffer was exchanged with Hepes 
buffer (20 mM Hepes pH 7.5, 150 mM NaCl and 10% glycerol). Inset: one single nanoparticle. The 
pictures were prepared by negative staining with 2% uranyl acetate; the concentration of the protein was 
50 µg/ml.               
 
In the second condition, the sample is observed in the refolding buffer containing 0 
M urea and no DTT (oxidizing condition; favoring intramolecular disulfide bridge 
formation).  
A 
D
B
C 
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From the EM pictures, we observed nanoparticles of roughly homogenous size (~ 17 
nm in diameter) and spherical shape already in reducing condition (Figure 5, B). In 
addition, we observed that the nature of the nanoparticles (referring to its homogenous 
size and shape) in reducing condition is not altered after the removal of DTT (oxidizing 
condition) (Figure 5, C) followed by buffer exchange (Figure 5, D). In both, 
preparation 3 and 4 refolding conditions the diameter of the observed nanoparticles is 
about 17 nm, in good agreement with the value predicted for a computer modeled 
regular icosahedron (Figure 1, C).        
Analytical Ultra Centrifugation (AUC) results 
The nanoparticles observed under preparation 4 refolding (Figure 5, D) are studied 
with AUC to determine their molecular weight and distribution.  
Sedimentation equilibrium (SE) runs of preparation 4 sample gave us a molecular 
mass corresponding to icosahedral shaped nanoparticles (4 even units) + higher order 
aggregates at lower speed (5600 rpm) (Table 1, B). At higher speed sedimentation 
equilibrium runs (12000 rpm), the calculated molar mass is roughly corresponded to 
even units (Table 1, B). The observation of two different species during SE runs is well 
corroborated by the sedimentation velocity runs forming two different boundaries 
(bimodal boundary) over time (Figure 6), with the calculated sedimentation coefficient 
(s) values of 5.7 S and 19.4 S (Table 1, A).  
 
Figure 6. Sedimentation 
velocity (SV) data for a preparation 
4 refolded np1 sample (oxidizing 
condition). The concentration is 
shown versus radius distributions 
at different times (in seconds), 
after the start of the sedimentation 
at 44,000 rpm. The protein 
concentration was 0.56 mg/ml. 
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The calculated 5.7 S value represent approximate mass of an even unit (129 kDa) 
and the 19.4 S represent the polydisperse species containing icosahedral nanoparticles 
(~700 kDa) and higher order aggregates (~ 2 million Daltons). 
Table 1: AUC results for np1 protein - Monomer molecular weight 10289.7 Daltons. 
A. Sedimentation velocity results 
Refolding 
condition# 
Rotor speed 
(rpm) 
Concentration 
(mg/ml) 
Calculated Sedimentation 
velocity coefficient value 
(s20,w) 
0.1 5.7 S  + 19.4 S preparation 4 44000 
0.56 4.5 S + 17 S 
 
B. Sedimentation equilibrium results 
Refolding 
condition# 
Rotor speed 
(rpm) 
Concentration 
(mg/ml) 
Calculated 
MW (kDa) 
No. of 
monomers 
No. of even 
units 
0.1 766 + 2228 74.4 + 
216.5 
4.9 + 14.4 5600 
0.56 710 + 2376 69 + 230.9 4.6 + 15.3 
0.1 129 12.5 
 
 
preparation 4 
12000 
0.56 121 11.8 
~ 1 even unit 
 
 # - Analyzed in buffer 20 mM Hepes pH 7.5, 150 mM NaCl and 10% glycerol.  
Parameters studied to understand its influence on nanoparticle 
assembly property of np1 protein under preparation 4 refolding 
condition 
We wanted to understand the effect of ionic strength, pH of the refolding buffer, 
DTT concentration and glycerol on nanoparticle assembly property of np1 protein 
under preparation 4 refolding condition. The observed effect of these parameters on 
nanoparticle assembly is presented in the following sections. 
Ionic strength 
To understand the effect of ionic strength on nanoparticle assembly, the np1 protein 
is refolded in two different salt concentrations: (i) 0 M NaCl and (ii) in 500 mM NaCl. 
Refolding was done according to preparation 4 refolding and in refolding buffer 20 mM 
Tris pH 7.5, 10% glycerol containing 1 mM DTT. After refolding, samples were 
analyzed in buffer 20 mM Tris pH 7.5, 10% glycerol containing either 0 M or 500 mM 
NaCl (oxidizing condition).  
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From the EM picture, the np1 protein refolded in 0 M NaCl is observed to form flat 
looking nanoparticles (indicated by blue arrow) along with structures of not regular in 
shape (Figure 7, A). The AUC result for the above sample gave a molar mass 
corresponding approximately to a trimer and an even unit (Table 2). 
The np1 protein refolded in 500 mM NaCl is observed to form nanoparticles of 
expected size, 17 nm in diameter. However, the formed nanoparticles are observed to 
be mostly clumped together, with a few individual particles around them (Figure 7, B). 
 
Figure 7. EM pictures of preparation 4 refolded np1 protein in 0 M and 500 mM NaCl. A, refolded np1 
protein in 0 M NaCl. Observed flat looking nanoparticles are highlighted in blue arrows. B, refolded np1 
protein in 500 mM NaCl. For better viewing, in A and B a portion of the EM picture (area denoted in 
rectangle box) is enlarged and presented on the right side. In both the conditions, samples were analyzed 
in the buffer containing 20 mM Tris pH 7.5 and 10% glycerol. The pictures were prepared by negative 
staining with 2% uranyl acetate; the concentration of the protein was 50 µg/ml. 
 
 
 
 
 
B 
A 
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Table 2: AUC result for preparation 4 refolded np1 protein in 0 M NaCl. 
 
Refolding 
condition# 
Rotor speed 
(rpm) 
Concentration 
(mg/ml) 
Calculated 
MW (kDa) 
No. of monomers 
0.1 25 + 119 2.4 + 11.6 preparation 4 14000 
0.7 119 11.6 
 
# - np1 protein refolded in buffer 20 mM Tris pH 7.5, 10% glycerol, 1 mM DTT and no salt 
pH of the refolding buffer 
The effect of pH on nanoparticle assembly is studied by refolding the np1 protein in 
buffers of varying pH, as summarized in Table 3. The other parameters of the refolding 
buffer such as NaCl concentration (150 mM), DTT concentration (1 mM DTT) and 
glycerol (10%) are kept constant. The refolded samples are analyzed in the buffer 
containing 150 mM NaCl and 10% glycerol (oxidizing condition). 
The np1 protein refolded at pH 5.6 and 6.5 resulted in protein precipitation at 6 M 
and 2 M urea concentration, respectively (Table 3). In pH 5.6 refolding, changing the 
buffer from sodium acetate to MES did not help as the protein precipitated at 6 M urea 
in both buffers. The np1 protein refolded in 20 mM Hepes buffer pH 7.5 is observed to 
form expected size nanoparticles of ~ 17 nm in diameter (Figure 8, A). Also, np1 
protein refolded at pH 8.5 is observed to form expected size nanoparticles (~ 17 nm in 
diameter) but with high amount of background (Figure 8, B). The background could 
possibly the mixture of trimers, pentamers, even units and multiples thereof. 
Table 3: Summary of np1 protein refolded under varying pH conditions 
Buffer# pH Observation 
20 mM sodium acetate 5.6 precipitates in 6 M urea 
20 mM MES 5.6 precipitates in 6 M urea 
20 mM HEPES 6.5 precipitates in 2 M urea  
20 mM HEPES 7.5 forms nanoparticles of 
expected size (~ 17 nm) 
20 mM TRIS 8.5 aggregated structures 
 
# - preparation 4 refolding condition was followed for refolding in varying pH conditions. 
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Figure 8. EM pictures of preparation 4 refolded np1 protein in varying pH. A, refolded np1 protein in 
20 mM Hepes buffer pH 7.5. Inset: highlighting one single nanoparticle. B, refolded np1 protein in 20 mM 
Tris buffer pH 8.5. Inset: highlighting one single nanoparticle. The pictures were prepared by negative 
staining with 2% uranyl acetate; the concentration of the protein was 50 µg/ml. 
DTT concentration 
To understand the effect of DTT concentration on nanoparticle assembly, the np1 
protein is folded in refolding buffer containing higher concentrations of DTT (2 mM 
DTT). 
We followed preparation 4 refolding and after refolding, the refolded np1 protein is 
studied in the buffer containing 20 mM Tris pH 7.5, 150 mM NaCl, 10% glycerol and 2 
mM DTT (reducing condition). From EM picture, we observed expected size 
nanoparticles of ~ 17 nm in diameter (Figure 9) similar to the observation of np1 
protein refolded in 1 mM DTT concentration (Figure 5, B).  
Glycerol 
The icosahedral nanoparticles observed in preparation 4 refolded sample are found to 
be stabilized by the presence of 10% glycerol, because in 10% glycerol the 
nanoparticles are mostly individual in nature (Figure 5, C) but upon removal of glycerol 
the nanoparticles are observed to be mostly clumped (Figure 10; highlighted in red 
arrows). 
A B
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Figure 9. EM picture of preparation 4 refolded np1 protein in refolding buffer (20 mM Tris pH 7.5, 150 
mM NaCl and 10% glycerol) with 2 mM DTT (reducing condition). Inset: highlighting the expected size 
nanoparticles of 17 nm in diameter. The picture was prepared by negative staining with 2% uranyl 
acetate; the concentration of the protein was 50 µg/ml. 
 
 
Figure 10. EM picture of np1 nanoparticles in buffer containing no glycerol (20 mM Tris pH 7.5, 150 
mM NaCl). For better viewing, a portion of the EM picture (area denoted in rectangle box) is enlarged and 
presented on the right side. Clumped (red) and single nanoparticles (blue) are highlighted. The picture 
was prepared by negative staining with 2% uranyl acetate; the concentration of the protein was 50 µg/ml. 
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Self-assembly properties of np2 protein 
As we know from our design principles, the np2 protein is designed to have charged 
residues at the interface between the two different coiled-coil oligomerization domains 
(Figure 2). The purpose of charged residues is to keep the helices of the two different 
oligomerization domains in close proximity to favor the formation of nanoparticles 
with regular icosahedral symmetry. To test our design principles, the purified np2 
samples were refolded under preparation 3 refolding condition (oxidizing condition 
refolding from 8 M to 0 M urea). We did not refold the samples under preparation 4 
refolding condition (reducing condition refolding from 8 M to 0 M urea), because, of 
the absence of cysteine residues in np2 protein sequence (for sequence details see 
Figure 1, A).  
Initially, the np2 samples are refolded in physiological salt concentration (150 mM 
NaCl), to understand the role of intramolecular ionic interactions in the assembly 
process.  
Biophysical characterization 
EM results 
The np2 protein refolded in 150 mM NaCl concentration and in buffer 20 mM Tris 
pH 7.5 containing 10% glycerol is observed to form mostly flat, spherical shaped 
nanoparticles (indicated in black arrows). In addition, we observed aggregated 
nanoparticles forming big aggregates (indicated in red arrows) (Figure 11).  
AUC results 
Initial runs of sedimentation equilibrium (SE) (8000 rpm speed) gave concentration 
dependent molecular mass values of 262 kDa (0.5 mg/ml) and 164 + 46 kDa (0.1 
mg/ml) (Table 4, A). The monomeric mass of np2 protein is 10372.2 Daltons. 
Therefore, the above molecular mass values suggest that it could be the mixture of 
species and can be roughly correlated to trimers and even units (15-mers). In the 
subsequent runs (11000 and 18000 rpm), over the time we observed only molecular 
weight species corresponding to pentamers and trimers (Table 4, A). 
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Figure 11. EM picture of np2 protein refolded in 150 mM NaCl concentration and in buffer 20 mM Tris 
pH 7.5, 10% glycerol. The observed flat, spherical shaped nanoparticles are indicated in black arrows and 
the big aggregates in red arrows. Inset: highlighting one single flat nanoparticle.  
 
 In addition, after the SE runs we performed sedimentation velocity (SV) runs. The 
result gave us a sedimentation velocity coefficient value of 2.3 S (Table 4, B). This 
again suggested us the presence of low molecular weight species possibly the 
pentamers sand trimers. Based on the result of SE and SV runs, it seems that the 
refolded np2 sample precipitates over the time. This was further supported by the 
observed precipitation behavior in the stored samples of refolded np2 protein. 
Table 4. Preliminary AUC results for refolded np2 protein  
A. Sedimentation equilibrium results. Monomer molecular weight - 10372.2 Daltons 
Refolding 
condition 
Rotor speed 
(rpm) 
Concentration 
(mg/ml) 
Calculated MW 
(kDa) 
No. of monomers 
0.5 262 25.3 8000 
0.16 46 + 164 4.4 + 15.8 
0.5 70 6.7 
0.25 52 5.0 
11000 
0.16 62 5.9 
0.5 40 3.9 
0.25 30 2.9 
 
 
 
preparation 3 
18000 
0.16 33 3.2 
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B. Sedimentation velocity results.   
Refolding 
condition 
Rotor speed 
(rpm) 
Concentration 
(mg/ml) 
Calculated Sedimentation 
velocity coefficient value 
(s20,w) 
preparation 3 50000 0.24 2.3 
 
The purified np2 samples were also refolded in buffer (20 mM Tris pH 7.5, 10% 
glycerol) containing no NaCl to understand the screening effect of salt on ionic 
interactions. From the refolding results, we observed strong precipitation in the 
refolded np2 samples, compared to the precipitation behavior of np2 protein refolded in 
150 mM NaCl concentration. 
Circular Dichroism (CD) spectral analysis of np1 and np2 
nanoparticles 
The np1 (Figure 5, C) and np2 (Figure 10) nanoparticles are studied for secondary 
structural contents and stability properties using CD spectroscopy. The CD spectra of 
np1 and np2 nanoparticles showed a typical and similar α-helical spectrum with 
characteristic minima at 222 and 208 nm (Figure 12, A). The α-helical values 
calculated from the CD spectra of np1 and np2 nanoparticles are in very good 
agreement with the theoretically calculated α-helical values (Table 5).  
 
 
 
 
 
 
 
 
 
 
Figure 12. A, far UV-CD spectra of np1 nanoparticles (○) (preparation 4 refolded) compared with np2 
nanoparticles (●) (preparation 3 refolded). The protein concentration was 0.1 mg/ml. B, Thermal 
denaturation profile of np1 nanoparticles.  The melting scan (blue open circles) and the corresponding 
annealing scan (red open squares) are shown. The protein concentration was 0.28 mg/ml. In both A and 
B, the nanoparticles were analyzed in the buffer 20 mM Tris pH 7.5, 150 mM NaCl and 10% glycerol. 
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Table 5. Calculated α-helical contents (%) from the CD spectra of np1 & np2 nanoparticles using CDPro 
program [4]. (http://lamar.colostate.edu/~sreeram/CDPro) 
 
Calculated α-helical content (%) 
from the CD spectra 
CDPro analysis 
programs 
np1 np2 
Theoretically calculated α-helical 
content (%) from the sequence# 
(for both np1 and np2 proteins) 
SELCON3 65.4 70.2 
CONTINLL 65.8 67.1 
CDSSTR 71.3 75.7 
 
72.1 
 
# - Calculated using the formula: (total number of aa (86)) / (number of aa from COMP domain (36)) + 
(number of aa from de novo designed trimer (26)). 
 
It is observed that the transition point of thermal denaturation curve exceeds 90°C 
(Figure 12, B; blue circles). This indicates the stability of the formed nanoparticles. The 
observed renaturation curve is very similar to the denaturation curve and more than 
90% of the initial signal is recovered up on cooling (Figure 12, B; red circles). 
Thrombin cleavage results for np1 and np2 nanoparticles 
The purpose of this experiment is to understand whether it is possible to remove the 
first 22 N-terminal amino acids which are of vector origin from np1 and np2 
nanoparticles, using thrombin cleavage site (see Figure 1, A). To achieve the above 
purpose, the np1 (preparation 4 refolded) and np2 (preparation 3 refolded) 
nanoparticles are digested with varying ratios of thrombin to nanoparticles. The np2 
nanoparticles showed a precipitation behavior during the incubation period with 
thrombin enzyme. Therefore, we are presenting only the thrombin cleavage result of 
np1 nanoparticles.  
The thrombin cleavage result of np1 nanoparticles are summarized in Figure 13. The 
thrombin digested np1 nanoparticles even in the presence of a 50 times greater 
concentration of thrombin to protein (lane 7; Figure 13) is observed to be similar to the 
undigested np1 nanoparticles (lane 2; Figure 13). This possibly suggest about the 
unavailability of the thrombin cleavage site in np1 nanoparticles.  
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Figure 13. 17% SDS-PAGE results of thrombin digested np1 nanoparticles. For cleavage reactions, 
the amount of np1 nanoparticles used was 10 µg. Lane 1 - positive control protein (4 µg) in the presence 
of 0.04 U of thrombin; lane 2 - undigested np1 nanoparticles; lane 3 - np1 nanoparticles in the presence of 
0.02 U of thrombin (2X); lane 4 - np1 nanoparticles in the presence of 0.05 U of thrombin (5X); lane 5 - 
np1 nanoparticles in the presence of 0.1 U of thrombin (10X); lane 6 - np1 nanoparticles in the presence 
of 0.2 U of thrombin (20X); lane 7 - np1 sample in the presence of 0.5 U of thrombin (50X). In the gel, the 
uncleaved positive control protein corresponds to a size of 48 kDa and its cleaved fragments to 32 and 16 
kDa, respectively. 
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Chapter 2B 
Peptide based nanoparticles as an antigen 
display carrier in vaccination 
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Design principles 
The arrangement of antigens in a highly ordered and repetitive manner on the 
surface of virus particles was shown to be a critical factor for directly activating B-cells 
to produce antigen specific antibodies [5, 6]. Also, many viruses examined for 
induction of B-cell responses were shown to exhibit repetitive, identical neutralizing 
epitopes that were of highly organized [7]. The antibodies produced against the 
repetitively arranged antigens were of high titer and were shown to have high affinity 
and specificity, as opposed to the antibodies produced against monomeric antigens [8]. 
Using this concept, systems such as virus like particles (VLPs) have been employed 
for producing novel vaccines which yield high titers of specific antibodies [9, 10].  
Because of its resemblance to VLPs in the property of repetitive arrangement of 
identical protein subunits, we wanted to use our nanoparticle system as a repetitive 
antigen display system. For comparison, in the hepatitis B virus core protein based 
VLPs, known as the ‘universal display model’, the particles were made up of 180 or 
240 identical protein subunits [11, 12] and in our peptide based nanoparticle system the 
particles were made up of 60 identical protein subunits (Chapter 1). So, by fusing the 
epitope of choice to np1 or np2 protein (for sequence details refer to Chapter 2A; 
Figure 1, A) at either the N- or C-terminus and assembling the proteins into 
nanoparticles, such a repetitive antigen display system could be built (Figure 14). 
Pseudomonas aeruginosa pilin protein as an epitope of choice 
In collaboration with Dr. Robert S. Hodges from University of Colorado Health 
Sciences Center, we wanted to develop an effective anti-adhesin vaccine against 
Pseudomonas pathogen using our peptide based nanoparticle as a repetitive antigen 
display system. In his review, Hodges et al. [13] describes the importance of a vaccine 
against pseudomonas as follows: ‘Pseudomonas aeruginosa and Pseudomonas 
maltophilia account for 80% of opportunistic infections by Pseudomonas. 
Pseudomonas aeruginosa is an opportunistic pathogen that causes urinary tract 
infections, respiratory system infections, dermatitis, soft tissue infections, bacteremia, 
and a variety of systemic infections, particularly in patients with severe burns, and in 
cancer and AIDS patients who are immunosuppressed. 
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Figure 14. Concept of the peptide based nanoparticles as a repetitive antigen display system. The 
monomeric chains of np1 or np2 protein attached with epitope sequence (red) forms the basic building 
blocks. The pentameric coiled-coil domain and the de novo designed trimeric coiled-coil domain in np1 or 
np2 protein is depicted in green and blue, respectively. The computer assembled nanoparticle model with 
the epitopes displayed repetitively on the surface is depicted on the right side. It was calculated to be a 
size of 17.8 nm. 
 
Pseudomonas aeruginosa is notable for its resistance to antibiotics, and is therefore 
a particularly dangerous pathogen. Only a few antibiotics are effective against 
Pseudomonas, including fluoroquinolones, gentamicin, and imipenem, and even these 
antibiotics are not effective against all strains. The difficulty in treating Pseudomonas 
infections with antibiotics is most dramatically illustrated in cystic fibrosis patients, 
virtually all of whom eventually become infected with a strain that is so resistant that it 
cannot be treated. Since antibiotic therapy has proved so ineffective as a treatment, we 
embarked on a research program to investigate the development of a synthetic peptide 
consensus sequence vaccine for this pathogen’.  
Dr. Hodges group provided us with the sequence of Pseudomonas aeruginosa strain 
O (PAO) pilin protein (pilA; C-terminal residues 124 to 149) as an epitope sequence to 
be attached to our nanoparticle system. We chose pilin protein as an epitope because it 
forms the basic building blocks of pilus, which is a key adhesin that P.aeruginosa 
employs to attach to epithelial cell surfaces [14-16] and mucous proteins [17].  
Also, Hodges and co-workers showed that the native P. aeruginosa strain K (PAK) 
monomeric protein subunit, PAK pilin, contains the epithelial cell-surface binding 
domain in the C-terminal region of the pilin protein sequence [18]. 
  
 
 Self-assembly 17.8 nm 
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Moreover, Hodges and co-workers showed that the antipeptide antibodies generated 
against the C-terminal region residues 128-144 of PAK strain, which is a disulfide 
bonded loop region, were able to block adhesion [19]. In PAO strain, this region 
corresponds to C-terminal region residues 133-149 and was also shown to form a loop 
structure through the formation of a disulfide bridge between residues 134 and 147 
[20]. The disulfide bonded loop region of PAO strain along with its sequence is 
depicted in Figure 15.                 
     
 
 
Figure 15. (A) Cartoon depicting the C-terminal disulfide 
bonded loop region of Pseudomonas aeruginosa PAO strain pilin 
protein (residues 133 to 149). The start and end amino acids of the 
loop region are indicated in pink. Cysteine residues involved in 
disulfide bond are indicated in red. (B) C-terminal amino acid 
sequences of Pseudomonas (PAO) pilin protein involved in this 
study (residues 124 to 149). Amino acids that form the loop region 
are highlighted in green. The picture was prepared using PyMol 
program (http://www.pymol.org) (PDB file 1PAN). 
 
Nanoparticle constructs for repetitive antigen display 
To test our nanoparticle system as a repetitive antigen display system, we 
recombinantly fused the Pseudomonas pilin epitope at the C-terminus of np1 and np2 
constructs, resulting in np1e and np2e constructs (for sequence details refer to Figure 
16, A and B). We also wanted to generate different sized nanoparticles in order to 
determine the effect of size on the immunogenicity of the nanoparticles.  
BA 
Disulfide bridge 
124   130        140       149 
LNRTADG VWACKSTQDP MFTPKGCDN 
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         1         10         20           30         40         50         60         70         80         90           
                              
np1 MGHHHHHHGDWKWDGGLVPRGSDEMLRELQETNAALQDVRELLRQQVKQITFLKCLLMGGRLLCRLEELERRLEELERRLEELERA 
 
np1e np11-86-RGLNRTADGVWACKSTQDPMFTPKGCDN 
                a   d    a   d    a  d 
np1ev1 np11-86-INTVDLELAALRRRLEELARGLNRTADGVWACKSTQDPMFTPKGCDN 
                 a  d    a   d    a  d    a   d    a  d    a   d 
np1ev2 np11-86-ISAIKADLSALKANLASLQADINTVDLELAALRRRLEELARGLNRTADGVWACKSTQDPMFTPKGCDN 
 
 
 
         1         10         20           30         40         50         60         70         80         90           
                              
np2 MGHHHHHHGDWKWDGGLVPRGSDEMLRELQETNAALQDVRELLRQQVKQIRRLKRLLRGGRLLAELEELRERLEELERRLEELERA 
 
np2e np21-86-RGLNRTADGVWACKSTQDPMFTPKGCDN 
                a   d    a   d    a  d 
np2ev1 np21-86-INTVDLELAALRRRLEELARGLNRTADGVWACKSTQDPMFTPKGCDN 
                a   d    a   d    a  d    a   d    a  d    a   d 
np2ev2 np21-86-ISAIKADLSALKANLASLQADINTVDLELAALRRRLEELARGLNRTADGVWACKSTQDPMFTPKGCDN 
 
 Figure 16. Sequence details our nanoparticle constructs for repetitive antigen display. In A, np1 construct formed the template for design and in B, the template is 
np2 construct. In both np1 and np2, the residues corresponding to the pentameric coiled-coil domain of COMP and the de novo designed trimeric coiled-coil domain are 
colored green and blue, respectively. In addition, for convenience the first 86 amino acids of np1 and np2 based constructs are denoted as np11-86 and np21-86, 
respectively. The pilin antigen residues from Pseudomonas pathogen (strain PAO) are colored red. The extended trimeric coiled-coil domain I in np1ev1 and np2ev1 
constructs is highlighted in turquoise. Similarly, in np1ev2 and np2ev2 constructs the extended trimeric coiled-coil domain II is highlighted in pink. The a and d positions 
of the heptad repeats in the extended trimeric coiled-coil domains are indicated. The first 22 amino acids of np1 and np2 constructs, which correspond to the vector 
sequence, are underlined. 
 
B 
A 
Chapter 2B - Results 
 77
As a first step, we extended the C-terminus of the trimeric coiled-coil domain of 
np1e and np2e constructs by adding an additional three heptad repeats, resulting in 
np1ev1 and np2ev1 constructs, respectively (for sequence details refer to Figure 16, A 
and B).  
Again, by using np1ev1 and np2ev1 as templates, we further extended the trimeric 
coiled-coil domain by adding an additional three heptad repeats resulting in np1ev2 and 
np2ev2 constructs, respectively (for sequence details refer to Figure 16, A and B). 
According to computer modeling, these will lead to nanoparticles ranging in size from 
about 17 nm to 29 nm (Figure 17, B). 
Results 
Modular nature of our nanoparticle constructs designed for 
repetitive antigen display 
Our nanoparticle constructs were designed so that they can be easily modulable, as 
depicted in the Figure 17, A. First of all, the core peptide of the designed constructs, 
comprising the pentameric coiled-coil domain (COMP) and the trimeric coiled-coil 
domain can easily be exchanged by cutting with BamHI and XhoI restriction enzymes. 
Similarly, the epitope attached to the core peptide or to the extended core peptide can 
be readily exchanged with other epitopes by cutting with XmaI and EcoRI restriction 
enzymes. Also, the first part of the extended trimeric coiled-coil domain (extended 
trimer I) can easily be exchanged by cutting with SalI + XmaI, and the second part of 
the extended trimeric coiled-coil domain (extended trimer II) by cutting with XhoI + 
SalI restriction enzymes.  
Purification results of our nanoparticle constructs designed for 
repetitive antigen display 
All the nanoparticle constructs were expressed along with the 22 amino acids of 
vector sequence at the N-terminus (underlined residues in Figure 16). All the constructs 
were purified using Ni2+-affinity column chromatography. The purification was carried 
out under denaturing conditions using 8 M urea (for expression and purification details 
refer to Materials and Methods section). 
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Purification results of np1e and np2e proteins 
The np1e protein is observed to elute during pH 5.0 (lane 2) and pH 4.5 (lanes 3 and 
4) elution fractions, in minute amounts (Figure 18, A). The eluted fractions correspond 
to a theoretically calculated monomer of molecular weight 13341.2 Daltons. A majority 
of the monomeric form of np1e samples are observed in 500 mM imidazole elution 
fractions (lanes 4 to 9; Figure 18, A). In the first two fractions of 500 mM imidazole 
elution, in addition to a monomeric band, bands corresponding to theoretically 
calculated dimeric (26682.4 Daltons), trimeric (40023.6 Daltons) and tetrameric 
(53364.8 Daltons) forms are observed.  
 
 
 
 
 
 
 
 
 
 
Figure 17. A, Modular nature of our nanoparticle constructs designed for repetitive antigen display. 
The pentameric coiled-coil domain of COMP (green) and the de novo designed trimeric coiled-coil domain 
(blue) form the core peptide in the designed constructs. Either np1 or np2 construct forms the core 
peptide region. The epitope sequence is depicted in red. The extended trimer I domain is depicted in 
rectangular meshed turquoise. The extended trimer II domain is depicted in completely filled turquoise. 
The restriction enzyme sites are marked with bold arrows. B, From left to right, the computer designed 
models of core peptide (np1 or np2), core peptide with epitope (np1e or np2e), core peptide with the one 
time extended trimer domain + epitope (np1ev1 or np2ev1) and core peptide with two times extended 
trimer domain + epitope (np1ev2 or np2ev2). Each model is depicted beneath its calculated size.  
 
BamHI XhoI EcoRI
XmaI
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SalI XmaI EcoRI 
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Figure 18. 15% SDS-PAGE of np1e and np2e purified fractions. A, np1e protein. Lane 1 - pH 5.0 
elution fraction; lanes 2 & 3 - pH 4.5 elution fractions; lanes 4 to 9 - 500 mM imidazole elution fractions. 
Western blot results correspond to the samples in lanes 3 to 6. B, np2e protein.  FT - Flow through; lane 1 
- pH 8.0 wash fraction; lane 2 - pH 6.3 wash fraction; lane 3 - pH 5.9 elution fraction; lanes 4 to 5 - pH 5.0 
elution fractions; lanes 6 to 10 - 250 mM imidazole elution fractions. In both A and B, M correspond to 
molecular weight marker, marked in kilo Daltons (kDa). 
 
The result of western blot confirmed the presence of oligomeric forms along with 
the monomeric form in 500 mM imidazole elution fractions (Figure 18, A). The np2e 
protein is observed to start eluting in pH 5.0 elution fractions (lanes 4 and 5) and to 
continue eluting in 250 mM imidazole elution fractions (lanes 6 to 10) (Figure 18, B).  
The pH 5.0 eluted fractions correspond to a theoretically calculated monomer of 
molecular weight 13424.2 Daltons. In the 250 mM imidazole elution fractions, in 
addition to monomeric band, bands corresponding to theoretically calculated dimeric 
(26848.4 Daltons), trimeric (40272.6 Daltons) and tetrameric (53698.8 Daltons) forms 
are observed, as in the case of np1e 500 mM imidazole elution fractions. 
M 1 2 3 4 5 6 7 8 9 Western blot
97 
66 
45 
30 
20.1 
14.4 
kDa 
Monomer 
Dimer 
Trimer 
Tetramer 
A 
M FT 1 2 3 4 5 6 7 8 9 10 
97 
66 
45 
30 
20.1 
14.4 
kDa 
Monomer
Dimer 
Trimer 
Tetramer 
B
Chapter 2B - Results 
 80
Purification results of np1ev1 and np2ev1 proteins 
The np1ev1 protein is observed to start eluting in a pH 5.0 elution fraction (lane 4) 
and to continue eluting in 500 mM (lanes 5 to 12) and 1 M (lanes 13 and 14) imidazole 
elution fractions (Figure 19, A). The pH 5.0 eluted fraction corresponds to a 
theoretically calculated monomer of molecular weight 15518.7 Daltons. In both 500 
mM and 1 M imidazole elution fractions, in addition to a monomeric band a strong 
band corresponding to theoretically calculated trimer (46556.1 Daltons) is observed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19. 15% SDS-PAGE of np1ev1 and np2ev1 purified fractions. A, np1ev1 protein. Lanes 5 to 12 
- 500 mM imidazole elution fractions; lanes 13 and 14 - 1 M imidazole elution fractions. B, np2ev1 protein. 
Lanes 5 to 12 - 250 mM imidazole elution fractions. In both A and B, FT denotes flow through; lane 1 - pH 
8.0 wash fraction; lane 2 - pH 6.3 wash fraction; lane 3 - pH 5.9 elution fraction; lane 4 - pH 5.0 elution 
fraction; M - molecular weight marker, marked in kilo Daltons (kDa). 
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Similar to np1ev1 protein elution, the np2ev1 protein is also observed to start eluting 
in a pH 5.0 elution fraction (lane 4; Figure 19, B). The eluted fractions correspond to a 
theoretically calculated monomer of molecular weight 15601.7 Daltons. In 250 mM 
imidazole elution fractions (lanes 5 to 12; Figure 19, B), in the 6th and 7th lane in 
addition to a monomeric band a faint band corresponding to a theoretically calculated 
dimer (31203.4 Daltons) is observed.  
Purification results of np1ev2 and np2ev2 proteins 
The np1ev2 protein is observed to start eluting in minute amounts during the pH 5.0 
elution step (lane 4; Figure 20, A). The eluted fraction corresponds to a theoretically 
calculated monomer with a molecular weight of 17614.1 Daltons.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20. 15% SDS-PAGE of np1ev2 and np2ev2 purified fractions. A, np1ev2 protein. Lanes 5 to 8 - 
500 mM imidazole elution fractions. WB - western blot result of 500 mM imidazole fraction. B, np1ev2 
protein. Lanes 5 to 8 - 250 mM imidazole elution fractions. In both A and B, FT denotes flow through; lane 
1 - pH 8.0 wash fraction; lane 2 - pH 6.3 wash fraction; lane 3 - pH 5.9 elution fraction; lane 4 - pH 5.0 
elution fraction; M - molecular weight marker, marked in kilo Daltons (kDa). 
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Most of the eluted samples are observed in 500 mM imidazole fractions (lanes 5 to 
8; Figure 20, A). In 500 mM imidazole eluted fractions, in addition to a monomeric 
band an extra band is observed, corresponding to a theoretically calculated trimer 
(35394.2 Daltons). The result of the western blot confirmed the presence of monomer 
and trimer species in 500 mM imidazole elution fractions (lane denoted as WB; Figure 
20, A).  
For np2ev2 protein, it is observed that the protein starts to elute in pH 5.9 and 5.0 
elution fractions (lane 3 and 4; Figure 20, B). The eluted samples in pH 5.9 and 5.0 
fractions correspond to a theoretically calculated monomer (17697.1 Daltons). But the 
majority of the samples are eluted in 250 mM imidazole eluted fractions (lanes 5 to 8; 
Figure 20, B). In 250 mM imidazole elution fractions, in the first two fractions in 
addition to a monomer band a faint band is observed, corresponding to a theoretically 
calculated dimer (35394.2 Daltons). 
Summary of purification results  
• In np1e (np1 protein with epitope) purified samples, we observed a dimer band 
in addition to monomeric band. Moreover, we observed faint bands 
corresponding to trimer and tetramer species of np1e protein (Figure 18, A).    
• Contrary to np1e protein, for np1ev1 (np1e protein with the extended trimeric 
coiled-coil domain by three heptad repeats) and np1ev2 (np1e protein with the 
extended trimeric coiled-coil domain by six heptad repeats) purified proteins, 
we observed a strong trimer band in addition to monomeric band (Figure 19, A 
and 20, A). No dimer and tetramer bands were observed, as in np1e protein. 
• For np2e purified samples (np2 protein with epitope), we observed a dimer band 
in addition to monomer band and faint bands corresponding to trimer and 
tetramer species (Figure 18, B). This observation was similar to np1e purified 
samples. Contrary to np1ev1 and np1ev2 purified samples, for np2ev1 and 
np2ev2 purified samples, we observed mainly monomeric band and in addition 
a less intense dimer band (Figure 19, B and 20, B).            
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Self-assembly properties of our nanoparticle constructs 
designed for repetitive antigen display 
The aim of this section is to understand the nanoparticle forming ability of each 
designed construct. Because of the complexities of folding a protein containing 
intramolecular disulfide bridges, the purified proteins are refolded under two different 
refolding conditions (for details see Chapter 1 under heading Self-assembly of 
nanoparticles). In the first refolding condition, the samples are refolded completely 
under oxidizing condition by step wise dialysis of the urea from 8 M to 0 M urea 
(preparation 3). In the second refolding condition, the samples are refolded in 
reducing condition (2 mM DTT) by step wise dialysis from 8 M to 0 M urea and then 
exchanged to oxidizing condition (preparation 4). The refolded samples are 
characterized by using Electron Microscopy (EM). The result of the constructs will be 
grouped according to their calculated size from the computer model (for size details 
refer to Figure 17, B). 
Self-assembly properties of np1e & np2e proteins 
EM results for np1e protein 
The preparation 4 refolded np1e protein is initially analyzed in buffer containing 0 
M urea and 2 mM DTT (reducing condition). From the EM picture, the protein is 
observed to form nanoparticles of roughly spherical in shape (Figure 21, A). The size of 
the observed nanoparticles was calculated to be 17 to 18 nm in diameter, which is in 
good correlation with the size of computer modeled icosahedron with epitope (17.8 nm) 
(refer to Figure 17, B). But, upon removal of DTT (0 M urea and no DTT; oxidizing 
condition), the observed nanoparticles are found to be mostly aggregate with a few 
individual particles (Figure 21, B).  
EM results for np2e protein 
The preparation 4 refolded np2e protein is analyzed in a buffer containing 0 M urea 
and 2 mM DTT. During refolding, the pH of the buffer is kept at pH 8.0 instead of pH 
7.5. This is because the calculated pI of the protein was around 7.03. 
 From the EM picture, the refolded protein is observed to form small, irregular 
shaped structures (Figure 22). No nanoparticle formation is observed. 
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Figure 21. EM pictures of preparation 4 refolded np1e protein. A, np1e protein in 0 M urea and 2 mM 
DTT. The overall view of the sample is presented on the left and an enlarged version is presented on the 
right. Inset: highlighting one single nanoparticle. B, np1e protein in 0 M urea and no DTT. 50X 
magnification of the sample is presented on the left and the 100X magnification on the right. 
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Self-assembly properties of np1ev1 & np2ev1 proteins 
EM results for np1ev1 protein 
The preparation 3 refolded np1ev1 protein is observed to precipitate at 4 M urea. 
From the EM picture, the precipitated material is observed to form large irregular 
aggregates (Figure 23, A).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22. EM picture of preparation 
4 refolded np2e protein. np2e protein in 0 
M urea and 2 mM DTT (20 mM Tris pH 
8.0, 150 mM NaCl and 10% glycerol). 
A 
C 
B
Figure 23. EM pictures of refolded 
np1ev1 protein. A, preparation 3 refolded 
np1ev1 protein in 4 M urea. B, 
preparation 4 refolded np1ev1 protein in 
0 M urea and 2 mM DTT. C, preparation 
4 refolded np1ev1 protein in 0 M urea 
and no DTT. 
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The preparation 4 refolded np1ev1 protein is observed to precipitate upon reaching 0 
M urea and in 2 mM DTT. From EM picture, the refolded np1ev1 in 0 M urea and in 2 
mM DTT is observed to form irregular aggregates (Figure 23, B). Also in 0 M urea and 
no DTT, we observed big aggregates (Figure 23, C).   
EM results for np2ev1 protein      
The preparation 4 refolded np2ev1 protein is analyzed in a buffer containing 0 M 
urea and 2 mM DTT (reducing condition). From the EM picture (Figure 24), the 
refolded protein is observed to form a large population of mostly flat, spherical shaped 
nanoparticles (indicated in red arrow). However, we also observed nanoparticles which 
are not of flat in shape (indicated in pink arrow) but appeared to lack the icosahedral 
symmetry.  
 
 
 
 
 
 
 
 
Figure 24. Preparation 4 refolded np2ev1 protein in 0 M urea and 2 mM DTT. The overall view of the 
sample is presented on the left and the enlarged view on the right. The observed nanoparticles of flat and 
not flat are highlighted in red and pink colored arrows, respectively. 
Fluorescence Correlation Spectroscopy (FCS) results for np2ev1 
nanoparticles 
Fluorescence correlation spectroscopy (FCS) is used to study the size distribution of 
preparation 4 refolded np2ev1 nanoparticles. The refolded protein was labeled with 
fluorophore Alexa Fluor 488 (for details see FCS section in Materials and Methods). 
The labeled protein was studied in Tris buffered saline (TBS) (pH 7.5, 10% glycerol, 
no DTT). 
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FCS is a singe molecule spectroscopy technique. It is based on the emitted 
fluorescence by molecules diffusing through a very small detection volume (1 
femtoliter) which is given by a confocal microscope. These intensity fluctuations, 
detected by a highly sensitive avalanche photo diode (APD), are reflected in the 
obtained intensity profile (Figure 25, A). The fluorescent intensity profile shows an 
average peak intensity of approximately 5 kHz (expressed as the difference from the 
base line intensity).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25. Fluorescence correlation spectroscopy results for np2ev1 nanoparticles (preparation 4 
refolded). A, graph representing the fluorescent intensity fluctuations and B, the corresponding calculated 
autocorrelation curve of np2ev1 nanoparticles. C, fluorescence intensity fluctuations graph representing 
the rarely observed peaks with higher peak intensity (indicated by red arrow) and D, the corresponding 
calculated autocorrelation curve. 
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The intensity autocorrelation function G (τ) (refer to equation 1 in methodology 
section of FCS in Materials and Methods), calculated from the fluorescent intensity 
peaks, shows an autocorrelation curve indicating that the measured sample consists of 
particles with a monomodal distribution (Figure 25, B). The autocorrelation curve can 
be fitted with a model resulting in the determination of the number of 
particles/molecules and their specific diffusion time through the detection volume. The 
diffusion time, τD, obtained from fitting the autocorrelation curve is 345 ± 192 µs. By 
using the Stoke-Einstein relation (refer to equation 3 in methodology section of FCS in 
Materials and Methods), the corresponding hydrodynamic radius is calculated to be 6.4 
± 3.6 nm. 
When including the whole data set obtained by FCS, an occurrence of rarely 
appearing peaks, with intensities up to five times higher than the values obtained from 
the restricted data set, can be observed (Figure 25, C; indicated by red arrow). The 
corresponding autocorrelation curve showed a bimodal distribution (Figure 25, D). 
From the fluorescent intensity fluctuations, in addition to the 345 ± 192 µs diffusion 
time, the diffusion time of the rarely observed peaks is calculated to be approximately 
13 ms. This finding suggest that the sample also contains aggregates with a 
significantly larger size. 
Self-assembly properties of np1ev2 & np2ev2 proteins  
EM results for np1ev2 protein 
The preparation 3 refolded np1ev2 protein is observed to start precipitating at 8 M 
urea and more precipitation is observed at 6 M urea. From the EM picture, the 
precipitated material at 8 M urea resemble short filament-like structures (Figure 26, A; 
indicated by black arrow).  
The preparation 4 refolded np1ev2 protein is observed to start precipitating during 2 
M to 0 M urea transition. From the EM picture, the sample at 2 M urea resemble short 
filament like structures (Figure 26, B; indicated by black arrow).  
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EM results for np2ev2 protein 
The preparation 4 refolded np2ev2 protein is analyzed in a buffer containing 0 M 
urea and 2 mM DTT. From the EM picture (Figure 27), the refolded protein is observed 
to form flat, spherical shaped nanoparticles (indicated in black arrow).   
 
Figure 26. EM pictures of refolded np1ev2 protein. A, preparation 3 refolded np1ev2 protein in 8 M 
urea. B, preparation 4 refolded np1ev2 sample in 2 M urea and 2 mM DTT. In both A and B, the observed 
short filament-like structures are indicated in black arrow. 
  
Figure 27. Preparation 4 refolded np2ev2 protein in 0 M urea and 2 mM DTT. The overall view of the 
sample is presented on the left and the enlarged version on the right. Observed flat, spherical shaped 
nanoparticles are indicated in black arrows. 
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Immunization results  
Immunization studies are done in order to understand the immune response 
generated against the nanoparticles carrying the Pseudomonas pilin epitope. The 
immunization studies are done in Dr.Hodge’s lab, using rabbit as the animal model.  
Preliminary immunization studies 
The nanoparticles of np1, np1e and np2ev1 proteins are used for the immunization 
studies. The np1 nanoparticles, which do not carry the epitope, are used as the negative 
control. For preliminary immunization studies, the nanoparticles are prepared in 
Freund’s complete/incomplete adjuvant (for immunization details refer to Materials and 
Methods section). The rabbits are immunized with four injections with a gap of four 
weeks between each injection. After the 4th injection, the rabbits are slaughtered and the 
obtained serum is diluted to different dilutions. The different dilutions of the serum are 
titrated against the pilin peptide conjugated BSA protein to estimate the antibody 
response generated against the pilin epitope. The antibody titers are estimated using 
Enzyme-Linked Immunosorbent Assay (ELISA). 
The ELISA results are summarized in Figure 28. From the ELISA results, it is 
observed that none of the preimmune sera recognized the pilin peptide. As 
expected, the final serum from rabbit immunized with np1 nanoparticles (np1 final 
serum), does not show any binding against the pilin peptide. The final serum from 
rabbit immunized with np1e nanoparticles (np1e final serum), showed 50 % binding at 
1: 29600 dilution. This observation indicates the high titers of antibody generated 
against the pilin epitope attached to np1e nanoparticles. The final serum from rabbit 
immunized with np2ev1 nanoparticles (np2ev1 final serum), showed 50 % binding at 
1:4000 dilution and at 1:29600 dilution it showed less than 10 % binding. This 
observation indicates the low titers of antibody titers generated against the pilin epitope 
attached to np2ev1 nanoparticles.   
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Figure 28. Each of three rabbits was immunized with either np1 or np1e or np2ev1 nanoparticles. 
np1e, np2ev1 nanoparticles carry the Pseudomonas (strain PAO) pilin epitope. Intramuscular route was 
used for immunization with 15 µg of nanoparticles formulated in Freund’s adjuvant (Complete/Incomplete). 
Rabbits were immunized four times, with a gap of four weeks between each immunization. Pilin epitope 
specific antibodies in the sera were measured after the 4th immunization. Results are shown as optical 
density (OD; at 450 nm) for individual serum dilutions. 
Comparison of profiles of immune response generated against np1e 
nanoparticles in the presence and absence of adjuvant 
Based on the observation of strong immune response generated against pilin epitope 
attached to np1e nanoparticles as compared to np2ev1 nanoparticles, it was decided to 
compare the profiles of immune response generated against np1e nanoparticles in the 
presence and absence of Freund’s adjuvant. To accomplish the above purpose, six 
rabbits are used, out of which three are immunized with np1e nanoparticles in 50% 
(v/v) Freund’s adjuvant and three with np1e nanoparticles in 50% (v/v) phosphate 
buffered saline (PBS). The same immunization is followed as in the preliminary 
immunization studies. After the final immunization, the sera are collected from the 
rabbits and tested for their titer values against three different antigens: np1e 
nanoparticles, pilin peptide conjugated to BSA and native pilin protein.  
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The titer values are represented in dilution values at which 50% binding of the 
serum is observed. The obtained antibody titer values of the serum against each antigen 
are presented in Figure 29 (the average of the values obtained from all three rabbits). 
The average titer values against each antigen are summarized in Table 6.  
The final sera from rabbits immunized with np1e nanoparticles + adjuvant showed 
a strong titer value (550, 000) against np1e nanoparticles. The same serum against pilin 
peptide conjugated to BSA and to native pilin protein showed titer values of 23293 and 
44091, respectively. From the obtained titer values, it is observed that the titer values 
against pilin peptide conjugated to BSA and native pilin protein are ~ 20 times less 
when compared to the titer values obtained against np1e nanoparticles. This 
observation proves that a majority of the produced antibodies are not directed against 
pilin antigen, but rather are directed against np1e nanoparticle backbone. 
 
 
 
 
 
 
 
 
 
 
 
Figure 29. Two groups, each group containing three rabbits were immunized with np1e nanoparticles 
in 50% (v/v) Freund’s adjuvant (Complete/Incomplete) system and np1e nanoparticles in 50% (v/v) 
phosphate buffered saline, respectively. In each group, four immunizations (intramuscular) were done with 
a gap of four weeks between each immunization.  The sera obtained from each group after the 4th 
immunization was titrated against three different antigens coated to the ELISA wells: np1e nanoparticles 
itself (violet); pilin peptide conjugated to BSA (green); native pilin protein (blue). Results are shown in the 
dilution factor at which 50% binding was observed. The titer value shown for each antigen is the average 
of the values obtained from three rabbits. OD = Optical density. 
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The sera from rabbits immunized with np1e nanoparticles without adjuvant 
showed a weak titer value of 5591 against np1e nanoparticles. Against pilin peptide 
conjugated to BSA and to native pilin protein it showed titer values of 1446 and 1822, 
respectively. From the obtained titer values, it is clear that the immune response 
generated against the pilin epitope is very low in the absence of adjuvant. But, the 
important point to note is that in absence of adjuvant the antibody fraction directed 
towards the pilin epitope is much higher 25% compared to 4.2% with adjuvant (see 
Table 6). Therefore, the adjuvant seems to make the core particle more accessible to the 
immune system, probably by partial unfolding of the nanoparticles. 
 
Table 6. Antibody titer values obtained against np1e nanoparticles in the presence and 
absence of Freund’s adjuvant.   
 
Antibody titer values# ELISA plate coated 
antigens with adjuvant$ without adjuvant£ 
np1e nanoparticles 550,000 5591 
pilin peptide conjugated 
to BSA 
23293 1446 
Native pilin protein 44091 1822 
 
# - represents the dilution values at which 50% binding was observed; average of values 
obtained from three rabbits. 
$ - final sera from rabbits immunized with np1e nanoparticles in Freund’s adjuvant. 
£ - final sera from rabbits immunized with np1e nanoparticles alone (no adjuvant). 
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Discussion 
Chapter 2A: Recombinant production of peptide based 
nanoparticles and their Biophysical characterization 
Purification results of proteins np1 and np2  
We have expressed and purified np1 and np2 proteins to near homogeneity. The 
purified proteins were obtained in a single step using Ni2+-affinity chromatography 
(Figure 3, A and B). By single step purification, we showed that the np1 and np2 
proteins which will be the building blocks of nanoparticles can be produced in an 
efficient and economic way. 
 The less stable nature of trimeric coiled-coil domain of np2 protein in SDS-PAGE 
when compared to the np1 protein (Figure 3, A and B) can be explained on the basis of 
interhelical ionic interactions within the trimeric coiled-coil domain. We did not take 
into account hydrophobic interactions because we have the same hydrophobic residues 
at a and d positions of the trimeric coiled-coil domain of np1 and np2 proteins (Figure 
1, A). Burkhard et al. showed that the interhelical ionic interactions improve the coiled-
coil stability by designing the ‘minimal coiled-coil domain’. In particular, the 
interhelical ionic interaction of g-e’ type with an Arg (R) residue in g position and Glu 
(E) in e’ position (g-e’ RE) [21]. In addition, Burkhard et al. showed that the opposite 
arrangement of g-e’ RE interhelical ionic interactions that is g-e’ ER reduces the 
coiled-coil stability [22]. This could be the reason for the less stable trimeric coiled-coil 
domain of np2 protein, as we identified the g-e’ ER interhelical ionic interactions 
whereas in np1 protein this region has favorable g-e’ RE interhelical ionic interactions 
(Figure 30).              
Self-assembly results of protein np1  
In preparation 3 and preparation 4 refolding, refolding starts from 8 M urea 
concentration, using low protein concentration (100 µg/ml).  
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Figure 30. The trimeric coiled-coil region of np1 protein indicated with g-e’ RE interhelical ionic 
interactions (red) whereas in np2 protein this region has g-e’ ER interhelical ionic interactions (red). The 
heptad positions are indicated above the sequence. We followed the same residue numbering as in 
Figure 1, Chapter 2A.   
 
We used low protein concentration in order to reduce intermolecular contacts, thus 
trying to avoid the intermolecular disulfide bridges between the cysteine residues of 
different np1 chains especially under oxidizing conditions of preparation 3 refolding. 
However, we cannot rule out the possibility of intermolecular disulfide bridges in 
oxidizing conditions of preparation 3 at 8 M urea where the monomeric chains of np1 
protein will be mostly in its unfolded state. If this happens, it will lead to network of 
np1 unfolded monomeric chains linked through intermolecular disulfide bridges, and in 
subsequent refolding steps the oligomerization of the coiled-coil domains will further 
cross link the chains. This can lead to irregular aggregates. Such a behavior was 
observed in preparation 3 refolded np1 samples: EM picture revealed irregular 
aggregates along with the expected size (~ 17 nm) nanoparticles (Figure 5, A). The 
observed nanoparticles in preparation 3, tell us about the properly formed 
intramolecular disulfide bridges between the helices of coiled-coil domains within the 
folded np1 chains. 
 In preparation 4 refolding, there is no chance of intermolecular disulfide bridge 
formation because of its reducing condition refolding from 8 M to 0 M urea. At 0 M 
urea and in reducing condition, the cysteine residues of the refolded np1 protein are 
already shielded from the solvent. Therefore, upon oxidizing condition, which is the 
final step of preparation 4 will allow only the formation of intramolecular disulfide 
bridges. From our preparation 4 refolding EM picture, we observed the expected size (~ 
17 nm in diameter) nanoparticles already in 0 M urea and in reducing condition (Figure 
5, B).  
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The observed nanoparticles of expected size (~ 17 nm in diameter) under 
preparation 4 refolding showed our success in recombinant production of peptide based 
nanoparticles (see Figure 5, B and C). In addition, the molecular mass results of AUC 
confirmed the presence nanoparticles with icosahedral symmetry (4 even units) along 
with high molecular weight aggregates and even units (15-mers) (see Table 1, B). The 
observed high molecular weight aggregates in AUC could possibly correspond to the 
clumped nanoparticles, as we observe few clumped nanoparticles in EM picture (see 
Figure 5, C). By using CD spectroscopy, especially, thermal melting scan of 
nanoparticles, we showed that the observed nanoparticles are quite stable in solution 
(see Figure 12, B). The inaccessibility of thrombin cleavage site in thrombin cleavage 
reaction of nanoparticles (see Figure 13) shows about the compactly packed np1 
subunits within the nanoparticle environment. 
The preparation 4 refolding results of np1 protein was in contrary to the synthetic 
peptide (sp) results in chapter 2 where we showed the importance of intramolecular 
disulfide bridge in obtaining nanoparticles with icosahedral symmetry. But, the 
important point to note is that in synthetic peptide (sp) preparation 4 refolding results, 
we did not observe the refolded samples in 0 M urea and in reducing condition. We 
only observed the samples in 0 M urea and in oxidizing condition (Figure 3, D; chapter 
1). Therefore, we cannot rule out the possibility of formed nanoparticles with 
icosahedral symmetry already in 0 M urea and in reducing condition. In addition, in our 
laboratory the np1 protein with the mutated cysteine (C) residues to alanine (A) 
residues was refolded under preparation 3 refolding and from EM picture the refolded 
protein was observed to form nanoparticles with icosahedral symmetry (~ 17 nm in 
diameter) (data not included in the thesis). Thus, it seems that the helices of two 
different oligomerization domain of single np1 chains come close enough in the 
absence of intramolecular disulfide bridge during refolding to favor the formation of 
nanoparticles with icosahedral symmetry.         
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Parameters studied to understand its influence on nanoparticle assembly 
property of np1 protein under preparation 4 refolding condition  
Ionic strength  
Ionic strength of the refolding buffer found to be an important parameter influencing 
the nanoparticle formation. The refolded np1 protein in physiological salt concentration 
(150 mM NaCl) is observed to form nanoparticles with icosahedral symmetry (~ 17 nm 
in diameter) (see EM picture Figure 5, C; AUC result Table 1, B). In contrary, the 
refolded np1 protein in 0 M NaCl is observed to form trimers and roughly 15-mers 
(even units) (see AUC result Table 2) and EM picture also confirmed the absence of 
nanoparticles with icosahedral symmetry (Figure 7, A). These findings support the 
possible role of ionic strength in stabilizing the ionic interactions during the assembly 
process of coiled-coil domains to form nanoparticles with icosahedral symmetry. 
The observed icosahedral nanoparticles which were of mostly clumped in nature in 
high salt concentration (500 mM NaCl) (see EM picture Figure 7, B) can be explained 
as follows: N-terminus of np1 protein which is a non coiled-coil sequence is populated 
with more of hydrophobic amino acids (18 out of 22 amino acids), as shown in Table 7.  
Table 7. Data representing the nature of the amino acids at N-terminus of np1 protein        
N-terminus amino acid sequence of np1 protein 
MGHHHHHHGDWKWDGGLVPRGS (22 amino acids) 
very hydrophobic amino acids MWWLV 
less hydrophobic amino acids GHHHHHHG 
GGPGS 
Total amino acids (very hydrophobic 
+ less hydrophobic) : 18 
very hydrophilic amino acids DKDR 4 amino acids 
 
We considered the 6-histidine residues at the N-terminus as less hydrophobic amino 
acids, because, the refolding was done at pH 7.5 which is around the pKa of histidine 
residue. In the nanoparticles, the N-terminus will be on the outer periphery, extending 
out from each chain of pentameric coiled-coil domain. In conditions like high salt 
concentration (500 mM NaCl), hydrophobic interactions are more favorable than ionic 
interactions because of the masking effect of ions on charged residues. Therefore, in 
500 mM NaCl there are more chances of forming interparticle hydrophobic interactions 
between the N-terminus of neighboring nanoparticle, which will lead to clumping of 
nanoparticles.   
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pH of the refolding buffer 
In addition to ionic strength, pH of the refolding buffer found to be another 
important parameter influencing the nanoparticle formation. pH mediated effect can be 
correlated to its influence on the electrostatic interactions between the charged residues. 
Therefore, we analyzed np1 sequence for stretch of negatively and positively charged 
residues that can be influenced during np1 refolding at different pH. From np1 
sequence, we found that the C-terminus of trimeric coiled-coil domain of np1 protein, 
especially from residues 74 to 86 is populated with more of negatively charged amino 
acids (6 glutamic acid (E) residues compared to 3 arginine (R) residues) (for sequence 
details see Figure 1, A). In addition, the 6 consecutive histidine (H) residues at the N-
terminus will either form positively charged patch at acidic pH or uncharged patch at 
neutral or basic pH. Based on these regions, in the following paragraphs we have 
discussed our observed refolding results of np1 protein at different pH (see Table 3). 
In our refolding studies of np1 protein at pH 5.6, especially in 8 M urea, the np1 
protein will be mostly in its unfolded state exposing the positively charged histidine 
residues at the N-terminus and negatively charged C-terminus. This can cause 
electrostatic interactions between N- and C-terminus of different np1 monomeric chains 
forming network of np1 chains linked to each other. Based on the observation of 
trimeric band in denaturing conditions of SDS-PAGE of np1 purified samples (see 
Figure 3, A), it seems that the trimeric coiled-coil domain of np1 protein folds already 
at urea concentrations that are moderately high (6 M urea). Therefore, the folding of 
trimeric coiled-coil domain at 6 M urea can further cross link the network of np1 
chains, as this can lead to protein precipitation. Such a behavior was observed for np1 
refolded samples at pH 5.6, as they precipitated in 6 M urea.  
In pH 6.5 and 7.5 refolding, the N-terminal histidine residues will carry a neutral 
charge as the pKa of histidine residue is pH 6.0. Therefore, at pH 6.5 and 7.5 the 
uncharged histidine residues will not favor the electrostatic interactions with the 
negatively charged C-terminus of unfolded np1 monomeric chains in 8 M urea. In the 
subsequent urea concentration, the folding of the trimeric coiled-coil domain and the 
pentameric COMP domain will favor the formation of icosahedral nanoparticles.  
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Such a behavior was observed for np1 refolded samples at pH 7.5, as they formed 
nanoparticles with icosahedral symmetry (~ 17 nm in diameter) (see EM picture Figure 
8, A). But, for np1 refolded samples at pH 6.5 we observed precipitation in 2 M urea. 
Also, the uncharged nature of histidine residues at pH 8.5 will not favor the 
electrostatic interaction with negatively charged C-terminus. This was supported by the 
observed nanoparticles with icosahedral symmetry in pH 8.5 refolded np1 samples, but 
they were found to be more of aggregated (see EM picture Figure 8, B).              
Reducing agent (DTT) 
The refolded np1 protein in 2 mM DTT concentration is observed to form nanoparticles 
with icosahedral symmetry already in 0 M urea and in 2 mM DTT (reducing condition) 
(see EM picture Figure 9). This observation was similar to the refolded np1 protein in 1 
mM DTT, as here also we observed nanoparticles with icosahedral symmetry already in 
0 M urea and in 1 mM DTT (reducing condition) (see EM picture Figure 5, B). 
Therefore, refolding at higher DTT concentration 2 mM DTT when compared to 1 mM 
DTT does not seem to influence the nanoparticle formation with icosahedral symmetry 
under preparation 4 refolding. 
Glycerol 
The observed nanoparticles with icosahedral symmetry in 10% glycerol (see EM 
picture Figure 5, C) were found to be more of clumped as we dialyzed out 10% 
glycerol (see EM picture Figure 10). In the nanoparticle, the N-terminus of np1 protein 
which is more of hydrophobic in nature (see Table 7), will be on the outer surface as it 
extends from each chain of pentameric coiled-coil domain of COMP. Thus, the outer 
surface of nanoparticles can be considered as more of hydrophobic in nature and the 
possible reason for nanoparticle clumping can be attributed to the interparticle 
hydrophobic interactions. Therefore, the observed nanoparticle clumping in the absence 
of 10% glycerol support the role of glycerol as a stabilizing agent by interacting with 
the hydrophobic outer surface of nanoparticles. 
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Self-assembly results of protein np2  
In np2 protein we introduced charged residues at the interface between the two 
oligomerization domains (see Figure 2). The idea is to understand whether the ionic 
interactions between the charged residues can bring the helices of two different 
oligomerization domains in a close proximity that will favor the formation of 
nanoparticles with icosahedral symmetry.  
From EM picture of oxidizing condition refolding results (preparation 3), we 
observed mostly flat, spherical shaped nanoparticles (Figure 11). Preliminary AUC 
analysis support that these nanoparticles might well correspond to even units (15 
monomeric chains) (see Table 4, A). But, after initial runs of AUC, the high molecular 
weight species roughly corresponding to even units and possibly the aggregates of even 
units disappeared and we could detect only pentamers and trimers (refer to Table 4, A). 
It seems that the above observation could be due to precipitation of high molecular 
weight species. Also, in solution we observed precipitation of the refolded sample. This 
shows about the instable nature of the observed nanoparticles.  
According to our design principles, if the two oligomerization domains of the 
monomeric chain properly folds they will first assemble into ‘even units’. The even 
units are nanoparticles but they are not of icosahedral shaped nanoparticles. To form 
icosahedron four such even units has to assemble together (60 monomeric chains) (see 
Table 1 of Chapter 1). Further assembly of even units to form icosahedral nanoparticles 
is determined by the angle between the two different oligomerization domains. One of 
the factors which influence the angle is the interactions at the interface between the two 
different oligomerization domains. In np2 protein, we used ionic interactions at the 
interface to optimize the angle between the two domains. But from the EM picture, it 
seems that the angle formed between the two oligomerization domains is not optimal to 
form the icosahedral nanoparticles, as we observe presumably the even units. In 
addition, these loosely packed even units can enclose more even units to form different 
sized nanoparticles lacking the icosahedral symmetry. This could be the probable 
explanation for the observed nanoparticles within the big aggregates (see EM picture 
Figure 11; indicated in red arrows).                
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 Chapter 2B: Peptide based nanoparticles as an antigen display 
carrier in vaccination 
Purification results 
All the purified protein samples for repetitive antigen display carry two different 
oligomerization domains in their protein sequence: a pentameric coiled-coil domain 
(COMP) and a de novo designed trimeric coiled-coil domain (Figure 16). The coiled-
coil domains of COMP and the de novo-designed trimer are known to form very stable 
oligomers [22, 23]. Therefore, under denaturing conditions of SDS-PAGE the purified 
samples can form trimers and pentamers in addition to monomers. Such a behavior was 
observed for np1ev1 and np1ev2 purified samples, as we observed a strong trimeric 
band in addition to monomeric band under SDS-PAGE (Figure 19, A and 20, A). 
Similar behavior was observed for np1 purified samples under SDS-PAGE (Figure 3, A 
of chapter 2A). These results show the very stable nature of trimeric coiled-coil domain 
in these samples, as it already folds under denaturing conditions of SDS-PAGE.  
 In addition, cysteine residues present in np1 and np2 based protein samples (See 
Table 8) can influence the formation of different oligomeric states of these samples 
under SDS-PAGE, by forming intermolecular disulfide bridges between different 
monomeric chains.  
Table 8. Data representing the cysteine (C) residues in np1 and np2 based proteins for repetitive antigen 
display.  
Constructs Domain Residue number 
pentameric coiled-coil 
domain (COMP)$ 
Cys 55 
trimeric coiled-coil 
domain$ 
Cys 64 
np1 based 
proteins: np1e, 
np1ev1 and np1ev2 
pilin epitope£ Cys 134 and 147 
np2 based 
proteins: np2e,  
np2ev1 and np2ev2 
pilin epitope£ Cys 134 and 147 
 
$ - residue numbering of np1 protein is followed as denoted in Figure 16, A. 
£ - residue numbering of full length pilin protein is followed as denoted in Figure 15, B.     
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Especially, under denaturing conditions of SDS-PAGE, the protein chains will be 
usually in its unfolded monomeric form and the presence of cysteine residues at this 
stage mostly favor intermolecular disulfide bridges between different chains. Therefore, 
the observed dimeric and tetrameric band for np1e and np2e protein samples under 
SDS-PAGE (Figure 18, A and B), can possibly correspond to the intermolecular 
disulfide linked monomers (dimers) and dimers (tetramers). Similarly, the observed 
dimeric band for samples np2ev1 and np2ev2 in SDS-PAGE can be of intermolecular 
disulfide linked monomers (Figure 19, B and 20, B). The less intense or even absence 
of trimer band in these samples show the formation of trimeric coiled-coil domain is 
less favored that is less stable under denaturing conditions of SDS-PAGE.                    
Self-assembly results  
np1 based proteins 
np1 protein with pilin epitope (np1e) 
The preparation 4 refolded np1e protein is observed to form nanoparticles of 
expected size (~ 17 to 18 nm in diameter) in refolding buffer containing 2 mM DTT 
(reducing condition) (see Figure 21, A). This observation shows that the nanoparticle 
forming ability of np1 protein is not affected by the fusion of pilin epitope. But 
upon oxidizing condition (removal of 2 mM DTT), we observed clumping of particles 
forming bigger aggregates (see Figure 21, B) and sometimes in solution we observed 
precipitation problem. This effect could possibly due to the interlinking of formed 
nanoparticles through interparticle disulfide bridges by the cysteine residues of pilin 
epitope. Because, in the observed nanoparticles which is in reducing condition (2 mM 
DTT), the surface exposed cysteine residues of pilin epitope will be in the reduced state 
and upon oxidizing condition there are chances of forming intramolecular, 
intermolecular and interparticle disulfide bridges. The formation of intramolecular and 
intermolecular disulfide bridges will not affect the individual nature of nanoparticles. 
Because, the intramolecular disulfide bridges will lead to disulfide bonded loop 
structures of pilin epitope (native state; see Figure 15, A) on the surface of nanoparticle 
and the intermolecular disulfide bridges will result in cross linking of pilin epitopes 
within nanoparticle. 
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But the formation of interparticle disulfide bridges will cross link the epitopes of 
adjacent nanoparticles as this will lead to aggregates. Such a behavior was observed for 
np1e nanoparticles in 0 M urea and no DTT (preparation 4).  
np1e protein with extended trimeric coiled-coil by three heptad repeats (np1ev1) 
and six heptad repeats (np1ev2) 
The presence of cysteine residues in np1ev1 and np1ev2 proteins (see Table 8) can 
lead to different possibilities of disulfide bridges during preparation 3 and preparation 4 
refolding conditions (see Table 9). During refolding, especially at 8 M urea the protein 
chains of np1ev1 and np1ev2 will be mostly in its unfolded state. The unfolded nature 
at 8 M urea and the oxidizing condition (preparation 3) at this stage will increase the 
possibility of intermolecular disulfide bridge formation between cysteine residues of 
different monomeric chains. This will lead to network of disulfide linked monomeric 
chains. In addition, it seems that the trimeric coiled-coil domain of np1ev1 and np1ev2 
proteins folds at relatively high urea concentration based on the observation of trimeric 
band at denaturing conditions of SDS-PAGE of np1ev1 and np1ev2 purified samples 
(Figure 19, A and 20, A). Therefore, the folding of the trimeric coiled-coil domain of 
these proteins at relatively high urea concentration can further cross-link the network of 
intermolecular disulfide linked monomeric chains. This will probably result in 
precipitation of the protein. Such a behavior was observed for np1ev1 and np1ev2 
proteins refolded under preparation 3 refolding condition (Figure 23, A and 26, A).               
Also, for the refolded np1ev1 (Figure 23, B and C) and np1ev2 (Figure 26, B) 
proteins in reducing condition (preparation 4), we observed aggregation and 
precipitation problem. This shows about the influence of the attached epitope sequences 
on the assembly of the nanoparticles and here it seems that the aggregation and 
precipitation problem is due to the cysteine residues of pilin epitope (Table 8). This 
statement was supported by the preparation 4 refolding results of np1ev1 protein fused 
with Salmonella D2 epitope (no cysteine residues) where we observed properly formed 
nanoparticles (D. Tropel, oral communication). 
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Table 9. Data depicting the cysteine (C) amino acid residue numbers and their possible type of disulfide 
bridges that can form during step-wise dialysis from 8 M to 0 M urea (preparation 3 and preparation 4). 
Data is shown for np1 and np2 based proteins. 
 
Type of disulfide bridge Constructs Residue number* 
np1 based proteins 
(np1e, np1ev1 and np1ev2) 
55-64; 55-134; 55-147;  
64-134; 64-147; 134-147  
Intramolecular£ 
np2 based proteins 
(np2e, np2ev1 and np2ev2) 
134-147 
np1 based proteins 
(np1e, np1ev1 and np1ev2) 
 
 
55-64; 55-134; 55-147 
64-134; 64-147; 55-55; 64-64 
134-147; 134-134; 147-147 
 
Intermolecular€ 
np2 based proteins 
(np2e, np2ev1 and np2ev2) 
134-147; 134-134; 147-147 
 
Interparticle$ for both np1 and np2 based 
proteins 
134-147; 134-134; 147-147 
 
* - for domain localization of respective residue number refer to Table 8. 
£ - within a peptide or protein chain 
€ - between the peptide or protein chain 
$ - between the nanoparticles 
np2 based proteins 
The np2 protein which forms the building block of np2e, np2ev1 and np2ev2 is 
observed to form mostly flat, spherical shaped nanoparticles (see Figure 11 of Chapter 
2A). Preliminary AUC analysis of these nanoparticles showed us that it might well 
correspond to ‘even units’ (15 monomeric chains) (Table 4, A of Chapter 2A). 
Therefore, based on the AUC results, the observed flat, spherical shaped nanoparticles 
of np2ev1 (see Figure 24) and np2ev2 (see Figure 27) might well also correspond to 
even units.  
Even units are of similar in size when compared to the icosahedral nanoparticles. 
This was supported by the calculated size of np2ev1 by FCS which is ~ 20 nm in 
diameter, well comparable to the size of computer modeled icosahedron of np2ev1 (23 
nm in diameter) (Figure 17, B). But, the even units are not of icosahedral nanoparticles 
and according to our nanoparticle design principles, four such even units has to come 
together to form icosahedral shaped nanoparticles (60 monomeric chains) (see Table 1 
of Chapter 1).   
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The association of even units to form icosahedral nanoparticles is determined by the 
angle between the two oligomerization domains within an even unit. One of the factor 
that determines the angle is the interactions at the interface between the two 
oligomerization domains. In np2 and np2 based proteins it is governed by the ionic 
interactions. Therefore, if the angle is not small enough to form icosahedron the even 
units can enclose less or more than four even units to form nanoparticles which are not 
of icosahedral in shape. Such type of nanoparticles is observed in np2ev1 protein (see 
Figure 24; highlighted in pink arrow). Based on the above results, it seems that the 
designed ionic interactions are not optimal enough to bring the helices of the two 
different oligomerization domains in close proximity to form icosahedral nanoparticles.   
Immunization results 
Preliminary immunization results 
The objective of the preliminary immunization studies is to know the optimal 
nanoparticle size that can elicit very good immune response against the fused pilin 
antigen from Pseudomonas. We classified the nanoparticles fused with pilin antigen 
according to their computer designed model size (see Figure 17, B) which is as follows: 
• Small size nanoparticles (~ 18 nm) - np1e, np2e 
• Medium size nanoparticles (~ 23 nm) - np1ev1, np2ev1 
• Large size nanoparticles (~ 29 nm) - np1ev2, np2ev2 
From the refolding results, among the np1 based proteins (np1e, np1ev1 and 
np1ev2), np1e protein (small size nanoparticle) assembled into icosahedral 
nanoparticles of expected size (~ 18 nm in diameter) (see EM picture Figure 21, A and 
B).  
For np1ev1 (medium size nanoparticle) and np1ev2 (large size nanoparticle) 
proteins, we faced aggregation and precipitation problem during or after refolding. 
From the refolding results of np2 based proteins, we observed mostly flat nanoparticles 
possibly the ‘even units’ (15-mers) and not the nanoparticles with icosahedral 
symmetry. But with refolded np2ev1 protein, in addition to flat nanoparticles we 
observed nanoparticles which were not of flat in shape (see EM picture Figure 24).  
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Therefore, based on the refolding results we decided to use np1e (small size 
nanoparticle), np2ev1 (medium size nanoparticle) and np1 as a negative control (small 
size nanoparticle without pilin antigen) for immunization studies. 
From the preliminary immunization results, we observed much weaker antibody 
titers (1:4000) against np2ev1 nanoparticles fused with pilin antigen (see Figure 28). 
The possible reason could be due to instable nature of the nanoparticles in solution as 
we observed precipitation in the stored protein samples after 1 month at 4°C (after 1st 
immunization). It seems that the precipitation problem has drastically reduced the 
nanoparticle concentration in solution during the booster immunizations (second, third 
and fourth). In turn, this will affect the generated antibody response, as we see in 
np2ev1 nanoparticle immunization results. 
Immunization results with np1e nanoparticles we observed good antibody titer 
values (1:29600) compared to np2ev1 nanoparticles (Figure 28). With stored np1e 
nanoparticles also we observed precipitation problem after 1 month at 4°C (after 1st 
immunization). But from the obtained antibody titer values, it seems that the 
precipitation rate was less in np1e nanoparticles when compared to np2ev1 
nanoparticles.   
In both np1e and np2ev1 nanoparticles, during dialysis from 0 M urea + 2 mM DTT 
to buffer containing no DTT (preparation 4 refolding), the formed nanoparticles can get 
interlinked with each other through interparticle disulfide bridge formation between 
cysteine residues of pilin antigen displayed on the surface of the nanoparticles (see 
Table 9). This could be the most likely reason for the aggregation of nanoparticles and 
slow precipitation over time.           
Immunization results of np1e nanoparticles - In the presence and absence 
of Freund’s Complete/Incomplete adjuvant  
Virus like particles (VLPs) is a well recognized antigen carrier system in vaccination 
because of its potent stimulation of the immune response in the absence of adjuvant 
against the attached antigens (either coupled or fused) on its surface [9, 10]. 
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VLPs themselves act as particulate adjuvant to boost the immune response against 
the attached antigens on its surface [24]. Our nanoparticle system resembles VLPs in 
properties like self-assembling, non-replicating, non-pathogenic and most importantly 
repetitive display of the attached antigens. Therefore, we wanted to understand our 
nanoparticle system efficiency as a particulate adjuvant by comparing the immunization 
results done with the nanoparticles formulated in Freund’s complete/Incomplete 
adjuvant and in PBS buffer (no adjuvant). As we did not get good immune response 
with medium size nanoparticle of np2ev1 we did these studies with small size 
nanoparticle of np1e.  
After the immunization the obtained final sera was titrated against three antigens: 
np1e nanoparticles, pilin peptide conjugated to BSA and to native pilin protein. From 
the immunization results of np1e nanoparticles formulated in Freund’s 
complete/incomplete adjuvant, we observed 20-fold higher antibody titer values against 
the np1e nanoparticles (1:550,000) compared to the pilin peptide conjugated to BSA 
(1:23293) and to native pilin protein (1:44091) (see Figure 29). This observation clearly 
shows that the majority of the antibodies are directed against the nanoparticle backbone 
and not against the pilin antigen. The above observation is due to the: 
• Effect of Freund’s complete/incomplete adjuvant on nanoparticles  
Freund’s adjuvant is essentially paraffin oil and when mixed with the aqueous 
solutions of antigens it forms a viscous water-in-oil emulsion [25, 26]. Our 
nanoparticles are formed by the self-assembly of coiled-coils and hydrophobic 
interactions form the primary driving force for coiled-coil assembly. Therefore, when 
nanoparticles mixed with hydrophobic Freund’s adjuvant, it can partially unfold the 
nanoparticles by interacting with the hydrophobic residues of coiled-coils and thus 
affecting the hydrophobic interactions within coiled-coils. This can expose the 
nanoparticles to the immune system and the results can be a strong immune response 
against the nanoparticles. It seems that such a result was observed in immunization 
results of np1e nanoparticles formulated in Freund’s complete/incomplete adjuvant. 
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From the immunization results of np1e nanoparticles formulated in PBS buffer (no 
adjuvant) we observed that the antibody fraction directed towards the attached pilin 
antigen is 25% higher when compared to the nanoparticles formulated in Freund’s 
adjuvant where it is 4.2%. This again supports the denaturing effect of Freund’s 
adjuvant on nanoparticles. From the titration results of sera obtained from rabbits 
immunized against np1e nanoparticles (no adjuvant), we observed very low antibody 
titer values against pilin peptide conjugated to BSA (1:1446) and to native pilin protein 
(1:1822) (see Table 6). This suggest about the very poor antibody response against the 
pilin antigen attached to np1e nanoparticles in the absence of adjuvant. The possible 
reasons for this observation could be: 
• Accessibility of fused or coupled antigens to B-cell bound receptors 
Viruses are known for its property of inducing strong antibody mediated immune 
response in its host (T-cell independent). This property is conferred by the optimally 
exposed antigens on their surface in a repetitive and orderly fashion which efficiently 
cross link B-cell bound receptors and sends activation signal for subsequent 
proliferation of B-cells and antibody production [5, 6]. Also, for antigen carriers such 
as VLPs, optimal presentation of antigens is considered as an important factor in 
inducing strong antibody mediated immune response. From EM picture of np1e 
nanoparticles, we see aggregation property of nanoparticles upon removal of DTT 
(Figure 21, B). Therefore, the aggregation of np1e nanoparticles can possibly interfere 
with optimal presentation of pilin antigen and hence the antibody response.  
• Size of nanoparticle 
In particulate carrier based vaccine formulations, particle size is considered as one 
of the important parameter because of its influence on immune response [27]. For 
example, VLPs which are in the size range of viruses (22-150 nm) are used as a 
potential immunogen and also as a particulate carrier system in vaccine formulations 
[28].  
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Considering the size of np1e nanoparticle (~ 18 nm), it seems that it would be rather 
small to be recognized by the immune system. This statement was supported by the 
immunization results from our laboratory with medium size np1ev1 nanoparticles (~ 23 
nm in diameter) displaying Salmonella epitope (D2), we obtained antibody titer values 
of 1:30000 without adjuvant (in collaboration with Cytos Biotechnology AG). This 
brings our nanoparticle system well in the range of VLPs.          
The important observation from the immunization results is that our nanoparticle 
system is able to represent the fused antigens in their native form, as we see the 
generated antibodies recognize the native pilin protein (see Figure 29). In addition, it is 
observed that the nature of the attached epitope to the nanoparticle constructs has a 
significant influence on the formation of icosahedral nanoparticles. 
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Materials and Methods - Chapter 2A and 2B 
Reagents and Enzymes 
All enzymes were purchased from BioConcept – New England Biolabs (Allschwil, 
Switzerland) and chemicals from Sigma, Applichem and Bio-Rad unless stated 
otherwise. They were used according to the manufacturer’s instructions. All 
oligonucleotides (Table 10) were synthesized by Microsynth AG (Balgach, 
Switzerland). Oligonucleotides had 5’ phosphate and were quality assured by PAGE 
purification. 
Bacterial strains and plasmids 
Escherichia coli DH5 α cells (Invitrogen, USA) and BL21 (DE3) pLysS cells 
(Novagen, USA) were used as the cloning and expression host cells, respectively. For 
our expression studies, we have used modified form of the prokaryotic expression 
vector pPEP-T [29, 30] and throughout this chapter it will be described as mpPEP-T 
vector. 
Molecular biology of designed constructs 
The designed constructs are depicted in Figure 16 of Chapter 2B. The cloning 
strategy of the designed constructs will be described under two main headings: (i) 
molecular biology of np1 and np2 constructs; (ii) molecular biology of np1 and np2 
based constructs. 
Molecular biology of np1 and np2 constructs 
Construction of np1 and np2 DNA sequences 
np1 DNA: Three pairs of oligonucleotides were synthesized to construct the np1 
DNA (Table 10). In Figure 31, A, they were represented as fragment 1 to 3. Fragments 
1 to 3 correspond to initial part, middle part and last part of np1 DNA, respectively. 
Each fragment was designed to have a 5’ overhang which gives the specificity during 
assembly of the fragments. That is, the C-terminal 5’ overhang of fragment 1 has 
specificity to N-terminal 5’ overhang of fragment 2 and C-terminal 5’ overhang of 
fragment 2 has specificity to N-terminal 5’ overhang of fragment 3.  
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In addition, the fragment 1 was designed to have a precut BamHI restriction site at 
its N-terminus and fragment 3 to have a precut EcoRI restriction site at its C-terminus 
(Figure 31, A). The precut BamHI and EcoRI restriction sites were created for cloning 
purposes.   
np2 DNA: We have synthesized two oligonucleotides for the construction of np2 
DNA (referred as fragment 1 and 2 in Table 10) (Figure 31, B). The first 
oligonucleotide (fragment 1; forward strand) encodes the N-terminal half of the np2 
DNA and contains the appropriate restriction site (BamHI) at the 5’ end for cloning in 
to the vector. The second oligonucleotide (fragment 2; reverse strand) encodes the C-
terminal half of the np2 DNA and contains the EcoRI restriction site. The N- and C-
terminal oligonucleotides were synthesized in such a way that they overlap by 20 
nucleotides (highlighted in grey color; Figure 31, B). This was done in order to anneal 
the two oligonucleotides and then to use it for subsequent filling reaction of 5’ 
overhangs to get the entire DNA fragment.     
Oligonucleotide fragment assembly 
All the oligonucleotides (both forward and reverse strand) (Table 10) of np1 and np2 
constructs were dissolved in MilliQ water to a concentration of 100 μM.  
The forward and reverse strand of each oligonucleotide were combined in 1 μM 
concentration and 5 μl of 20X SSC buffer (30 mM sodium citrate dihydrate pH 7.0 and 
300 mM NaCl for 100 ml) and water were added to give 50 μl. Annealing reaction was 
done in a thermocycler by first incubating at 90°C for 1 min followed by 70°C for 1 
min and then cooling at 1°/15 sec to 20°C (Tpersonal, Biometra, UK) to give the 
annealed product. The annealed products were desalted using Micro Bio-Spin P-30 
columns as per the manufacturers protocol (Bio-Rad, USA) and then checked in 4% 
NuSieve GTG-Agarose (Cambrex Bio Science, USA) to confirm the annealing 
reaction. Annealed products were stored at -20°C until required. 
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Preparation of mpPEP-T vector for cloning 
For the cloning of np1 and np2 DNA in to mpPEP-T vector, the vector DNA was 
prepared as follows: 1μg mpPEP-T vector, 1μl of 10X NEBuffer EcoRI (10 mM Tris-
HCl, 10 mM MgCl2, 50 mM NaCl and 1 mM DTT pH 7.9), 1 μl of 10X BSA, 1 units 
of EcoRI and BamHI enzyme and water up to 10 μl were combined and incubated at 
37°C for 3 hrs. Double digested vector was recovered using QIAquick Gel Extraction 
Kit (Qiagen, Switzerland) from a 1% agarose gel. After gel extraction, the digested 
vector ends were dephosphorylated by adding both 1 unit of shrimp alkaline 
phosphatase (Promega, USA) and 1 μl of 10X SAP reaction buffer (50 mM Tris-HCl 
and 10 mM Mgcl2 pH 9.0) to a final volume of 10 μl, followed by incubation at 37°C 
for 15 min, then heat inactivation (15 min, 65°C). 
Preparation of mpPEP-T-np1 and mpPEP-T-np2 constructs 
The annealed oligonucleotides of np1 DNA were depicted in the Figure 31, A. In 
np2 annealed oligonucleotides (Figure 31, B), the 5’ overhang was filled in with 
Klenow polymerase (Roche, Switzerland) and dNTPs. After the filling reaction, the np2 
DNA was double digested with BamHI and EcoRI enzymes. 
Dephosphorylated mpPEP-T vector was ligated to fragments 1 to 3 of np1 DNA and 
in other reaction to np2 insert. The ligation reaction was done as follows: Equimolar 
concentration of insert (vector: insert ratio 1:3), 100 ng of dephosphorylated plasmid 
DNA and water were added and incubated at 45°C for 5 min. Then the reaction mixture 
was cooled in ice and then 1 μl of 10X T4 DNA ligase buffer (50 mM Tris-HCl pH 7.5, 
10 mM MgCl2, 10 mM DTT, 1 mM ATP, 25 μg/ml BSA) along with 1 unit of T4 DNA 
ligase and incubated at 16°C overnight. 
Transformation 
Five μl of ligated mixture was added to 100 μl of DH5α competent cells and was 
incubated on ice for 30 min. Followed by heat shock treatment for 90 sec at 42°C, and 
incubated on ice for further 2 min. Then, 0.9 ml LB medium was added and incubated 
at 37°C for 1h with shaking at 225 rpm.  
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Followed by centrifugation of cells at 7000 rpm, 5 min, and the obtained pellet was 
kept in 100 μl of LB and the remaining LB was thrown out. The pelleted cells were 
mixed with the LB by gentle tapping and the mixture was plated on LB-agar plates 
(ampicillin 100 μg/ml) and incubated overnight at 37°C. Putative positive colonies 
were picked from plates and placed in a 3 ml LB-ampicillin (100 μg/ml) broth and 
grown overnight at 37°C with shaking at 180 rpm.  
Plasmid mini prep was done from the grown cultures using QIAprep spin mini prep 
kit (Qiagen, Switzerland) and the obtained plasmid DNA was subjected to enzymatic 
digestion with BamHI and EcoRI enzyme to verify the presence of the insert in the 
transformed bacterial colonies. Products were analyzed by 2% gel electrophoresis. 
DNA sequencing (Microsynth AG, Balgach, Switzerland) was done to verify the 
putative positive clones using T7 promoter and terminator primer sequences. 
Molecular biology of np1 and np2 based constructs 
Construction of DNA cassettes involved in generation of np1 and np2 
based constructs 
Pseudomonas pilin epitope DNA cassette: A pair of oligonucleotides (forward 
and reverse strand) encoding the pilin DNA was synthesized (Table 10; Figure 32, A). 
The oligonucleotides have a precut XhoI and EcoRI restriction sites at their N- and C-
terminus, respectively (Figure 32, A). 
Extension I trimeric coiled-coil DNA cassette: A pair of oligonucleotides 
(forward and reverse strand) encoding the extension I trimeric coiled-coil DNA was 
synthesized (Table 10; Figure 32, B). The oligonucleotides have a precut XhoI and 
XmaI restriction sites at their N- and C-terminus, respectively (Figure 32, B).       
Extension II trimeric coiled-coil DNA cassette: A pair of oligonucleotides 
(forward and reverse strand) encoding the extension II trimeric coiled-coil DNA was 
synthesized (Table 10; Figure 32, C). The oligonucleotides have a precut XhoI and SalI 
restriction sites at their N- and C-terminus, respectively (Figure 32, C). 
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Preparation of np1 and np2 based constructs 
 The synthesized oligonucleotides (Figure 32) were annealed and purified according 
to the protocol described under section ‘Oligonuclotide fragment assembly’.  
mpPEP-T-np1e and mpPEP-T-np2e constructs: Insertion of pilin epitope DNA 
sequence (Figure 32, A) into mpPEP-T-np1 and mpPEP-T-np2 plasmids resulted in 
mpPEP-T-np1e and mpPEP-T-np2e plasmids, respectively. The XhoI and EcoRI 
restriction enzyme sites in mpPEP-T-np1 and mpPEP-T-np2 plasmids was used for 
inserting pilin epitope DNA sequence.  
mpPEP-T-np1ev1 and mpPEP-T-np2ev1 constructs: Insertion of extension I 
trimeric coiled-coil DNA sequence (Figure 32, B) into mpPEP-T-np1e and mpPEP-T-
np2e plasmids resulted in mpPEP-T-np1ev1 and mpPEP-T-np2ev1 plasmids, 
respectively. The XhoI and XmaI restriction enzyme sites in mpPEP-T-np1e and 
mpPEP-T-np2e plasmids was used for inserting extension I trimeric coiled-coil DNA 
sequence.  
mpPEP-T-np1ev2 and mpPEP-T-np2ev2 constructs: Insertion of extension II 
trimeric coiled-coil DNA sequence (Figure 32, C) into mpPEP-T-np1ev1 and mpPEP-
T-np2ev1 plasmids resulted in mpPEP-T-np1ev2 and mpPEP-T-np2ev2 plasmids, 
respectively. The XhoI and SalI restriction enzyme sites in mpPEP-T-np1ev1 and 
mpPEP-T-np2ev1 plasmids was used for inserting extension II trimeric coiled-coil 
DNA sequence. 
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Table 10: Oligonucleotides 
Constructs Oligonucleotide sequence 
                                           
       np1 fragment 1 (forward & reverse strand) 
                                                    (P) 5’ GATCCGATGAAATGTTGCGTGAATTACAGGAAACCAACGCTGCTCTGCAAGACGTTCGTGAACTGCTGCGTCAAC 3’ 
                                                    (P) 5’ AACCTGTTGACGCAGCAGTTCACGAACGTCTTGCAGAGCAGCGTTGGTTTCCTGTAATTCACGCAACATTTCATCG 3’ 
                                    fragment 2 (forward & reverse strand) 
                                                    (P) 5’ AGGTTAAACAGATCACCTTTCTGAAATGTCTGCTGATGGGTGGTCGTCTGCTGTGTCGTCTGGAAGAACTGGAACGT 3’ 
                                                    (P) 5’ AGACGACGTTCCAGTTCTTCCAGACGACACAGCAGACGACCACCCATCAGCAGACATTTCAGAAAGGTGATCTGTTT 3’ 
                            fragment 3 (forward & reverse strand) 
                                                    (P) 5’ CGTCTGGAAGAACTGGAACGTCGTCTGGAAGAACTCGAGCGTGCCTGATAAG 3’ 
                                                    (P) 5’ AATTCTTATCAGGCACGCTCGAGTTCTTCCAGACGACGTTCCAGTTCTTCC 3’ 
 
     np2 fragment 1 (forward strand) 
                                                    (P) 5’ GGATCCGACGAAATGCTGCGTGAACTGCAGGAAACCAACGCTGCTCTGCAGGACGTTCGTGAACTGCTGCGTCAG 
                                                              CAGGTTAAACAGATCCGTCGTCTGAAACGTCTGCTGCGTG 3’ 
                                              fragment 2 (reverse strand)       
                                                    (P) 5’ GAATTCTTATCAGGCACGTTCCAGTTCTTCCAGACGACGTTCCAGTTCTTCCAGACGTTCACGCAGTTCTTCCAGTTC 
                                                              AGCCAGCAGACGACCACCACGCAGCAGACGTTTCAGA 3’ 
 
  Pseudomonas                     fragment 1 (forward & reverse strand) 
  pilin epitope                               (P) 5’ TCGAGCGTGCCCGGGGGCTGAACCGTACCGCTGACGGTGTTTGGGCTTGCAAATCCACCCAGGACCCGATGTTCA 
                                                              CCCCGAAAGGTTGCGACAACTGATAAG 3’   
                                                    (P) 5’ AATTCTTATCAGTTGTCGCAACCTTTCGGGGTGAACATCGGGTCCTGGGTGGATTTGCAAGCCCAAACACCGTCA 
                                                             GCGGTACGGTTCAGCCCCCGGGCACGC 3’ 
 
Extension I trimeric fragment 1 (forward & reverse strand) 
Coiled-coil                                    (P) 5’ TCGAGCGTGCTATCAACACCGTCGACCTGGAACTGGCTGCTCTGCGTCGTCGTCTGGAAGAACTGGC 3’ 
                                                    (P) 5’ CCGGGCCAGTTCTTCCAGACGACGACGCAGAGCAGCCAGTTCCAGGTCGACGGTGTTGATAGCACGC 3’ 
 
Extension II trimeric fragment 1 (forward & reverse strand) 
Coiled-coil                                    (P) 5’ TCGAGCGTGCTATCTCCGCTATCAAAGCTGACCTGTCCGCTCTGAAAGCTAACCTGGCTTCCCTGCAGGCTGACATCA 
                                                              ACACCG 3’ 
                                                    (P) 5’ TCGACGGTGTTGATGTCAGCCTGCAGGGAAGCCAGGTTAGCTTTCAGAGCGGACAGGTCAGCTTTGATAGCGGAG 
                                                              ATAGCACGC 3’ 
 
 
 
(P) - 5' phosphorylation; All the oligonucleotide pairs (forward and reverse strand) were underlined for their complementary regions. 
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                  |GATCCGATGAAATGTTGCGTGAATTACAGGAAACCAACGCTGCTCTGCAAGACGTTCGTGAACTGCTGCGTCAAC      
                      |GCTACTTTACAACGCACTTAATGTCCTTTGGTTGCGACGAGACGTTCTGCAAGCACTTGACGACGCAGTTGTCCAA 
                        D  E  M  L  R  E  L  Q  E  T  N  A  A  L  Q  D  V  R  E  L  L  R  Q  Q  V 
 
 
                  AGGTTAAACAGATCACCTTTCTGAAATGTCTGCTGATGGGTGGTCGTCTGCTGTGTCGTCTGGAAGAACTGGAACGT       
                       TTTGTCTAGTGGAAAGACTTTACAGACGACTACCCACCAGCAGACGACACAGCAGACCTTCTTGACCTTGCAGCAGA 
                       K  Q  I  T  F  L  K  C  L  L  M  G  G  R  L  L  C  R  L  E  E  L  E  R  R  L 
 
 
                  CGTCTGGAAGAACTGGAACGTCGTCTGGAAGAACTCGAGCGTGCCTGATAAG| 
                       CCTTCTTGACCTTGCAGCAGACCTTCTTGAGCTCGCACGGACTATTCTTAA| 
                        E  E  L  E  R  R  L  E  E  L  E  R  A  *  * 
 
 
 
GGATCCGACGAAATGCTGCGTGAACTGCAGGAAACCAACGCTGCTCTGCAGGACGTTCGTGAACTGCTGCGTCAGCAGGTTAAACAGATCCGTCGTCTGAAACGTCTGCTGCGTG 
G  S  D  E  M  L  R  E  L  Q  E  T  N  A  A  L  Q  D  V  R  E  L  L  R  Q  Q  V  K  Q  I  R  R  L  K  R  L  L  R 
 
 
AGACTTTGCAGACGACGCACCACCAGCAGACGACCGACTTGACCTTCTTGACGCACTTGCAGACCTTCTTGACCTTGCAGCAGACCTTCTTGACCTTGCACGGACTATTCTTAAG 
                   G  G  R  L  L  A  E  L  E  E  L  R  E  R  L  E  E  L  E  R  R  L  E  E  L  E  R  A  *  *   
 
Figure 31. A, the initial part (fragment 1), middle part (fragment 2) and last part (fragment 3) of np1 DNA. 1 - precut BamHI restriction enzyme site; 2 - precut EcoRI 
restriction enzyme site. The introduced XhoI restriction enzyme site for cloning purposes in fragment 3 of np1 DNA was highlighted in pink. B, N-terminal half (fragment 
1) and C-terminal half (fragment 2) of np2 DNA. Highlighted grey colored letters represent the 20 bp overlapping region between fragment 1 and 2.   Highlighted yellow 
and red colored letters represent the BamHI and EcoRI restriction enzyme sites, respectively. In both A and B, each fragment was represented along with their amino 
acid sequences (bold colored letters).  Green colored bold letters represent the pentameric coiled coil domain of COMP and the blue colored bold letters represent the 
de novo designed trimeric coiled coil. * represent the stop codons. 
A 
B 
fragment 1
fragment 2
fragment 3
fragment 1 (forward strand) 
fragment 2 (reverse strand) 
XhoI site
1 
1 
2
2
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|TCGAGCGTGCCCGGGGGCTGAACCGTACCGCTGACGGTGTTTGGGCTTGCAAATCCACCCAGGACCCGATGTTCACCCCGAAAGGTTGCGACAACTGATAAG| 
    |CGCACGGGCCCCCGACTTGGCATGGCGACTGCCACAAACCCGAACGTTTAGGTGGGTCCTGGGCTACAAGTGGGGCTTTCCAACGCTGTTGACTATTCTTAA| 
      R  A  R  G  L  N  R  T  A  D  G  V  W  A  C  K  S  T  Q  D  P  M  F  T  P  K  G  C  D  N  *  * 
 
 
 
                |TCGAGCGTGCTATCAACACCGTCGACCTGGAACTGGCTGCTCTGCGTCGTCGTCTGGAAGAACTGGC| 
                    |CGCACGATAGTTGTGGCAGCTGGACCTTGACCGACGAGACGCAGCAGCAGACCTTCTTGACCGGGCC| 
                      R  A  I  N  T  V  D  L  E  L  A  A  L  R  R  R  L  E  E  L  A  R 
 
 
 
           |TCGAGCGTGCTATCTCCGCTATCAAAGCTGACCTGTCCGCTCTGAAAGCTAACCTGGCTTCCCTGCAGGCTGACATCAACACCG| 
               |CGCACGATAGAGGCGATAGTTTCGACTGGACAGGCGAGACTTTCGATTGGACCGAAGGGACGTCCGACTGTAGTTGTGGCAGCT| 
                 R  A  I  S  A  I  K  A  D  L  S  A  L  K  A  N  L  A  S  L  Q  A  D  I  N  T  V   
 
Figure 32. A, Pseudomonas pilin epitope DNA sequence. Amino acid sequence of pilin epiotpe was represented below the DNA sequence (bold red colored). The 
introduced XmaI restriction enzyme site for cloning purposes was highlighted in pink. B, Extension I trimeric coiled coil DNA sequence. Amino acid sequence of 
extension I trimeric coiled coil was represented below the DNA sequence (bold turquoise colored). The introduced SalI restriction enzyme site for cloning purposes was 
highlighted in pink. C, Extension II trimeric coiled coil DNA sequence. Amino acid sequence of extension II trimeric coiled coil was represented below the DNA 
sequence (bold turquoise colored). 1- precut XhoI restriction enzyme site; 2 - precut EcoRI restriction enzyme site; 3 - precut XmaI restriction enzyme site; 4 - precut 
SalI restriction enzyme site.            
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Protein biology of designed constructs 
Construction of mpPEP-T expression plasmid 
We have constructed mpPEP-T expression plasmid (Figure 33, B) for the expression 
of DNA constructs that assembles into nanoparticles upon refolding. The rational 
behind the construction of mpPEP-T plasmid was initially we expressed our 
nanoparticle constructs in pPEP-T expression plasmid but upon refolding we faced the 
precipitation problem. We thought the problem might be with the laminin 
oligomerization domain in pPEP-T expression plasmid (Figure 33, A). Therefore, to 
construct pPEP-T expression without laminin oligomerization domain, we synthesized 
an oligonucleotide sequence (codes for 22 aa) devoid of laminin domain and had precut 
ends of Nco I and BamH I restriction sites (Figure 33, C). This oligonucleotide 
sequence was inserted into the pPEP-T plasmid which also had precut ends of Nco I 
and BamH I restriction sites to yield mpPEP-T expression plasmid. The inserted 
oligonucleotide sequence codes for the following residues: 6X-Histidine tag (pink), 
residues for UV detection (two tryptophan (W) residues; red), residue for coupling 
reactions (lysine (K); yellow) and thrombin recognition sequence (LVPRGS) (grey) 
(Figure 33, C). The nanoparticle constructs were cloned in between BamHI and EcoRI 
restriction enzyme sites.  
Protein expression 
All the nanoparticle constructs in mpPEP-T vector were transformed into E.coli 
strain BL21 (DE3) pLysS (Novagen, Merck Biosciences) as described in section 
‘Transformation’. The transformed cells were plated on fresh ampicillin (100 μg/ml) 
and chloramphenicol (30 μg/ml) LB agar plates and incubated at 37°C overnight. A 
single colony from the transformed plate was inoculated in 50 ml LB broth with 
ampicillin (200 μg/ml) and chloramphenicol (30 μg/ml) and grown overnight at 28°C 
with shaking at 180 rpm. 1% of the overnight grown culture was inoculated into 3 liters 
of the same medium as above and incubated at 37°C with shaking at 200 rpm.  
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Protein expression was induced when OD600nm reached 0.5 by adding IPTG to a final 
concentration of 1 mM. After induction at 37°C for 3 hrs, the cell pellet was collected 
by centrifugation at 6000g for 20 min at 4°C (Sorvall, GSA rotor) and frozen at -80°C 
until later use. 
 
 
   C 
         M  G  H  H  H  H  H  H  G  D  W  K  W  D  G  G  L  V  P  R  G  S 
 5’Po4-CCATGGGTCACCATCATCATCATCATGGTGACTGGAAATGGGACGGTGGTCTGGTTCCGCGTGGATCC-3’OH 
 
 
Figure 33. Overview of the mpPEP-T expression plasmid design. A, schematic representation of 
pPEP-T expression vector, highlighting transcriptional start (promoter) and stop (terminator) signals and 
6X histidine tag followed by 34aa residue oligomerization domain of laminin as the N-terminal fusion along 
with the thrombin cleavage site. The gene to be expressed was cloned in between the BamHI and EcoRI 
sites. B, construction of mpPEP-T vector was done by digesting the pPEP-T vector with NcoI and BamHI 
and inserting the oligonucleotide sequence that removed the laminin oligomerization domain. C, 
oligonucleotide sequence used to create the mpPEP-T vector. Highlighting the Nco I site (bold) and BamH 
I restriction enzyme sites (italic), initial codon (underlined) and also the sequence that codes for 6X 
Histidine sequence (pink), for UV detection (red), for coupling reactions (yellow) and the thrombin 
recognition sequence (gray). Cleavage sites of Nco I and BamH I were highlighted by an arrow. Amino 
acid residues coded by oligonucleotide sequence was highlighted above the oligonucleotide sequence (22 
amino acids). 
Protein purification under denaturing conditions using nickel 
column affinity chromatography 
Following expression, bacterial pellets (from 3 liter culture) were thawed in ice and 
to each gram of pellet (wet weight) 3 ml of lysis buffer (8 M Urea, 10 mM Tris pH 8.0 
and 100 mM NaH2Po4) was added along with 10 mM β-mercaptoethanol.  
T7 Ø10 promoter
Xba I
SD
Nco I
His tag laminin Thrombin site
BamH I
EcoR I
T7 Ø10 
terminator
T7 Ø10 promoter
Xba I
SD
Nco I
His tag Thrombin site
BamH I
EcoR I
T7 Ø10 
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A 
B 
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Pellets were thoroughly resuspended in lysis buffer and sonicated on ice for 5 min (4 
sec of sonication and 6 sec of gap). The supernatant was recovered after centrifuging 
the lysate at 12,000g at 4°C for 30 min.  
The resulted cleared lysate was mixed with 4 ml of the Ni2+-NTA slurry (Qiagen, 
Switzerland) and gently shaked for 1 hr in room temperature (batch method). After the 
incubation, the lysate and the Ni2+-NTA slurry were loaded on to the econo-column 
(Bio-Rad, USA) and the resultant flow through was collected for analysis. Then the 
column matrix was subjected to three separate wash steps with lysis buffer of different 
pH (pH 6.3, 5.9 and 5.0) and in all these buffers 10 mM β-mercaptoethanol was added. 
The pH 5.0 washing step was included to remove the contaminant FKBP-type peptidyl-
prolyl cis-trans isomerase (20 kDa protein) which was co-eluting with the purified 
samples initially. It was also reported to be a major contaminant of E. coli in denaturing 
IMAC-based procedures [31]. After wash step, the bound protein samples were eluted 
with lysis buffer pH 8.0, containing different concentrations of imidazole. 10 mM β-
mercaptoethanol was included in elution buffers. The eluted samples were analyzed 
using SDS-PAGE and western blotting as described in Materials and Methods section 
of Chapter 3.  
Prior to refolding step, the purified samples were dialyzed against the buffer (8 M 
Urea, 20 mM Tris-HCl pH 7.5, 150 mM NaCl, 2 mM DTT) to remove the imidazole. In 
addition, in the above buffer 10 mM EDTA was added to chelate the Ni2+ metal ions 
that might have leached along with the samples. The idea behind this step was to avoid 
the metal mediated cross linking of polyhistidine tag to form aggregates [32].        
Estimation of protein concentration 
For all the samples, protein concentrations were calculated using the absorbance 
value at 280 nm with extinction coefficient (M-1 cm-1) and molecular weight (Daltons) 
of the protein (Table 11).  
Extinction coefficient and the molecular weight of the proteins was calculated using 
ProtParam tool (http://www.expasy.ch/tools/protparam.html) [33]. For protein 
concentration measurements, we have also used the dye binding method [34] using 
Bio-Rad Bradford assay reagent with BSA as the standard. 
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Table 11. Physico-chemical properties of np1 and np2 based proteins#   
Constructs Molecular weight 
(Daltons) 
Number 
of amino 
acids 
Isoelectric 
point (pI) 
Extinction 
coefficient 
(M-1 cm-1) 
np1 10289.7 86 6.05 11125 
np1e 13341.2 114 6.30 16750 
np2ev1 15518.7 133 6.08 16750 
np1 and  
np1 based 
proteins 
np2ev2 17614.1 154 6.08 16750 
np2 10372.7 86 6.59 11000 
np2e 13424.2 114 7.03 16625 
np2ev1 15601.7 133 6.60 16625 
np2 and  
np2 based 
proteins 
np2ev2 17697.1 154 6.60 16625 
 
# - All the properties were calculated using the online tool PROTPARAM from the expasy server 
(http://www.expasy.org/tools/protparam.html) [33]. 
Refolding conditions 
The protein refolding procedure was carried out using two different refolding regimes. 
Preparation 3 (denaturation, renaturation under oxidizing conditions)    
The purified protein in denaturing conditions was refolded by step wise dialysis 
procedure. Initially, the denatured protein was dialyzed against the refolding buffer 20 
mM Tris pH 7.5, 150 mM NaCl and 10% glycerol containing 8 M urea followed by 
6 M urea, 4 M urea, 2 M urea and no urea in the same buffer as above. Finally, the 
protein was concentrated to the required concentration for further characterization in 
the buffer 20 mM Tris pH 7.5, 150 mM NaCl and 10% glycerol. 
Preparation 4 (denaturation, renaturation under reducing conditions) 
In this condition also the step wise dialysis procedure was followed. Initially, the 
protein was dialyzed against the refolding buffer 20 mM Tris pH 7.5, 150 mM NaCl, 
10% glycerol containing 8 M urea and reducing agent (1 mM or 2 mM DTT) followed 
by 6 M urea + DTT, 4 M urea + DTT, 2 M urea + DTT and 0 M urea + DTT in the 
same refolding buffer as above. Finally, the refolded protein samples were dialyzed 
against either 20 mM Tris or Hepes buffer pH 7.5, containing 150 mM NaCl and 10% 
glycerol to remove DTT and concentrated to required concentration for further 
characterization in the same buffer. During refolding in both the conditions, the protein 
concentration was kept at 0.1 mg/ml. 
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Thrombin cleavage reaction 
The refolded np1 and np2 nanoparticles were subjected to thrombin cleavage to 
remove the N-terminal amino acids that were of expression plasmid origin. 
Theoretically, 1 U of thrombin can able to cleave 1 mg of protein. In our cleavage 
conditions, we tried with different higher concentrations of thrombin (2x, 5x, 10x, 20x 
and 50x) to protein concentration to understand the optimal concentration of thrombin 
for cleavage.  
We used human plasma thrombin (Sigma, USA) and the cleavage reactions were 
carried out at room temperature for 16 to 18 hrs with gentle shaking or sometimes for 
24 hrs.      
Biophysical methods 
Circular Dichroism (CD) measurements 
The CD measurements were acquired on an Aviv 62A DS spectropolarimeter. The 
far-ultraviolet spectra (200-250 nm) were measured in a 1 mm path-length quartz cell at 
4°C. The spectra were normalized for concentration and path length to obtain the mean 
molar residue ellipticity (θ, theta) after subtraction of the buffer contribution. The 
melting and annealing curves were measured at 222 nm and in case of melting curve it 
was from 4° to 90°C (1 degree per minute) and for annealing curve 90° to 4°C. 
The following formula was used to calculate the concentration independent theta (θ) 
values (deg cm2 dmol-1): θ (observed) * MRW / [10 * path length (cm) * 
concentration (mg/ml)], where MRW - mean residue weight (molecular mass of the 
peptide or protein divided by number of amino acids). Data analysis and the 
wavelength scan plots were performed with the pro Fit software package 
(QuantumSoft, Switzerland). 
Electron microscopy (EM) analysis 
Electron microscopy analysis was performed by Dr. Gia Machaidze in Professor 
Ueli Aebi group, M.E. Muller Institute, University of Basel and also by Vesna Olivieri 
in Microscopy center, Pharmazentrum, University of Basel.  
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To prepare samples for electron microscopy, 5 μl protein samples were applied to a 
freshly glow discharged 200 mesh copper grids coated with parlodium/carbon film for 
45 sec, washed 3 times with water and finally the samples were stained in 2% uranyl 
acetate for 15-20 sec. Excess of stain on the grids was removed using blotting paper 
and subsequently air-dried. The particles were examined using either Hitachi 7000 or 
Philips Morgagni 268D model transmission electron microscope with an acceleration 
voltage 80 or 100 kV. 
Analytical ultracentrifugation (AUC) 
AUC experiments were performed by Ariel Lustig, Biophysics Department, 
Biozentrum, University of Basel (http://www2.biozentrum.unibas.ch/auc/) 
  Sedimentation velocity (SV) and Sedimentation equilibrium data were recorded 
using Optima XLA analytical ultracentrifuge (Beckman Instruments, Palo Alto, 
California).  
All runs were performed at 20°C using An-60 Ti rotor in 12 and 4 mm thickness 
double-sector cells. np1 and np2 nanoparticles were analyzed in the buffer 20 mM Tris 
or Hepes pH 7.5 containing 150 mM NaCl or no NaCl, 10% glycerol.  
For all runs we used a partial specific volume       of 0.73 mL/g and a buffer density 
(ρ) of 1.029 g/mL and in case of SV a buffer viscosity of 1.26 centipoise (cP) was used. 
The molecular masses (M) were calculated from SE data using the SEGAL computer 
program [35]. The formula that the SEGAL program uses to calculate the molecular 
mass (M) of the sample was given below: 
M = 2RT/ (1-       ρ) ω2 * d (ln c)/d (r2)                                                               Equation 1 
Where R is Gas constant and T is the absolute temperature. ω is angular velocity, c is 
concentration (g/L) and r is radial distance from the axis of rotation.   
Fluorescence correlation spectroscopy (FCS) 
FCS measurements were performed by Dr. Per Rigler, Chemistry Department, 
University of Basel. 
 
(ν)
(ν)
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Instrumentation: A commercial confocal fluorescence laser scanning microscope 
(Zeiss LSM 510 META/Confocor2) equipped with the following laser lines: 405, 458, 
477, 488, 514, 543 and 633 nm, was used to excite the sample either to obtain laser 
scanning micrographs or FCS data.  
In LSM mode the appropriate wavelength with corresponding filter set was chosen. 
In order to get high signal to noise micrographs, the laser beam was typically focused 
on the sample with a 40x water immersion objective (Zeiss C-Apochromat, 40x, NA 
1.2) and the sensitivity of the detectors (photon multiplier tubes) was adjusted 
accordingly. For FCS measurements dye molecules or labeled nanoparticles were 
excited with the appropriate wave length and filters in order to obtain maximal signal to 
noise ratio. A droplet of 5 μl was applied to the glass surface of a 8-well chamber 
(NUNC, USA) which had previously been positioned inside the xy-stage above the 
immersion objective through which the laser beam passes. Fluorescence emission was 
collected through the same objective and finally detected by highly sensitive avalanche 
photo diodes. The intensity fluctuations were analyzed in terms of an autocorrelation 
function.   
Evaluation of FCS data: The analysis of the autocorrelation curve of a single species 
was carried out by a nonlinear least squares’ fitting program by either using a 
commercial software package (LSM 510/Confocor2 software package, Zeiss AG) or a 
home-made procedure (Igor Pro, Wavemetrics Inc.) using the autocorrelation function:  
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where N and τD denote the mean number and the diffusion time of the fluorescent 
particles, respectively. τ is the channel time and R is the ratio between ωz and ωxy 
corresponding to the extensions of the Gaussian volume element of the laser beam in 
the axial and radial direction, respectively. The fraction and the lifetime of triplet states 
are denoted by T and τT, respectively.  
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The diffusion time (τD) is related to the laser beam dimensions and the translational 
diffusion coefficient D by: 
2
4
xy
D D
ωτ =      Equation 2 
With the assumption that the studied species are spherical, the hydro-dynamic radii, Rh, 
can be obtained from the Stoke-Einstein equation: 
                               D = kT/ (6πηRh)                                                                                Equation 3 
where η is the viscosity, k is Boltzmann’s constant and T is the absolute temperature.     
By combining Equation 2 and Equation 1 we can now write the general autocorrelation 
function for multiple fluorescent species: 
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Immunization protocol 
Immunization experiments were done by Daniel Kao in Dr. Robert S. Hodges lab, 
University of Colorado Health Sciences Center, Denver, USA. 
For our immunization studies we have used rabbit as the animal model. 4 injections 
were performed with a gap of 4 weeks between each immunization. During each 
immunization, rabbits were immunized with 15 µg of nanoparticles and administered 
through intramuscular route in the hind leg.  
For preliminary immunization studies, nanoparticles (np1, np1e and np2ev1) were 
formulated with 50% (v/v) Freund’s incomplete/complete adjuvant (Freund’s complete 
adjuvant for the initial injection and Freund’s incomplete adjuvant for the subsequent 
injections). For detail immunization studies with np1e nanoparticles, nanopartilcles 
were formulated with two different formulations: one with 50% (v/v) Freund’s 
incomplete/complete adjuvant and the second one with 50% (v/v) phosphate buffered 
saline (PBS) (no adjuvant). The idea is to assess the immune response generated against 
np1e nanoparticles in the presence and absence of adjuvant. 
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After the final immunization (4th injection), rabbits were exsanguinated. The 
obtained serum was analyzed for antibody response using Enzyme-Linked 
Immunosorbent Assay (ELISA). A standard sandwich ELISA was used to measure anti 
pilin antibodies. Briefly the ELISA plates were coated with different antigens such as 
nanoparticles itself, pilin peptide conjugated to bovine serum albumin (BSA) and native 
pilin protein (200 µl of 0.1 µM of each antigen per well) . These plates were then 
incubated with different dilutions of rabbit sera and then incubated with an anti-rabbit 
IgG secondary antibody conjugated to horseradish peroxidase (HRP). Then the 
substrate was added and product formation was measured by monitoring the 
absorbance at 450 nm.         
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Design Principles 
In chapter 1 and 2, we showed that the viral symmetry based designed peptides can 
be self-assembled into regular icosahedral nanoparticles. In these studies, the basic 
building blocks of nanoparticles are the coiled-coil oligomerization motifs, which 
represent the most frequently encountered oligomerization motifs of proteins [1-3]. 
Also, we wanted to study whether oligomerization motif other than coiled-coils can be 
used in our design principles along with coiled-coil oligomerization motif to form 
regular icosahedral nanoparticles? Therefore, the aim of this chapter is to use non 
coiled-coil oligomerization motif along with coiled-coil oligomerization motif and to 
study their self-assembly properties. 
Based on the aim of the project, we made the following de novo design. The 
monomeic chain of small, globular, three-fold related β-propeller structure of the 
foldon domain [4] which is a trimerization domain of T4 phage fibritin protein, and has 
been linked to the monomeric chain of coiled-coil pentamerization domain of COMP 
[5] to reproduce correctly the relative three dimensional (3D) configuration of the 
three-fold and five-fold symmetry elements of an icosahedral virus capsid (Figure 1) 
[6]. The two-fold symmetry element was then generated by interaction between these 
two domains. 
In order to characterize the de novo design, we engineered four different constructs 
(UC1 to UC4). The schematic representation and the amino acid sequences of these 
constructs are shown in Figure 2, A and B. Construct UC1 depicts the de novo model 
comprising the foldon domain (residues 55-82; highlighted in blue), COMP domain 
(residues 85-126; highlighted in green) and two glycine (GG) residues (highlighted in 
brown) which act as a linker region, linking the foldon domain to the COMP domain. 
The cysteine residues (Cys122 and Cys125) at the C-terminal end of COMP domain can 
possibly form intermolecular disulfide bridges within the pentameric coiled coil of 
COMP, as in the crystal structure of COMP domain [5]. The glycine residues are used 
to provide flexibility between two domains relative to each other. 
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Figure 1. Design of icosahedral nanoparticles (stereo). A, The picture depicts the monomeric chain of 
foldon domain (blue) joined to the monomeric chain of COMP domain (green) as a single subunit. The 
COMP domain in the subunit was placed along the 5-fold axis of the icosahedron and the foldon domain 
along the 3-fold axis of the icosahedron. The rotational symmetry axis of the icosahedron (5, 3 and 2) was 
shown as red lines and was viewed along the centre of the icosahedron. B, computer designed model 
obtained by applying the symmetry elements along the 3-fold and 5-fold axes of the icosahedron. The 
view was along the 5-fold symmetry axis of the icosahedron. The pictures were adopted from [6].  
   In construct UC2, a single point mutation is introduced in the foldon domain 
(aspartic acid (D)64 to cysteine (C)64; bold and underlined residue), otherwise it is the 
same as that of construct UC1. The principle behind the mutation of amino acid (D) to 
(C) is to favor the formation of a disulfide bridge with the same residue of another 
monomeric building block, to which it is symmetrically related by the two-fold rotation 
axis of the icosahedron, with the intention to connect two neighboring foldon trimers in 
the icosahedron related by this two-fold symmetry (Figure 3). By doing so, the 
objective is to stabilize the nanoparticles. In the foldon domain structure [4], the above 
mutated aspartic acid (D) residue is located in the loop region which connects the β 
hairpin motif to the end of the last α helical segment and is not involved in any kind of 
interaction expected to stabilize the trimeric form of the foldon domain. So, the 
mutation of residue (D) to (C) should not abolish the oligomeric state of the foldon 
domain. 
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Figure 2. A, schematic representation of constructs involved in this study. UC1 to UC4 represent the expressed constructs along with the N-terminal vector coded 
laminin domain (pink rectangle). Blue oval shape - foldon domain; green rectangle - COMP domain. The brown colored amino acids in between the foldon and COMP 
domain represent the linker residues. * represents the mutated amino acid aspartic acid (D) to cysteine (C) in the foldon domain. Vertical line (|) represents thrombin 
cleavage site. C1 to C4 represent the thrombin cleaved constructs UC1 to UC4. In C1 to C4 constructs, the two extra amino acids at the N-terminus which are result of 
thrombin cleavage, are highlighted red. B, amino acid sequence of UC1 to UC4 and C1 to C4 constructs. In UC1 to UC4 constructs, the N-terminal 54 amino acids are 
vector sequences coding for His-tag (grey), laminin domain (pink) and thrombin recognition sequence (red). The green and blue colored amino acids represent the 
foldon and COMP domain, respectively. The mutated aspartic acid (D) to cysteine (C) amino acid in the foldon domain is indicated in bold and underlined. The C-
terminal cysteine residues of the COMP domain are indicated in bold.  
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Figure 3. Computer model of UC2 nanoparticle (stereo), showing the laminin domain (red), foldon 
domain (blue) and the COMP domain (green).  Within the nanoparticle, two monomeric building blocks 
are highlighted with a special emphasis on the engineered intermolecular disulfide bridge between the 
foldon domains (blue), which are related by the two-fold symmetry axis of the icosahedron.    
According to our nanoparticle design principles (chapter 1), if the two different 
oligomeric domains of the monomeric building blocks folds properly, the monomeric 
building blocks will first assemble into ‘even units’. The monomer content of even unit 
will depend on the least common multiple (LCM) of the oligomeric state of the 
domains involved. Therefore, in our design 15 monomers will form an even unit 
(Figure 4). One of the factors that determine the further assembly of these even units 
into nanoparticles would probably be the length of the linker region that links the two 
oligomerization domains together. To test this principle, we extended the linker region 
of UC2 construct by four (GGSG) and six residues (GGSGSG) resulting in UC3 and 
UC4 constructs, respectively. 
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Figure 4. Computer model of an ‘even unit’ comprising 15 monomeric building blocks (stereo). The 
pentameric coiled-coil domain of COMP and the foldon domain are highlighted in green and blue, 
respectively. The view is down the three-fold symmetry axis.    
All the four constructs (UC1 to UC4) has an additional 54 amino acids at the N-
terminus which is a result of cloning in pPEP-T expression vector. This region includes 
the vector coded His-tag (residues 3-8; grey), laminin fusion protein (residues 10-43; 
pink) and thrombin recognition sequence (residues 49-54; red). After thrombin 
cleavage, all the four constructs will have two extra residues (glycine (G) and serine 
(S)) at their N-terminus. The thrombin cleaved constructs are depicted in Figure 2, A as 
C1 to C4.  
Results 
Purification results of uncleaved proteins UC1 to UC4    
The 6xHis-tagged proteins are purified by means of Ni2+-affinity column 
chromatography under denaturing conditions. The purification results for all four 
constructs are summarized in Figure 5.  
From the purification results, it is observed that in all the purified proteins the 
monomeric protein (black arrow) started to elute during the wash step pH 8.0 (lane 2) 
and pH 6.3 (lanes 3 and 4) (UC1-14182.1 daltons; UC2-14170.2 daltons; UC3-14314.3 
daltons; UC4-14458.4 daltons).  
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The reason for this could be the over saturation of the Ni2+ binding sites in the 
column by the His-tagged proteins, which would be an indication of very good protein 
expression. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. 15% SDS-PAGE analysis of purified samples of uncleaved proteins UC1 to UC4. A, UC1 
purified fractions; B, UC2 purified fractions; C, UC3 purified fractions; D, UC4 purified fractions. The figure 
lane labels are explained as follows and it applies to all the four constructs: M - molecular weight marker 
in kilo Daltons (kDa); CL - cleared lyaste; lane 1 - Flow through; lane 2 - pH 8.0 wash fraction; lanes 3 and 
4 - pH 6.3 wash fractions; lanes 5 and 6 - pH 5.9 elution fractions; lanes 7 and 8 - pH 4.5 elution fractions. 
The black, orange, sky blue, blue and red arrows represent the monomer, dimer, trimer, tetramer and 
pentamer forms of the above proteins, respectively.  
For proteins UC2, UC3 and UC4 (Figure 5, B, C and D) a strong band is observed 
above the monomeric protein in both wash (lanes 2, 3 and 4) and elution fractions 
(lanes 5, 6, 7 and 8) which correspond to a theoretically calculated dimer (orange 
arrow) (UC2-28340.4 daltons; UC3-28628.6 daltons; UC4-28916.8 daltons). The 
observation of dimer could be due to the formation of a disulfide bridge between the 
monomers.  
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In the purified fractions of UC1 protein (Figure 5, A), the dimeric band (28364.2 
daltons) is observed only in pH 4.5 elution fraction 1 (lane 7) along with a faint band 
corresponding to a theoretically calculated trimer (sky blue arrow) (42546.3 daltons). 
However, for UC2, UC3 and UC4 purified samples, in addition to dimeric band the 
possible higher order oligomers are also observed in the pH 5.9 and 4.5 elution 
fractions (lanes 5, 7 and 8). The observed oligomers correspond to a theoretically 
calculated tetramer (blue arrow) (UC2-56680.8 daltons; UC3-57257.2 daltons; UC4-
57833 daltons) and pentameric (red arrow) (UC2-70851 daltons; UC3-71571.5 daltons; 
UC4-72292 daltons) forms of the protein.  
The eluted fractions (pH 5.9 and 4.5) of proteins UC1 to UC4 are analyzed by 
western blotting using anti His-tag monoclonal antibody. The western blotting results 
supported the presence of monomeric and dimeric forms observed on the SDS-PAGE 
of all the purified proteins (Figure 6). 
 
 
 
 
 
 
 
 
Figure 6. Western blot analysis of purified samples of uncleaved proteins UC1 to UC4. Purified 
fractions of pH 5.9 and 4.5 eluted samples of UC1 (S1, S2), UC2 (S3, S4), UC3 (S5, S6) and a purified 
fraction of pH 5.9 eluted sample of UC4 (S7). Anti His-tag monoclonal antibody is used. The monomer 
and dimer band is indicated by the black and the orange arrow, respectively. M - Molecular weight marker 
in kiloDaltons (kDa). 
Thrombin cleavage and Purification results of cleaved proteins 
C1 to C4 
The purified uncleaved UC1 to UC4 samples are dialyzed against thrombin cleavage 
buffer cleaved by thrombin and purified, as described in the Materials and Methods 
section. The SDS-PAGE results of the cleaved, purified samples of C1 to C4 are 
summarized in Figure 7. 
M S1 S2 S3 S4 S5 S6 S7 
30 
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The cleaved monomeric band of C1 protein (8368.5 daltons) is observed in the flow-
through samples as expected (Figure 7, A; lanes FT1 to FT3) (green arrow). This result 
confirmed successful cleavage of the His-tag along with the upstream fusion domain 
laminin. The cleavage is further supported by the elution of uncleaved full length 
protein (black arrow) along with the cleaved His-tagged N-terminal fusion domain 
(5831.6 daltons) (orange arrow) in the pH 6.3 wash fractions (lanes W1 to W3) and in 
the pH 5.9 elution fraction (lane E1) (Figure 7, A). 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 7. 17% SDS-PAGE analysis of purified 
samples of cleaved proteins C1 to C4. A, C1 
protein. S1 to S3 - thrombin cleaved UC1 
samples. FT1 to FT3 - flow through; W1 to W3 - 
pH 6.3 wash fractions. E1 - pH 5.9 elution fraction. 
B, C2 protein; C, C3 protein; D, C4 protein. The 
figure lane labels of C2, C3 and C4 purified 
fractions are explained as follows: FT1 to FT2 - 
flow through; W1 to W4 - pH 8.0 wash fractions; E1 - pH 6.3 wash fraction; E2 - pH 5.9 elution fraction. M 
- Molecular weight marker in kiloDaltons (kDa). The monomeric and dimeric forms of the cleaved proteins 
C1 to C4 are indicated by green and white arrows, respectively. The monomeric and dimeric forms of the 
uncleaved proteins UC1 to UC4 are indicated by black and red arrows, respectively. The cleaved His-
tagged laminin fusion domain is indicated by an orange arrow. 
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For cleaved proteins C2, C3 and C4 (Figure 7, B, C and D), the expected monomeric 
band (C2-8356.6 daltons; C3-8500.7 daltons; C4-8644.8 daltons) is observed in the 
flow-through samples (lanes FT1, FT2) and in the pH 8.0 wash fraction (lane W1) 
(green arrow). This again confirmed the successful cleavage of the His-tagged N-
terminal fusion domain laminin. In the above samples, in addition to the monomeric 
band we observed a band which correspond to a theoretically calculated cleaved 
dimeric band (C2-16713.2 daltons; C3-17001.4 daltons; C4-17289.6 daltons) (white 
arrow). 
As observed for C1 protein, the uncleaved full length protein (black arrow) and the 
cleaved His-tagged laminin fusion domain (orange arrow) of proteins C2 to C4 is 
eluted at pH 6.3 wash fraction (lane E1) and at pH 5.9 elution fraction (lane E2). In 
case of the pH 6.3 wash fraction, we also observed the uncleaved dimeric band (red 
arrow). 
The cleaved and purified samples of the C1 to C4 are subjected to western blotting 
using anti His-tag monoclonal antibody. The objective is to confirm the cleavage of the 
His-tag by comparing with the uncleaved fractions of pH 6.3 step. From the western 
blot results, it is clear that the purified fractions of C1 to C4 are devoid of His-tag, since 
none of them shows recognition by anti His-tag monoclonal antibody (Figure 8; lanes 
S2, S4, S6 and S8). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Western blot analysis of purified samples of cleaved proteins C1 to C4. The thrombin 
cleaved sample of UC1 protein (S1) is compared with the purified fraction of cleaved C1 protein (S2). In 
the same way, the purified uncleaved pH 6.3 eluted fractions of UC2 (S3), UC3 (S5) and UC4 (S7) are 
compared with the purified fractions of cleaved C2 (S4), C3 (S6) and C4 (S8), respectively. Anti His-tag 
monoclonal antibody is used. M - Molecular weight marker in kiloDaltons (kDa).  
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Self-assembly properties of cleaved proteins C1 to C4 
The cleaved proteins C1 to C4 (Figure 2, A) are studied for their self-assembling 
properties. Because of the presence of cysteine amino acids in these proteins as they 
can form different combinations of intra- and intermolecular disulfide bridges during 
refolding, we tried with two different refolding conditions. In the first refolding 
condition, the purified protein samples in 8 M urea are refolded by means of step-wise 
dialysis of the urea completely under oxidizing condition (preparation 1). In the second 
refolding condition, the protein samples are refolded by step-wise dialysis of the urea 
under reducing condition (2 mM DTT) up to 0 M urea, followed by the oxidizing 
condition by dialyzing out the reducing agent (2 mM DTT) (preparation 2).  
The self-assembly behavior of the cleaved proteins under these two different 
refolding conditions are analyzed by Blue Native (BN)-PAGE and AUC to determine 
the molecular weight of the oligomers formed. Furthermore, the morphology of the 
oligomers is investigated by EM. 
Self-assembly properties of protein C1 
BN-PAGE results: For protein C1, refolded under preparation 1 condition we 
observed a band corresponding to pentamers (41.9 kDa) (Figure 9; lane 3). However, 
for the preparation 4 refolded samples we observed an additional band which 
corresponds to decamers (10-mers) (83.8 kDa) (Figure 9; lane 4).  
AUC results: The refolded samples under both conditions (preparation 1 and 2) 
gave a molecular mass which corresponds to pentamers (Table 1).  
EM results: In both preparation 1 (Figure 10, A) and preparation 2 (Figure 10, B) 
refolded samples of C1 protein, we observed short fragment like structures. Based on 
the results of BN-PAGE and AUC, the observed short fragment like structures might 
well correspond to pentamers and decamers.   
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15-mer (even unit) 
440 
232 
140 
66 
M 1 2 3 4 5 B 6 7 8 9 B 10 11 12kDa 
Trimer 
Pentamer  
Decamer 
20-mer
Table 1: AUC results for refolded protein C1. Monomer molecular weight 8.37 kDa 
 
 
 
 
Self-assembly properties of protein C2 
BN-PAGE results: For protein C2, refolded under preparation 1 condition we 
observed bands corresponding to trimers (25.1 kDa), pentamers (41.9 kDa) and 15-
mers (even units) (125.6 kDa) (Figure 9; lane 6). However, for preparation 2 refolded 
samples we observed bands which correspond to pentamers and even units and we did 
not observe the trimeric band (Figure 9; lane 7).  
 
Figure 9. 5 - 12% gradient Blue Native (BN) PAGE of refolded uncleaved (UC1 to UC4) and cleaved 
(C1 to C4) proteins. The figure lanes are explained as follows: M - High molecular weight native gel 
marker; lane 1 corresponds to UC1 sample (preparation 2 refolded). Analyzed in the buffer 20 mM Tris pH 
8.5, 150 mM NaCl and 2 mM DTT; lanes 2, 5, 10 correspond to UC1, UC2 and UC4 samples, respectively 
(preparation 2 refolded). Analyzed in the buffer 20 mM Tris pH 8.0, 150 mM NaCl and 2 mM DTT; lanes 3, 
6, 8 and 11 correspond to preparation 1 refolded samples of C1, C2, C3 and C4, respectively; lanes 4, 7, 
9 and 12 correspond to preparation 2 refolded samples of C1, C2, C3 and C4, respectively; both 
preparation 1 and preparation 2 refolded samples are analyzed in the buffer 20 mM Tris pH 7.5, 150 mM 
NaCl; B- blank lanes. In each lane, ~ 15 µg of protein was loaded. 
Sedimentation Equilibrium 
MW (kDa) 
Refolding 
condition 
Concentration
(mg/ml) 
Rotor speed 
(rpm) 
Observed 
MW 
No. of 
monomers 
0.05 18000 44 5.3 preparation 1 
0.1 20000 40 4.8 
0.1 18000 44 5.3 preparation 2 
0.2 20000 43 5.1 
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AUC results: The refolded samples under both conditions (preparation 1 and 2) 
gave molecular mass values which correspond to pentamers and 20-mers (Table 2). 
Based on the results of BN-PAGE, the observed 20-mers might well correspond to the 
mixture of even units and possibly the even units linked to pentamers through disulfide 
bridges. 
EM results: In both preparation 1 (Figure 10, C) and preparation 2 (Figure 10, D) 
refolded samples, we observed nanoparticles but not of regular in shape. In addition, we 
observed a lot of background material. Based on the results of BN-PAGE and AUC, the 
observed nanoparticles which are not of regular in shape might well correspond to even 
units and 20-mers, and background material to trimers and pentamers. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Electron micrographs of C1 and C2 refolded proteins. A and C correspond to preparation 1 
refolded C1 and C2 proteins, respectively. B and D correspond to preparation 2 refolded C1 and C2 
proteins, respectively. The pictures were prepared by negative staining with 2% uranyl acetate; the 
concentration of the protein was 50 µg/ml. 
 
 
 
 
C D
A B
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Table 2. AUC results for refolded protein C2. Monomer molecular weight 8.37 kDa 
  
Sedimentation Equilibrium 
MW (kDa) 
Refolding 
condition 
Concentration 
(mg/ml) 
Rotor 
speed 
(rpm) Observed 
MW 
No. of monomers 
0.2 18000 44 + 166 
 
5.3 + 19.8 preparation 
1 
0.4 12000 46 + 164 5.5 + 19.6 
preparation 
2 
0.4 12000 51 + 179 6 + 21.4 
 
Self-assembly properties of protein C3 
BN-PAGE results: For protein C3, refolded under preparation 1 condition we 
observed bands corresponding to trimers (25.5 kDa), pentamers (42.5 kDa) and even 
units (127.5 kDa) (Figure 9; lane 8). However, for preparation 2 refolded samples we 
observed bands which correspond to pentamers and even units but not to trimers 
(Figure 9; lane 9).  
AUC results: The preparation 1 refolded sample gave molecular mass values 
which correspond to pentamers and 20-mers (Table 5). On the other hand, preparation 2 
refolded samples gave molecular mass values which correspond to pentamers and 30-
mers (Table 3). The observation of 30-mers possibly suggests the two self-assembled 
even units. Again, the observation of 20-mers might well correspond to mixture of even 
units and possibly the even units linked to pentamers through disulfide bridges.  
Table 3. AUC results for refolded protein C3. Monomer molecular weight 8.5 kDa 
 
Sedimentation Equilibrium 
MW (kDa) 
 Refolding 
condition 
Concentration 
(mg/ml) 
Rotor 
speed 
(rpm) Observed 
MW 
No. of monomers 
0.13 14000 49 + 183 5.8 + 21.5 preparation 
1 0.4 12000 56 + 176 6.6 + 20.7 
0.16 12000 45 + 245 5.3 + 28.8 preparation 
2 0.2 12000 52 + 253 6.1 + 29.8 
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Self-assembly properties of C4 protein  
BN-PAGE results: For C4 protein, refolded under preparation 1 condition we 
observed bands corresponding to trimers (25.9 kDa), pentamers (43.2 kDa) and even 
units (129.7 kDa) (Figure 9; lane 11). However, for preparation 2 refolded sample we 
observed bands which correspond to pentamers (43.2 kDa) and even units (129.7 kDa) 
and in addition we observed an additional faint band which corresponds to 20-mers 
(Figure 9; lane 12).  
AUC results: The refolded samples under both conditions (preparation 1 and 2) 
gave a molecular mass values which correspond to pentamers and high molecular 
weight species. The high molecular weight species seems to be the mixed population of 
20-mers and 30-mers (Table 4). 
Table 4. AUC results for refolded C4 protein. Monomer molecular weight 8.6 kDa 
 
Sedimentation Equilibrium 
MW (kDa) 
Refolding 
condition 
Concentration 
(mg/ml) 
Rotor 
speed 
(rpm) Observed 
MW 
No. of monomers 
0.13 48 + 314 5.6 + 36.5 
0.2 52 + 294 6 + 34.2 
preparation 
1 
0.4 175 + 248 20.3 + 28.8 
0.14 48 + 234 5.6 + 27.2 
0.2 44 + 231 5.1 + 26.9 
preparation 
2 
0.45 
 
 
12000 
200 23.3 
 
 
EM results for refolded proteins C3 and C4: In both, preparation 1 refolded 
samples of C3 and C4 (Figure 11, A and C) and in preparation 2 refolded samples of 
C3 and C4 (Figure 11, B and D), we observed nanoparticles but not with regular shape.   
Based on the BN-PAGE and AUC results of C3 and C4 proteins, the observed 
nanoparticles which are not of regular in shape might well correspond to even units and 
multiples thereof. 
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C D
 
Figure 11. Electron micrographs of C3 and C4 refolded proteins. A and C correspond to preparation 1 
refolded C3 and C4 proteins, respectively. B and D correspond to preparation 2 refolded C3 and C4 
samples, respectively. The pictures were prepared by negative staining with 2% uranyl acetate; the 
concentration of the protein was 50 µg/ml. 
Self-assembly properties of uncleaved proteins UC1 to UC4 
From the self-assembly studies of cleaved proteins C1 to C4, we understood that the 
cleaved proteins do not form icosahedral nanoparticles composed of 60 monomers. 
This observation prompted us to study the self-assembly properties of uncleaved 
proteins UC1 to UC4 (for construct details refer to Figure 2).   
For self assembly studies, the purified samples of uncleaved proteins UC1 to UC4 in 
8 M urea are subjected to step wise dialysis of the urea under reducing condition and at 
low protein concentration (preparation 2). The reason for reducing condition (2 mM 
DTT) refolding is that the initial refolding experiment of UC2 protein under oxidizing 
condition (preparation 1), showed precipitating behavior of the protein at 4 M urea 
concentration. Therefore, we decided to refold the proteins under reducing condition 
refolding (preparation 2). 
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Initial refolding results of UC1 protein 
Initially for UC1 protein, the reducing condition refolding (preparation 2) is done at 
pH 7.5. However, the refolded protein started to precipitate in refolding buffer 
containing 0 M urea and 2 mM DTT (reducing condition). Subsequent change to the 
refolding buffer containing 0 M urea and no DTT (oxidizing condition), the refolded 
protein precipitated heavily. From the EM analysis of sample in 0 M urea and no DTT, 
large aggregated structures with few individual icosahedral nanoparticles are observed 
(Figure 12, A). The possible reason for precipitation in the refolding buffer containing 
0 M urea and 2 mM DTT could be due to pI of the protein which is calculated to be 
6.29. In addition, the observed heavy precipitation upon oxidizing condition could be 
due to linking of aggregates through intermolecular disulfide bridges. Therefore, the 
UC1 samples are refolded at pH 8.0 and 8.5 and analyzed in the refolding buffer 
containing 0 M urea and 2 mM DTT (reducing condition). The refolded samples are 
found to be stable in 0 M urea containing 2 mM DTT. From EM pictures, the refolded 
samples at pH 8.0 and 8.5 are observed to form icosahedral nanoparticles (Figure 12, B 
and C).  
 
 
 
 
 
 
 
Figure 12. Electron micrographs of 
preparation 2 refolded UC1 protein in varying pH. 
A, refolded at pH 7.5. Analyzed in the buffer 
containing 0 M urea and no DTT. Figure inlet 
showing the enlarged image of aggregates and 
single nanoparticles. B and C, correspond to 
refolded samples at pH 8.0 and 8.5, respectively. 
In B and C, the samples are analyzed in the buffer 
containing 0 M urea and 2 mM DTT. The pictures 
were prepared by negative staining with 2% uranyl 
acetate and at a protein concentration of 50 µg/ml. 
A B
C 
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Self-assembly properties of proteins UC1, UC2, UC3 and UC4  
To compare their self-assembly properties, all four proteins are refolded under 
reducing condition (preparation 2) and the pH of the refolding buffer is kept at 8.0. The 
protein samples are refolded up to 0 M urea containing 2 mM DTT and analyzed in the 
same buffer for EM and AUC studies.  
EM results: From the EM pictures, all four proteins are observed to form 
icosahedral nanoparticles (Figure 13, A to D).  
 
Figure 13. Electron micrographs of refolded UC1 to UC4 proteins. A, UC1; B, UC2; C, UC3; D, UC4. 
All the four proteins were refolded under reducing condition after denaturation (preparation 2) and finally 
studied in the buffer 20 mM Tris pH 8.0, 150 mM NaCl and 2 mM DTT. The pictures were prepared by 
negative staining with 2% uranyl acetate; the concentration of the protein was 50 µg/ml. 
 
AUC results: The AUC results for uncleaved proteins are summarized in Table 5. 
The sedimentation equilibrium (SE) results for the UC1 to UC4 proteins refolded at pH 
8.0, showed high molecular weight aggregates ranging from 17.3 MDa to 1.7 MDa.  
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For the UC1 protein refolded at pH 8.5, the SE results at lower speed (2800 rpm) 
showed molecular weight values ranging from 7.2 MDa to 611 kDa. The smallest 
molecular weight species 611 kDa corresponds to a molecular weight of 3 even units. 
At higher speed (4800 rpm), the smallest molecular weight species showed mixed 
population of molecular weight values 632 kDa (3 even units) and 756 kDa (3.6 even 
units). Therefore, the observed low molecular weight species can corresponds to 
icosahedral nanoparticles composed of 4 even units. This is supported by the EM 
picture of UC1 protein refolded at pH 8.5, where we observed icosahedral nanoparticles 
(Figure 12, C). The observed high molecular weight aggregates in all refolded proteins 
(UC1 to UC4) suggest the aggregating nature of the icosahedral nanoparticles.  
BN-PAGE results: The BN-PAGE results for UC1, UC2 and UC4 proteins, 
showed no bands in the separating gel (5 - 12 % gradient gel) (Figure 9; lanes 1, 2, 5, 
10). This shows that the loaded proteins got stuck in the stacking gel (4.5%). The 
reason could be aggregation of the icosahedral nanoparticles to high molecular weight 
aggregates. The aggregation behavior is also evident from AUC results (Table 5). 
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Table 5: AUC results for uncleaved proteins UC1 to UC4  
 
Sedimentation Equilibrium 
MW (kDa) 
Construct# Concentration 
(mg/ml) 
Rotor 
speed 
(rpm) 
Sedimentation velocity 
(S20,W) 
Observed No. of particles 
(60-mers) 
Expected MW for an 
even unit (15-mers) 
& for a nanoparticle 
(60-mers) 
UC1 refolded in 
pH 8.0 buffer 
0.5 22000 74 S + 59 S + 52 S + 46 S 8199 + 5049 + 4078 + 2767 
+ 1791$ (2800 rpm) 
9.6 + 5.9 + 4.8 + 
3.3 + 2.1 
 
28000 56 S + 34 S + 28 S 7244 + 2682 + 2756 + 611 
(3200 rpm) 
8.5 + 3.2 + 3.2 + 
3 even units 
UC1 refolded in 
pH 8.5 buffer 
0.48 
50000 7.8 S 632 + 756 (4800 rpm) 3 even units + 
3.6 even units 
 
 
even unit - 212.7 
nanoparticle - 850.9 
16000 211 S + 138 S + 109 S + 57 S 13434 + 11263 + 4128 
(2400 rpm) 
15.8 + 13.2 + 4.9 UC2 refolded in 
pH 8.0 buffer 
0.19 
48000 low S 1-2   
even unit - 212.6 
nanoparticle - 850.2 
16000 241 S + 157 S 17314 + 9379 + 7361 + 4240 
(2400 rpm) 
20.2 + 10.9 + 8.6 
+ 4.9 
UC3 refolded in 
pH 8.0 buffer 
0.27 
48000 no sedimentation   
even unit - 214.7 
nanoparticle - 858.9 
UC4 refolded in 
pH 8.0 buffer 
0.28 16000 194 S + 164 S + 194 S 16151 + 7509 + 4019 + 2331 
(2400 rpm) 
18.6 + 8.7 + 4.6 
+ 2.7 
even unit - 216.9 
nanoparticle - 867.5 
 
# All the constructs are refolded in reducing condition (preparation2) after denaturation up to 0 M urea and 2 mM DTT and analyzed in the buffer 20 mM Tris pH 8.0 or 
8.5, 150 mM NaCl and 2 mM DTT. 
$ Only small concentration which is not detected as a boundary in sedimentation velocity. 
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CD spectroscopy results for refolded proteins UC1 to UC4 and 
C1 to C4  
We performed CD experiments in order to understand the secondary structural 
contents of the refolded samples, because the laminin and COMP domain in the 
refolded samples are well characterized α-helical coiled-coil proteins [5, 7, 8]. Also, the 
foldon domain is a well studied β-hairpin motif structure [4].  
CD spectroscopy results for proteins UC1 to UC4  
The uncleaved UC1 to UC4 samples showed a typical and similar α-helical spectrum 
(Figure 14, A to D; open circles). For uncleaved proteins UC1 to UC4, if both the 
laminin and COMP domain folds into an α-helical structure, the theoretical α-helical 
content will be: UC1, UC2 proteins - 61.4 %; UC3 protein- 60.5 %; UC4 protein - 59.5 
%. The theoretical α-helical content is calculated using the formula: (number of amino 
acids from COMP domain (44)) + (number of amino acids from laminin domain (34) / 
(total number of amino acids). The calculated α-helical content values from CD spectra 
using CD Pro software (Table 6; indicated in red boxes) [Sreerama, N et al., 2000] are 
similar to the theoretically calculated values. Also, the theoretically calculated β-sheet 
content values (UC1 and UC2 - 7.9%; UC3 - 7.8% and UC4 - 7.6%) are similar to the 
calculated β-sheet content values from CD spectra (Table 6; indicated in pink boxes). 
The theoretical β sheet content is calculated using the formula:  (number of amino acids 
contributing to β sheet structure in foldon domain (10))/ (total number of amino acids). 
The above results support the formed α-helical structures in both the laminin and 
COMP domain and the β-sheet structures in the foldon domain.  
CD spectroscopy results for proteins C1 to C4   
The CD spectrum of both preparation 1 (p1; closed circles) and preparation 2 (p2; 
open squares) refolded C1 to C4 proteins also showed a typical and similar α-helical 
spectrum (Figure 14, A to D). The cleaved proteins C1 to C4 showed a higher α-helical 
spectrum compared to the α-helical spectrum of UC1 to UC4 samples.  
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The α-helical content values calculated from CD spectra using CD Pro software 
(Table 6; cleaved samples C1 to C4) showed 8 to 10% higher α-helical content values 
compared to the theoretically calculated α-helical content values (C1, C2 constructs - 
58.7 %; C3 construct - 57.1%; C4 construct - 55.7%). The theoretical α-helical content 
of C1 to C4 constructs is calculated using the formula: (number of amino acids from 
COMP domain (44)) / (total number of amino acids). The calculated β-sheet content 
values from the CD spectra of C1 to C4 samples (Table 6) showed ~ 6% less when 
compared to the theoretically calculated β-sheet content values (C1, C2 - 13.3%; C3 - 
13%; C4 - 12.7%). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14. Far-UV Circular Dichroism (CD) analysis of uncleaved (UC1 to UC4) and cleaved (C1 to 
C4) samples. In A, B, C and D, open circles (○) represent the preparation 2 refolded CD spectrums of 
UC1, UC2, UC3 and UC4 samples, respectively; closed circles (●) represent the preparation 1 (p1) 
refolded CD spectrums of C1, C2, C3 and C4 samples, respectively;  open squares (□) represent the 
preparation 2 (p2) refolded CD spectrums of C1, C2, C3 and C4 samples, respectively. UC1 to UC4 
samples were studied in the buffer 20 mM Tris pH 8.0, 150 mM NaCl and 2 mM DTT. C1 to C4 samples 
were studied in the buffer 20 mM Tris pH 7.5, 150 mM NaCl. The protein concentration was always 0.1 
mg/ml. 
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Table 6: Estimation of secondary structural contents from CD spectra using CD Pro software [9]. (http://lamar.colostate.edu/~sreeram/CDPro) 
 
Calculated secondary structures (%) from the CD spectra Secondary 
structures 
CDPro 
analysis 
programs 
uncleaved  
UC1# 
cleaved 
C1& 
cleaved 
C1$ 
uncleaved 
UC2# 
cleaved 
C2& 
cleaved 
C2$ 
uncleaved 
UC3# 
cleaved 
C3& 
cleaved 
C3$ 
uncleaved 
UC4# 
cleaved 
C4& 
cleaved 
C4$ 
CDSSTR 55.7 68.3 63.1 55.4 74.1 70.9 55.4 74.6 68.5 56.4 74.1 67.1 
SELCON3 55.3 65.9 64.4 52.8 66 67.3 52.4 69.3 68.1 57.3 67.9 65.9 
α - helix 
CONTINLL 54.1 63.3 54.4 52.8 61.2 62.3 53 61.9 61.6 51.5 61.3 60.4 
CDSSTR 12.5 9.8 14.3 10.7 6.7 9.2 10.5 10.1 10 15.4 8.5 10.5 
SELCON3 11 4.7 4.6 13.2 4.3 3.9 9.6 2.8 3.8 8.2 2.9 4.3 
β - sheet 
CONTINLL 9.2 5.4 9.7 11.1 4.9 5.1 9.4 4.5 4.9 10.6 4.3 5.3 
CDSSTR 11.2 9.5 10.6 13.2 6.7 7.2 10.9 6.6 10.3 10.4 8.8 10.4 
SELCON3 15.3 11.2 11.7 16.1 11.7 11.4 14.2 10.5 11.1 12.6 10.4 12.1 
Turns (T) 
CONTINLL 13.6 10 14.5 14.4 12.1 11.9 14.7 12 12.6 14.5 12.6 13.3 
CDSSTR 20.9 11.3 12 21.6 11.6 12.7 22.9 8.4 10.2 17.7 9.1 11.2 
SELCON3 21.3 20.5 20.6 16.9 20.9 19.7 24.2 18.8 19 24.4 18.8 20.4 
Unordered 
(U) 
CONTINLL 23.1 21.3 21.4 21.8 21.8 20.8 23 21.6 20.9 23.4 21.8 21 
 
# - uncleaved proteins UC1 to UC4, refolded in reducing condition after denaturation up to 0 M urea buffer containing 2 mM DTT and analyzed in the buffer 20 mM Tris 
pH 8.0, 150 mM NaCl and 2 mM DTT. 
& - cleaved proteins C1 to C4, refolded completely in oxidizing condition after denaturation (preparation 1).  
$ - cleaved proteins C1 to C4, refolded in reducing condition up to 0 M urea and then to oxidizing condition (preparation 2). 
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Discussion 
 For the sake of simplicity, the cysteine in the foldon domain will be called 1 and the 
two cysteines at the C-terminus of COMP domain will be called 2 and 3, in order to 
explain the different combinations of intra- and intermolecular disulfide bridges that 
could form during preparation 1 and preparation 2 refolding conditions. 
Cleaved proteins C1 to C4 
The cleaved proteins C1 to C4 (Figure 2, A) was rationally designed so as to form 
nanoparticles of regular icosahedral symmetry, consisting of 60 monomeric building 
blocks. Computer modeling predicted that such particles would each have a diameter of 
about 17 nm (Figure 1, B). The observed oligomeric forms of these proteins after 
refolding under preparation 1 and preparation 2 conditions are discussed in the 
following sections. 
Self-assembly result of protein C1 
The pentameric coiled-coil domain of COMP is known to form very stable 
oligomers [10]. During refolding out of 8 M urea, the coiled-coil domain of COMP will 
already form in urea concentrations that are moderately high. Formation of helices 
within the COMP domain will bring the two cysteines of the COMP domain (2 and 3) 
in close contact. Under oxidizing conditions with low protein concentration 
(preparation 1) intramolecular disulfide bridge formation will then immediately and 
predominantly occur. Therefore, the pentamers observed in the preparation 1 refolded 
sample of C1 (Figure 9; lane 3) (Table 1) suggest the folded COMP domain with the 
intramolecular disulfide bridges (2-3). During preparation 2 refolding, there is no 
possibility of forming either intra- or intermolecular disulfide bridges because of its 
reducing condition refolding up to 0 M urea. As a result, the cysteine residues will be in 
reduced state up to 0 M urea, however, upon proceeding to oxidizing condition (0 M 
urea and no DTT), they will form disulfide bridges. Therefore, the pentamers and 
decamers observed in preparation 2 refolded samples (0 M urea and no DTT) (Figure 9; 
lane 4) can be the intramolecular disulfide linked pentamers (2-3) and two pentamers 
linked through intermolecular disulfide bridges (either 2-2, 2-3 or 3-3) (Table 7), 
respectively.  
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The observed pentamers and decamers for C1 protein suggest that the trimeric 
foldon domain is not folded in these structures. Because, if the trimeric foldon domain 
folds along with the pentameric COMP domain they will assemble into ‘even units’ 
(15-mers) (Figure 4). In addition, it seems that the folding rate of pentamer domain is 
faster than the trimer domain, as this will inhibit the folding of trimer domain. 
Schematic models of a pentamer and a decamer are shown in Figure 15, B and C, 
respectively.  
Table 7. Data depicting the cysteine (C) amino acid residue numbers and their possible type of disulfide 
bridges that can form during step-wise dialysis from 8 M to 0 M urea (preparation 1 and preparation 2).  
 
Type of disulfide bridge                     Constructs Residue number* 
Uncleaved protein UC1 
Cleaved protein C1 
2-3  Intramolecular£ 
Uncleaved proteins UC2, UC3 and UC4 
Cleaved proteins C2, C3 and C4 
1-2; 1-3; 2-3 
Uncleaved protein UC1 
Cleaved protein C1 
 
2-2; 2-3; 3-3 Intermolecular€ 
and Interparticle$ 
Uncleaved proteins UC2, UC3 and UC4 
Cleaved proteins C2, C3 and C4 
1-1; 1-2; 1-3 
2-2; 2-3; 3-3 
 
 
* - cysteine amino acid in the foldon domain is denoted as 1 and the two cysteine amino acids at the C-
terminus of COMP domain is denoted as 2 and 3. 
£ - within a peptide or protein chain 
€ - between the peptide or protein chain 
$ - between the nanoparticles. 
Self-assembly result of proteins C2, C3 and C4 
For proteins C2, C3 and C4, the even units observed in both preparation 1 and 
preparation 2 refolding conditions (Figure 9; lanes 6, 7, 8, 9, 11 and 12), are evidence 
of the properly folded COMP and the foldon domain. In addition, the observed even 
units support properly formed intermolecular disulfide bridges between the monomeric 
chains of foldon domain (1-1) and between the monomeric chains of COMP domain (2-
3). A schematic model of an even unit is shown in Figure 15, D.  
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C2, C3 and C4 proteins have an additional cysteine residue in the foldon domain (1) 
in addition to the two cysteines in the COMP domain (2 and 3) (for sequence details see 
Figure 2, B). During refolding out of 8 M urea under oxidizing conditions (preparation 
1) if the unfolded monomeric chains form either 1-2 or 1-3 intramolecular disulfide 
bridges, it will lead to formation of pentamers or trimers. Therefore, the trimers 
observed in preparation 1 refolded samples of C2, C3 and C4 (Figure 9; lane 6, 8 and 
11) support the folded foldon domain with 1-2 or 1-3 intramolecular disulfide bridges. 
During reducing condition refolding up to 0 M urea (preparation 2), the formation of 1-
2 or 1-3 intramolecular disulfide bridges is not possible, as this is supported by the 
absence of trimers in preparation 2 refolded samples of C2, C3 and C4 proteins (Figure 
9; lane 7, 9 and 12). A schematic model of a trimer is shown in Figure 15, A. The 
observation of trimers and even units in the refolded samples of C2, C3 and C4 proteins 
and not in the refolded samples of C1 protein, support the folded trimeric foldon 
domain. Therefore, for proteins C2, C3 and C4 the mutation of Asp (D) to Cys (C) (for 
sequence details see Figure 2, B) in the foldon domain seems to stabilize the foldon 
domain in terms of its folding property. 
Also, BN-PAGE result (Figure 9) for proteins C2, C3 and C4 refolded under both 
preparation 1 (lanes 6, 8 and 11) and preparation 2 conditions (lanes 7, 9 and 12) 
showed 20-mers. AUC result for proteins C2, C3 and C4 suggest the higher order 
oligomers (more than 15-mers) could be a mixture of 20-mers and 30-mers (see Table 
2, 3 and 4). The observation of 20-mers suggests the linked even units and pentamers 
through intermolecular disulfide bridges. A schematic model of 20-mers is shown in 
Figure 15, E. Furthermore, the observed pentamers in both the refolding conditions for 
proteins C1 to C4 suggests it as a common ‘intermediate form’ during the refolding 
process. 
For proteins with extended linkers C3 (four residues) and C4 (six residues) there is 
no significant observation regarding assembly when compared to the proteins with two 
residues of linker region C1 and C2 (see Figure 9). This suggests that for proteins C3 
and C4, the increased linker size does not help the observed even units to assemble 
further into icosahedral nanoparticles. 
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The even units observed in proteins C2, C3 and C4 support our design principles 
(Figure 4). Even units are nanoparticles but not with icosahedral symmetry. But, the 
observed even units failed to associate further into icosahedral nanoparticles (see EM 
pictures of Figure 10, C and D and Figure 11). 
Uncleaved proteins UC1 to UC4 
The preparation 2 refolded proteins UC1 to UC4 were observed to form icosahedral 
nanoparticles (see EM pictures of Figure 13). The observation of icosahedral 
nanoparticles in uncleaved proteins UC1 to UC4 can be explained on the basis of 
domain architecture. The domain architecture of uncleaved proteins comprises a 34 
amino acid N-terminal laminin domain followed by the foldon and the COMP domain 
(refer to Figure 2, A). The laminin domain was derived from the C-terminal region of 
laminin β-chain of mouse (1750-1784 amino acids) and from the literature this region 
was known to be α-helical region with a heptad repeat pattern characteristic of coiled-
coils [8, 11]. In our study, the formation of α-helical structures in the laminin domain of 
the uncleaved proteins was supported by the α-helical content values calculated from 
the CD spectra of these proteins (refer to results section of CD spectroscopy).  
Kammerer, R et al. [12] showed using AUC technique that the laminin β-chain of 
residues 1700-1786, tends to associate into trimers. This study includes the laminin 
domain residues of uncleaved proteins. Therefore, the laminin domain in the uncleaved 
proteins, based on its α-helical structure with the heptad repeat pattern and the likely 
trimeric form suggest it as a trimeric coiled-coil structure. In addition, the trimerization 
potential of foldon domain [13, 14] will also influence the formation of trimeric coiled-
coil structure in the laminin domain. Hence, the monomeric chain comprising the 
laminin domain together with the foldon domain as a trimeric oligomerization domain 
connected to the pentameric oligomerization domain of COMP (Figure 16), mimics the 
design principles of our structure based designed peptide which was shown to form 
regular icosahedral nanoparticles (chapter 1).  
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Figure 15. Proposed schematic models for observed oligomers of proteins C1 to C4. A, trimer with 
intramolecular disulfide bridge (either 1-2 or 1-3). B, pentamer with intramolecular disulfide bridge (2-3). 
C, two pentamers of B linked through intermolecular disulfide bridge. D, even unit with properly formed 
intermolecular disulfide bridge between the monomeric chains of foldon domain (1-1) and between the 
monomeric chains of COMP domain (2-3). E, Even unit of D linked to pentamer of B through 
intermolecular disulfide bridge. In all the models, the blue and green represent the foldon domain and the 
COMP domain, respectively. Red line represents the disulfide bridge.                                                                                              
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Figure 16. A, the laminin domain (red) along with the foldon domain (blue) forms the trimeric 
oligomerization domain and it is connected to the pentameric oligomerization domain of COMP (green) as 
a single chain. The two different oligomerization domains are shown along their respective symmetry axis 
of the icosahedron. The three symmetry axes (5, 3 and 2) extending from the center of the icosahedron 
are shown as red lines. B, applying the symmetry elements to the monomeric chain of section A 
generates an artificial nanoparticle with icosahedral symmetry. The view is down the five-fold symmetry 
axis. 
 
 
 
 
 
 
 
A 
B 
5 
2 3 
5 
23
Materials and Methods - Chapter 3                          
 
 163
Materials and Methods 
Reagents and Enzymes 
All enzymes were purchased from BioConcept – New England Biolabs (Allschwil, 
Switzerland) and chemicals from Sigma, Applichem and Bio-Rad unless stated 
otherwise. They were used according to the manufacturer’s instructions. All 
oligonucleotides (Table 8) were synthesized by Microsynth AG (Balgach, Switzerland). 
Oligonucleotides had 5’ phosphate and were quality assured by PAGE purification. 
Bacterial strains and plasmids 
Escherichia coli DH5 α cells (Invitrogen, USA) and BL21 (DE3) pLysS cells 
(Novagen, USA) were used as the cloning and expression host cells, respectively. For 
our expression studies, we have used prokaryotic expression vector pPEP-T [15, 16]. 
Molecular biology of designed constructs 
The constructs used in this study are depicted in Figure 2, A. The cloning strategy of 
these constructs was done as follows:   
Oligonucleotide fragment assembly 
All the oligonucleotides (both forward and reverse strand) (Table 8) of UC1 to UC4 
constructs were dissolved in MilliQ water to a concentration of 100 μM. The forward 
and reverse strand of each oligonucleotide were combined in 1 μM concentration and 5 
μl of 20X SSC buffer (30 mM sodium citrate dihydrate pH 7.0 and 300 mM NaCl for 
100 ml) and water were added to give 50 μl. Annealing reaction was done in a 
thermocycler by first incubating at 90°C for 1 min followed by 70°C for 1 min and then 
cooling at 1°/15 sec to 20°C (Tpersonal, Biometra, UK) to give the annealed product. 
The annealed products were desalted using Micro Bio-Spin P-30 columns as per the 
manufacturers protocol (Bio-Rad, USA) and then checked in 4% NuSieve GTG-
Agarose (Cambrex Bio Science, USA) to confirm the annealing reaction. Annealed 
products were stored at -20°C until required.  
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Table 8: Oligonucleotides of UC1 to UC4 constructs 
 
Constructs                      Oligonucleotide sequences 
        UC1               fragment 1 (forward & reverse strand) 
                                                      (P) 5’ GATCCGGTTACATCCCGGAAGCTCCGCGTGACGGTCAGGCATACGTTCGTAAAGACG 3’ 
                                                      (P) 5’ TTCACCGTCTTTACGAACGTATGCCTGACCGTCACGCGGAGCTTCCGGGATGTAACCG 3’  
 
                                           fragment 2 (forward & reverse strand) 
                                                      (P) 5’ GTGAATGGGTTCTGCTGTCCACCTTCCTGGGTGGTCTGGCTCCGCAGATGCTGCGTGAAC 3’ 
                                                      (P) 5’ CTGCAGTTCACGCAGCATCTGCGGAGCCAGACCACCCAGGAAGGTGGACAGCAGAACCCA 3’      
       
                                           fragment 3 (forward & reverse strand) 
                                                      (P) 5’ TGCAGGAAACCAACGCTGCTCTGCAGGACGTTCGTGAACTGCTGCGTCAGCAGGTTAAAC 3’ 
                                                      (P) 5’ GATCTGTTTAACCTGCTGACGCAGCAGTTCACGAACGTCCTGCAGAGCAGCGTTGGTTTC 3’  
               
                                           fragment 4 (forward & reverse strand) 
                                                      (P) 5’ AGATCACCTTCCTGAAAAACACCGTTATGGAATGCGACGCTTGCGGTTGATAAG 3’ 
                                                      (P) 5’ AATTCTTATCAACCGCAAGCGTCGCATTCCATAACGGTGTTTTTCAGGAAGGT 3’  
 
        UC2                            fragment 1_1 (forward & reverse strand) 
                                                      (P) 5’ GATCCGGTTACATCCCGGAAGCTCCGCGTTGCGGTCAGGCATACGTTCGTAAAGACG 3’ 
                                                      (P) 5’ TTCACCGTCTTTACGAACGTATGCCTGACCGCAACGCGGAGCTTCCGGGATGTAACCG 3’  
 
        UC3                            fragment 2_1 (forward & reverse strand) 
                                                      (P) 5’ GTGAATGGGTTCTGCTGTCCACCTTCCTGGGTGGTTCGGGTCTGGCTCCGCAGATGCTGCGTGAAC 3’ 
                                                      (P) 5’ CTGCAGTTCACGCAGCATCTGCGGAGCCAGACCCGAACCACCCAGGAAGGTGGACAGCAGAACCCA 3’ 
 
        UC4                            fragment 2_2 (forward & reverse strand) 
                                                      (P) 5’ GTGAATGGGTTCTGCTGTCCACCTTCCTGGGTGGTTCGGGTTCGGGTCTGGCTCCGCAGATGCTGCGTGAAC 3’  
                                                      (P) 5’ CTGCAGTTCACGCAGCATCTGCGGAGCCAGACCCGAACCCGAACCACCCAGGAAGGTGGACAGCAGAACCCA 3’ 
 
 
(P) - 5’ phosphorylation; all the oligonucleotide pairs (forward and reverse strand) were underlined for their complementary regions. 
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|GATCCGGTTACATCCCGGAAGCTCCGCGTGACGGTCAGGCATACGTTCGTAAAGACG         GTGAATGGGTTCTGCTGTCCACCTTCCTGGGTGGTCTGGCTCCGCAGATGCTGCGTGAAC        
   |GCCAATGTAGGGCCTTCGAGGCGCACTGCCAGTCCGTATGCAAGCATTTCTGCCACTT         ACCCAAGACGACAGGTGGAAGGACCCACCAGACCGAGGCGTCTACGACGCACTTGACGTC 
     G  Y  I  P  E  A  P  R  D  G  Q  A  Y  V  R  K  D  G  E           W  V  L  L  S  T  F  L  G  G  L  A  P  Q  M  L  R  E  L  Q 
 
 
TGCAGGAAACCAACGCTGCTCTGCAGGACGTTCGTGAACTGCTGCGTCAGCAGGTTAAAC         AGATCACCTTCCTGAAAAACACCGTTATGGAATGCGACGCTTGCGGTTGATAAG| 
    CTTTGGTTGCGACGAGACGTCCTGCAAGCACTTGACGACGCAGTCGTCCAATTTGTCTAG         TGGAAGGACTTTTTGTGGCAATACCTTACGCTGCGAACGCCAACTATTCTTAA| 
    E  T  N  A  A  L  Q  D  V  R  E  L  L  R  Q  Q  V  K  Q  I           T  F  L  K  N  T  V  M  E  C  D  A  C  G  *  *   
 
 
 
GATCCGGTTACATCCCGGAAGCTCCGCGTTGCGGTCAGGCATACGTTCGTAAAGACG        GTGAATGGGTTCTGCTGTCCACCTTCCTGGGTGGTTCGGGTCTGGCTCCGCAGATGCTGCGTGAAC 
    GCCAATGTAGGGCCTTCGAGGCGCAACGCCAGTCCGTATGCAAGCATTTCTGCCACTT        ACCCAAGACGACAGGTGGAAGGACCCACCAAGCCCAGACCGAGGCGTCTACGACGCACTTGACGTC                      
    G  Y  I  P  E  A  P  R  C  G  Q  A  Y  V  R  K  D  G  E        W  V  L  L  S  T  F  L  G  G  S  G  L  A  P  Q  M  L  R  E  L  Q 
        
 
 
GTGAATGGGTTCTGCTGTCCACCTTCCTGGGTGGTTCGGGTTCGGGTCTGGCTCCGCAGATGCTGCGTGAAC 
     ACCCAAGACGACAGGTGGAAGGACCCACCAAGCCCAAGCCCAGACCGAGGCGTCTACGACGCACTTGACGTC 
    W  V  L  L  S  T  F  L  G  G  S  G  S  G  L  A  P  Q  M  L  R  E  L  Q 
 
Figure 17. A, fragments 1 to 4 (sequential order) which have the overlapping bases at their ends constitute the UC1 construct. Fragment 1 has pre cut BamHI 
restriction site (marked in brown colored solid line) and fragment 4 has pre cut EcoRI restriction site (marked in orange colored solid line). Below each fragment their 
corresponding amino acid sequences were highlighted (bold colored letters). Green colored bold letters, correspond to the foldon domain of the T4 phage fibritin protein 
followed by two glycine residues (bold black color) as the linker which were then linked to the blue colored bold letters correspond to COMP (Cartilage Oligomeric Matrix 
Protein) domain. * denotes stop codons.  B, fragment 1_1 which has the aspartic acid (D) to cysteine (C) mutation (highlighted in red color) along with the fragment 2, 3 
and 4 constitutes the UC2 construct. C, Fragment 2_1 which has two extra glycine residues (highlighted in red color) as linker was inserted in between fragment 1_1 
and fragment 3 which was then followed by fragment 4 constitutes the UC3 construct. D, fragment 2_2 which has two more extra glycine residues (highlighted in red 
color) as linker was inserted in between fragment  1_1 and fragment 3 which was then followed by fragment 4 constitutes the UC4 construct.                                                                              
 
fragment 1 fragment 2 
fragment 3 fragment 4 
A 
B 
fragment 1_1 fragment 2_1 
D fragment 2_2 
C
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Preparation of pPEP-T-UC1, UC2, UC3 and UC4 constructs 
The annealed oligonuclotides and their involvement in the construct deign of UC1 to 
UC4 constructs were depicted in the Figure 17. For the cloning of UC1 to UC4 DNA 
fragments in to pPEP-T vector, the vector DNA was prepared as follows: 1 μg of 
pPEP-T vector, 1 μl of 10X NEBuffer EcoRI (10 mM Tris pH 7.9, 10 mM MgCl2, 50 
mM NaCl and 1 mM DTT), 1 μl of 10X BSA, 1 units of EcoRI and BamHI enzyme 
and water up to 10 μl were combined and incubated at 37°C for 3 hrs. Double digested 
vector was recovered using QIAquick Gel Extraction Kit (Qiagen, Switzerland) from a 
1% agarose gel. After gel extraction, the digested vector ends were dephosphorylated 
by adding 1 unit of shrimp alkaline phosphatase (Promega, USA) and 1 μl of 10X SAP 
reaction buffer (50 mM Tris pH 9.0, 10mM Mgcl2) to a final volume of 10 μl, followed 
by incubation at 37°C for 15 min, then heat inactivation (15 min, 65°C). 
Dephosphorylated plasmid DNA was ligated to the fragments that corresponds to the 
respective constructs UC1 to UC4 as follows: Equimolar concentration of assembled 
oligonuclotide fragments (vector to insert ratio 1:3), 100 ng of dephosphorylated 
plasmid DNA and water were added and incubated at 45°C for 5 min. Finally, the 
reaction mixture was cooled in ice and 1 μl of 10X T4 DNA ligase buffer (50 mM Tris 
pH 7.5, 10 mM MgCl2, 10 mM DTT, 1 mM ATP, 25 μg/ml BSA) along with 1 unit of 
T4 DNA ligase was added and incubated at 16°C overnight. 
Transformation 
Five μl of ligated mixture was added to 100 μl of DH5α competent cells and was 
incubated on ice for 30 min, heat shocked for 90 sec at 42°C, and incubated on ice for 
further 2 min. Then, 0.9 ml of LB medium was added and incubated at 37°C for 1h 
with shaking at 225 rpm. Followed by centrifugation of cells at 7000 rpm, 5 min and 
the pelleted cells were kept in 100μl of LB and the remaining LB was thrown out. The 
cells were mixed with the LB by gentle tapping and the mixture was plated on LB-agar 
plates (ampicillin 100 μg/ml) and incubated overnight at 37°C.  
Putative positive colonies were picked from plates and placed in a 3 ml LB-
ampicillin (100 μg/ml) broth and grown overnight at 37°C with shaking at 180 rpm.  
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Plasmid mini prep was done from the cultures using QIAprep spin mini prep kit 
(Qiagen, Switzerland) and the obtained plasmid DNA was subjected to enzymatic 
digestion with BamHI and EcoRI enzyme to verify the presence of the insert in the 
transformed bacterial colonies. Products were analyzed by 2% gel electrophoresis. 
DNA sequencing (Microsynth AG, Balgach, Switzerland) was done to verify the 
putative positive clones using primers of T7 promoter and terminator sequence. 
Protein expression & Purification 
Protein expression 
For UC1 to UC4 constructs (Figure 2, A), we followed the same protocol for protein 
expression. The sequence verified positive clones were transformed into E.coli strain 
BL21 (DE3) pLysS cells as described in section 3.3.3. The transformed cells were 
plated on ampicillin (100 μg/ml) and chloramphenicol (30 μg/ml) LB agar plates and 
incubated at 37°C overnight. A single colony from the plate was inoculated in 50 ml 
LB broth with ampicillin (200 μg/ml) and chloramphenicol (30 μg/ml) and grown 
overnight at 28°C with shaking at 180 rpm. 1% of the overnight grown culture was 
inoculated into 3 liters of LB with ampicillin (200 μg/ml) and chloramphenicol (30 
μg/ml) and incubated at 37°C with shaking at 180 rpm. Protein expression was induced 
when the cell density at OD600nm reached 0.5 by adding IPTG to a final concentration of 
1 mM. After induction at 37°C for 3 hr, the cell pellet was collected by centrifugation 
at 6000 g for 20 min at 4°C (Sorvall, GSA rotor) and frozen at -80°C until further use. 
The physicochemical properties of the expressed proteins UC1 to UC4 were outlined in 
Table 9 along with the thrombin cleaved counterparts of UC1 to UC4 proteins (C1 to 
C4). 
Protein purification under denaturing conditions using nickel-
column affinity chromatography 
 Purification principle: The purification procedure was carried out by exploiting 
the pKa of histidine residues in the 6xHis tag. The histidine residues in the 6xHis tag 
will have a pKa of approximately at pH 6.0 and at high pH (8.0), it will be uncharged 
and the imidazole ring of histidine residues binds to the Ni2+-NTA resin.  
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But at acidic pH (pH 5.9 and 4.5), the imidazole ring of histidine residues will get 
protonated and under these conditions the 6xHis-tagged proteins can no longer bind to 
the nickel ions and will dissociate from the Ni2+-NTA resin. During the elution process, 
monomers generally elute at approximately pH 5.9, whereas aggregates and proteins 
that contain more than one 6xHis tag elute at approximately pH 4.5. 
Methodology: Following expression, bacterial pellets (from 3 liter culture) were 
thawed on ice and to each gram of pellet (wet weight) 3 ml of lysis buffer pH 8.0 (8 M 
Urea, 10 mM Tris, 100 mM NaH2PO4) was added along with 10 mM β-
mercaptoethanol. Pellets were thoroughly resuspended in lysis buffer and sonicated on 
ice for 5 min (4 sec of sonication and 6 sec of gap) followed by centrifugation at 16000 
rpm at 4°C for 45 min to recover the supernatant from the cell debris. The resultant 
supernatant was mixed with Ni2+-NTA slurry (Qiagen, Switzerland) and the amount of 
nickel resin was determined by the level of protein expression (usually 1 ml of resin 
can bind up to 10 to 15 mg of protein)  and it has to be optimized. The mixture was 
then gently mixed for 1 hr at room temperature (batch method).  
Table 9: Physico-chemical properties of UC1 to UC4 (uncleaved) and C1 to C4 (cleaved) proteins#  
 
Constructs Molecular 
weight 
(Daltons) 
Number 
of amino 
acids 
Isoelectric point (pI) Extinction coefficient 
(M-1 cm-1) 
UC1 14182.1 127 6.29 11585 (1 g/l=0.817) 
C1 8368.5 75 4.93 8605 (1 g/l=1.028) 
UC2 14170.2 127 6.58 11585 (1 g/l=0.818) 
C2 8356.6 75 5.26 8605 (1 g/l=1.030) 
UC3 14314.3 129 6.58 11585 (1 g/l=0.809) 
C3 8500.7 77 5.26 8605 (1 g/l=1.012) 
UC4 14458.4 131 6.58 11585 (1 g/l=0.801) 
C4 8644.8 79 5.26 8605 (1 g/l=0.995) 
 
# All the properties were calculated using the online tool PROTPARAM from the expasy server 
(http://www.expasy.org/tools/protparam.html) [17]. 
 
After the incubation, the lysate and the Ni-NTA slurry were loaded on the econo 
column (Bio-Rad, USA) and the resultant flow through was collected for analysis.  
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Then the column matrix was subjected to two separate wash steps: one with lysis 
buffer pH 8.0 and second one with wash buffer 1 pH 6.3 (8 M Urea, 10 mM Tris, 100 
mM NaH2PO4) along with 10 mM β-mercaptoethanol. Finally, the protein elution was 
performed using elution buffer 1 pH 5.9 (8 M Urea, 10 mM Tris, 100 mM NaH2PO4) 
and elution buffer 2 pH 4.5 (8 M Urea, 10 mM Tris, 100 mM NaH2PO4) along with 10 
mM β-mercaptoethanol.   
Thrombin cleavage and purification of cleaved products 
The eluted constructs were dialyzed against the thrombin cleavage buffer 20 mM 
Tris pH 8.4, 150 mM NaCl and 2.5 mM CaCl2. The dialysis was performed in a step-
wise manner from 8 M Urea to 6 M followed by 4 M and 2 M and finally to 0 M urea. 
For cleavage reactions, 1 U of human plasma thrombin (Sigma, USA) was used per mg 
of protein and the reactions were carried out at room temperature for 16 to 18 hrs with 
gentle shaking or sometimes for 24 hrs.  
The resultant digested samples were purified as follows: Initially the digested 
samples were mixed with Ni2+-NTA slurry and the amount of nickel slurry that was 
used depending on the amount of protein used for cleavage (1 ml of nickel slurry can 
bind up to 10 to 15 mg of protein). The mixture was then incubated at room 
temperature with gentle shaking for 1hr (batch method). Followed by packing of 
mixture on the econo columns and the resultant flow through fractions were collected 
to analyze for the presence of cleaved constructs C1 to C4 (Figure 3, A). The bound 
uncleaved samples were eluted using the same elution buffer 1 and 2 as mentioned in 
the section ‘Protein purification’. 
Analysis of purified samples 
SDS-PAGE 
Standard SDS-PAGE was performed [18] using Bio-Rad mini gel apparatus (Bio-
Rad, USA). 15% and 17% SDS-PAGE were run to analyze the purified samples of 
UC1 to UC4 and C1 to C4 proteins, respectively. The protein samples were mixed with 
1X sample buffer (45 mM Tris pH 6.8, 10% glycerol, 1% SDS, 0.01% bromophenol 
blue and 50 mM DTT) before loading on SDS-PAGE. After the run, protein bands were 
visualized using Coomassie Brilliant blue R-250 (Bio-Rad, USA). 
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Western blot 
Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose 
membrane was done as described in the literature [19, 20].  
We used 0.2 µm size nitrocellulose membrane (Sigma, USA) and Bio-Rad Mini-
PROTEAN 2 Electrophoresis / Mini Trans-Blot Module for the transfer process. The 
transfer was carried out in the presence of blotting buffer (20 mM Tris buffer pH 8.3, 
150 mM glycine and 20% methanol) at 100V, 4°C for 1 hour. Immunological detection 
of proteins was carried out as follows: The electroblotted nitrocellulose membrane was 
transferred to TTBS buffer (20 mM Tris pH 7.4, 150 mM NaCl, 0.1 (v/v) Tween 20) 
containing 5% (W/V) dry skim milk powder to prevent non-specific binding of primary 
antibody and incubated for 1 hour at room with gentle shaking. Subsequently, the 
nitrocellulose membrane was transferred to a fresh solution of TTBS buffer containing 
5% (W/V) milk powder and the monoclonal antibody (1: 3000 dilutions) raised in 
mouse against the polyhistidine tag (Sigma) and incubated for 1 hour at room 
temperature with gentle shaking. The nitrocellulose membrane was then transferred to a 
fresh TTBS solution without milk powder and incubated for 10 minutes with gentle 
shaking. This procedure was repeated four times (wash step). After the wash step, the 
nitrocellulose membrane was transferred to a fresh solution of TTBS buffer containing 
5% (W/V) milk powder and the anti-mouse IgG (Fc specific) antibody (1:5000 
dilutions) raised in goat and conjugated to horseradish-peroxidase enzyme  (Sigma) and 
incubated for 1 hour at room temperature with gentle shaking. Again, the membrane 
was washed extensively in TTBS buffer as described before (second wash step).  
The second time washed nitrocellulose membrane was incubated in ECL western 
blotting detection reagents according to the manufacturers protocol (Amersham 
Biosciences). The nitrocellulose membrane was subsequently exposed to Kodak X-
OMAT XAR-5 radiography film (Sigma) for 15 seconds to 30 minutes, until the 
positive bands were visualized by enhanced chemiluminescence.       
Estimation of protein concentration 
For all the samples, protein concentrations were calculated using the absorbance 
value at 280 nm with extinction coefficient (M-1 cm-1) and molecular weight (Daltons) 
of the protein.  
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Extinction coefficient and the molecular weight of the proteins was calculated using 
ProtParam tool (http://www.expasy.ch/tools/protparam.html) [17]. For protein 
concentration measurements, we have also used the dye binding method [21] using 
Bio-Rad Bradford assay reagent with BSA as the standard. 
Refolding conditions 
The protein refolding procedure was carried out using two different refolding 
regimes. 
Preparation 1 (denaturation, renaturation under oxidizing conditions)    
The purified protein in denaturing conditions was refolded by step wise dialysis 
procedure. Initially, the denatured protein was dialyzed against the buffer 20 mM Tris 
pH 7.5, 150 mM NaCl containing 8 M urea followed by 6 M urea, 4 M urea, 2 M urea 
and no urea in the same buffer as above. Finally, the protein was concentrated to the 
required concentration for further characterization in the buffer 20 mM Tris pH 7.5, 
150 mM NaCl. 
Preparation 2 (denaturation, renaturation under reducing conditions) 
In this condition also the step wise dialysis procedure was followed. Initially, the 
protein was dialyzed against the buffer 20 mM Tris pH 7.5, 150 mM NaCl and 2 mM 
DTT containing 8 M urea followed by 6 M urea, 4 M urea, 2 M urea and no urea in the 
same buffer as above. Finally, the protein was dialyzed against the buffer 20 mM Tris 
base pH 7.5, 150 mM NaCl at pH 7.5 to remove DTT and concentrated to required 
concentration for further characterization in the same buffer.  
During refolding in both the conditions, the protein concentration was kept at a 
concentration of 0.1 mg/ml. 
Analytical Ultracentrifugation 
 Analytical ultracentrifugation (AUC) was carried out on an Optima XL-A analytical 
ultracentrifuge (Beckman Instruments, Palo Alto, CA) equipped with a 12-mm Epon 
double-sector cell in an An-60 Ti rotor.  
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Sedimentation equilibrium runs were performed at 20°C at rotor speeds of 12,000 to 
18,000 rpm and protein concentrations of 0.1 to 0.5 mg/ml. Average molecular masses 
were evaluated by using a floating base-line computer program SEGAL that adjusts the 
baseline absorbance to obtain the best linear fit of ln (absorbance) versus the square of 
the radial distance [22]. A partial specific volume (ν) of 0.73 mL/g and a buffer density 
(ρ) of 1.005 g/mL was used. The formula that the SEGAL program uses to calculate the 
molecular mass (M) of the sample was given below: 
M = 2RT/ (1- ν ρ) ω2 * d (ln c)/d (r2)                                                               Equation 1 
Where R is Gas constant and T is the absolute temperature. ω is angular velocity, c 
is concentration (g/L) and r is radial distance from the axis of rotation. All the AUC 
measurements were performed at the AUC facility in the Biozentrum by Ariel Lustig 
(http://www2.biozentrum.unibas.ch/auc/).  
Electron Microscopy 
Protein samples were prepared for electron microscopy (EM) by negative staining 
with 2 % uranyl acetate and at a protein concentration of 50 or 100 µg/ml. They were 
analyzed and photographed on a Philips Morgagni 268D model transmission electron 
microscope with an acceleration voltage of 80 kV. Electron microscopy analysis was 
performed by Vesna Olivieri in Microscopy center, Pharmazentrum, University of 
Basel and also by Dr. Gia Machaidze in Professor Ueli Aebi group, M.E. Muller 
Institute, University of Basel. 
Circular Dichroism (CD) measurements   
The CD measurements were acquired on an Aviv 62A DS spectropolarimeter. The 
far-ultraviolet spectra (200-250 nm) were measured in a 1 mm path-length quartz cell at 
4°C. The spectra were normalized for concentration and path length to obtain the mean 
molar residue ellipticity (θ, theta) after subtraction of the buffer contribution.  
The following formula was used to calculate the concentration independent theta (θ) 
values (deg cm2 dmol-1): θ (observed) * MRW / [10 * path length (cm) * 
concentration (mg/ml)], where MRW - mean residue weight (molecular mass of the 
peptide or protein divided by number of amino acids).  
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Data analysis and the wavelength scan plots were performed with the pro Fit 
software package (QuantumSoft, Switzerland).  
Blue-Native PAGE (BN-PAGE) electrophoresis 
For all the samples, 15 µg of protein per gel lane was resuspended in the buffer 
composed of 50 mM Bistris-HCl pH 7.0, 500 mM 6-aminocaproic acid and 50% 
glycerol. Samples were resolved on 5-12% gradient acrylamide gel overnight at 100 V; 
anode buffer composition 50 mM Bistris-HCl pH 7.0; cathode buffer contained 50 mM 
Tricine, 15 mM Bistris-HCl pH 7.0 with 0.005% Coomassie G250 (Bio-Rad, USA) 
[23]. High molecular weight standards for native gel electrophoresis (Amersham 
Biosciences, USA) were stained with Coomassie R250 (Bio-Rad, USA).  
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